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Abstract
Two parasitic trypanosomatids, T. b. gambiense and T. b. rhodesiense, are responsible for 
around 150,000 death a year by Human African Trypanosomiasis (HAT). Prevalence 
values in some villages reaches up to 50%, making HAT the leading cause of mortality. 
There are cuiTently only four drugs available for treating HAT, but problems with 
availability, administration, disease stage specificity and severe side effects have hindered 
their uses.
The most used drug is the arsenical, Melarsoprol, but resistance is increasingly reported in 
the field. Some reports have suggested that point mutations within the TbATl, encoding the 
P2 transporter, were associated with drug resistance in both laboratory-derived strains and 
field isolates. However, analysis o f a ATbATl cell showed a low level o f resistance and 
50% of field isolates had a non-mutated P2 transporter. Consequently, it seems likely that 
multiple mechanisms can confer a resistance phenotype but these have been largely 
undescribed to date.
The advantage o f a global proteomic expression profiling study of drug sensitive and dmg 
resistant isogenic T. brucei lines is that, in principle, all possible mechanisms could be 
identified without pre-supposing a specific mechanism. The release o f an almost complete 
T. brucei genome database, the advances in 2DE technology and mass spectrometry 
techniques, and the availability o f drug sensitive and resistant isogenic T. brucei lines 
rendered this analysis feasible.
Subtractive analysis of the whole proteome of the drug sensitive and resistant isogenic line 
of STIB 386 identified two proteins whose loss of expression was associated witli 
Cymelarsan resistance. Cymelarsan is a drug that is structurally and functionally closely 
related to Melarsoprol. Tandem mass spectrometry analysis matched the first protein onto 
either open reading frame (ORF) 274 or 277, present as identical tandem repeats on 
chromosome IX. This protein spot was shown to be an isoform o f a spot located a similar 
molecular weight but with a more basic pi. As both ORFs have identical predicted amino 
acid sequences, are transcribed and no other homologues were found in the T. brucei 
genome, it is likely that the missing protein is an iso form o f the adjacent protein which 
arose due to a post-translational modification. I have named this protein the Cymelarsan 
Associated Resistance (CAR) protein. The absence o f the protein was not associated with 
Cymelarsan resistance in a pair of isogenic drug sensitive and resistant lines o f247.
The second protein spot associated with Cymelarsan resistance was identified as an 
arginine kinase fi'om either ORF 342 or 343. These two ORF, present as tandem repeat on 
chromosome IX are not identical. However, the degree of sequencing obtained fi'om the 
Tandem mass spectrometry analysis did not enable to differentiate between product o f each 
ORF.
Finally, a diminished reduction o f the Alamar Blue dye was found associated with 
Cymelarsan resistance in both pairs of isogenic lines analysed. An attempt was made to 
determine the mechanism that impaired the reduction of the Alamar blue dye in the drug 
resistant lines. The transport and efflux o f the dye were analysed and did not account for 
the difference in reduction of the Alamar Blue dye. The dye was found to concentrate in 
vesicle-like stmctures thought to be acidocalcisomes.
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Chapter I; General introduction
Chapter I 
General introduction
1.1 Trypanosomes
1.1.1 Introduction
1.1.1.1 Current status of Human African Trypanosomiasis (HAT)
The latest data published by the World Health Organisation (WHO, 2003) indicate that
300,000 people suffer currently from HAT, and a further 50 million people in sub-Saharan 
Africa are at risk of infection. In 1996, 150,000 people died and 100,000 were handicapped 
by the disease and in the same year 30,000 new cases were reported. In 1998, 45,000 new 
cases were reported (Barrett, 1999). Sixty million people, living in 36 sub-Saharan 
countries ( 2 2  o f which are among the poorest countries in the world) are under the daily 
threat of contracting HAT (Figure 1.1). Only four million of them have access to diagnosis 
and treatment.
There are at least 200 foci o f HAT in sub-Saharan Africa and a resurgence of 
trypanosomiasis is occurring in the Democratic Republic of Congo (Van Nieuwenhove et 
al., 2001), the Central African Republic (Smith et al., 1998), Uganda (Olila et al., 2002), 
Sudan (Moore and Richer, 2001) and Angola (Stanghellini and Josenando, 2001). 
Prevalence rates reach up to 50% in some villages, making HAT the leading cause of 
mortality. In two provinces of tlie Democratic Republic of Congo the number o f deaths due 
to HAT have been estimated to be equal to or higher than the number o f deaths due to 
Acquired Immune Deficiency Syndrome (AIDS) (WHO, 2003).
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In addition, resistance to Melarsoprol, the dmg of first choice for the treatment of HAT, 
has been reported in many epidemic areas of Africa. The overall relapse rate over the past 
50 years was of 5 - 8% (Pepin and Milford,1994), but this rate has risen to 25% in Angola 
(Stanghellini and Josenando, 2001) and 30% in Uganda (Legros et ah, 1999) in recent 
years.
The increase in prevalence and distribution o f HAT associated with the increase in drug 
resistance reported cases have initiated new research interests in tlie discovery ofthe 
mechanisms of dmg resistance to the existing dmgs and the development of new treatment 
for HAT.
Taxonomy/Classification
African trypanosomes are flagellated parasitic protozoa belonging to the order 
kinetoplastidae and the family trypanosomatidae. Kinetoplast flagellates are characterised 
by the possession of a unique organelle called the kinetoplast which contains 
deoxyribonucleic acid (DNA) and is an integral part o f the mitochondrial system.
The genus Trypanosoma is classically subdivided into two groups o f infective parasites, 
the stercorarian trypanosomes and the salivarian trypanosomes. In the stercorarian 
trypanosomes, the flagellates divide in the hind gut o f the insect vector and metacyclic 
forms are passed out with the faeces. The most important species is T. cruzi which infects 
12 to 24 million people in South and Central America. The disease it causes is called 
Chagas’ disease and the most serious clinical consequences of infection are cardiac failure 
due to the presence o f the parasite in the heart muscles or the loss o f nei-vous control of the 
alimentary tract due to the presence of the parasites in the nervous system. In contrast to
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the stercorarian trypanosomes, the salvarian trypanosomes typically develop in the mid gut 
ofthe vector and either in the salivary glands (T. brucei) or the mouthparts {T. vivax and T. 
congolense). One ofthe major species o f salivarian trypanosomes is T. brucei which is 
divided into three subspecies T. b. brucei, T. b. rhodesieme and T. b. gambiense. These 
three subspecies are morphologically identical, but can be distinguished by isoenzyme 
analysis and restriction enzyme fragment length polymorphism (RFLP) (Gibson, 2002; 
Kanmogne et a l,  1996; Truc and Tibayrenc, 1993). T. b. brucei primarily infects cattle, 
goats, and sheep; T. b. gambiense is distributed in West and Central Africa and causes 
Western African HAT; and T. b. rhodesiense in Eastern and Southern Africa is the cause of  
Eastern African HAT (Figure 1.1) (Wang. 1995). Only two taxonomic groups of tsetse 
flies commonly transmit the flagellate protozoan parasite that causes HAT. Thepalpahs 
group is the chief carrier o f T. b. gambiense and the morsitans group is the chief carrier of 
T. b. rhodesiense. There are several species within the palpahs group and withm the 
morsitans group. Other species o f salivarian trypanosomes T. congolense and T. vivax are 
the causative agent o f Nagana, a trypanosomiasis in domesticated animals. Several species 
oiGlossina transmit T. congolense and T. vivax.
Molecular phylogenetic analysis ofthe Trypanosoma, undertaken by sequencing the 18S 
RNA genes of 31 different species and subspecies, showed the existence o f three distmct 
clades (Stevens et a l, 1999). The T. brucei clade consists ofthe salivarian tsetse 
transmitted trypanosomes from Africa. T. exansi and T. equiperdum, although non-tsetse 
transmitted and not restricted to Africa, also belong here by virtue o f their close 
morphological and genetic similarity with T. brucei. Importantly, this clade is characterised 
by the expression o f a dense variable surfece glycoprotein coat (VSG coat) in the 
bloodstream forms of the parasite (section 1.1.2). The variability lies in the fact that
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Figure 1.1: Geographic distribution of Human African Trypanosomiasis. The black 
line represents the approximate division for the distribution ofT. b. gambieme and T. b. 
rhodesiense. Reproduced from medilinks.org/Features/Articles/june2002/tryps.htm
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the parasite can change its VSG coat by switching between expression o f multiple VSG 
genes, a process called antigenic variation (Barry and McCulloch, 2001). This process 
enables the parasite to evade tlie host immune response. The T. cruzi clade originates 
mainly from South American mammals, with some interesting exceptions: two species of 
European bat trypanosomes and one as yet unnamed species o f kangaroo trypanosome 
from Australia. Finally, an aquatic clade comprising trypanosome species isolated fi-om 
both marine and fresh water fish and amphibian has been observed (Stevens et al, 1999). 
Interestingly, the molecular phylogenetic analysis agreed with the classical classification of 
the Trypanosoma species.
1.1.2 Life cycle
Parasites of the T. brucei group are transmitted fr om the tsetse fly to their mammalian host 
where they replicate first in the bloodstream, lymphatic system and interstitial spaces, and 
then, during the latter stages of the infection in the central nervous system. In the mammal 
the bloodstream trypanosomes multiply as “long slender” forms by binary fission and 
eventually differentiate into a non-dividing “short stumpy” forms. The bloodstream 
trypanosomes have the ability to evade the host immune system by antigenic variation. A 
diagram of the life cycle o f T. brucei is shown in Figure 1.2, which includes some o f the 
intermediate forms that have been previously described (Vickerman, 1985). Trypanosomes 
are ingested by the tsetse fly {Glossina spp.) when a blood meal is taken (Vickerman, 
1965). Once the short, stumpy trypomastigote reaches the mid-gut o f the tsetse fly, it 
transforms into a long, slender procyclic form. The parasites multiply in the lumen of the 
midgut by binary fission. After approximately two weeks, the parasites migrate to the 
salivary glands through the hypopharynx, where the parasites attach to the epithelial cells 
o f the salivary glands and then transform to the epimastigote form (Evans and Ellis, 1983),
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Figure 1.2: Life cycle of Trypanosoma brucei. Schematic representation of the 
developmental cycle in a mammal and in a tsetse fly vector.
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This stage undergoes multiplication within the salivary gland, and after two to five days 
metacyclic (infective) forms develop Jftom the epimastigotes (Tetley and Vickerman,
1985). With development o f the metacyclic form, the parasite is now infective for the 
mammalian host and can be introduced into the puncture wound by the tsetse fly when it 
takes the next blood meal. The entire developmental cycle in the fly takes about three 
weeks. Once infected, the tsetse fly remains infected for life.
1.2 Control of Trypanosomiasis
1.2.1 Introduction
A concerted effort has been made to control Afi*ican tiypanosomiasis in both domestic 
livestock and humans, and there have been four main approaches taken. Firstly, avoid 
tsetse-infected areas, which is difficult to apply as the high risk areas are often flie best 
grazing land. Secondly, control o f the tsetse fly vector by using insecticides, fly traps and 
odour baits has been put to practice with varying degree o f success (Schofield and 
Maudlin, 2001). Thirdly, the problem of animal trypanosomiasis could be overcome by 
increasing the use of trypanotolerant cattle that are able to resist trypanosome infection 
(Murray and Morrisson, 1979). Finally, the last and most widely used method for 
controlling both the animal and the human diseases still lies with the use of trypanocidal 
drugs.
1.2.2 Control of the vector
1.2.2.1 Insecticides
Following the discovery o f DTT and other persistent insecticides in 1945, ground spraying 
became tire main line of defence against tsetse flies throughout Africa for over 40 years. 
Selective sparying o f insecticides was successfully applied to fly resting sites in riverine
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fringing vegetation in Sudan in the 1950’s, which led to the elimination of tsetse from
200,000 W  by 1978 (Snow et a l, 1991).
1.2.2.2 Bait technology
Bait technology involves an odour bait which attract flies to a visual target treated with 
insecticide. Attractants such as acetone and octenol are so effective that good control with 
low density of treated target (four per km^) can be achievable (V ale et a l ,  1988). This 
technique was developed further by using “live bait” such as cattle treated with 
insecticides. This strategy was applied with some success in Ethiopia (Leak et ah, 1995), 
Zambia (Chizyuka and Linguru, 1986) and Tanzania (Fox et a l ,  1993).
1.2.2.3 Sterile insect technique (SIT)
Sterile insect technique involves sustained and systematic releases o f sterile male insects 
among a wild population (Aksoy et a l,  2001). The insects are mass reared in large-scale 
insectaries where the males are sterilized by irradiation and then taken to the selected area 
and released by air. The sterile males fertilise wild females, which are then unable to 
produce progeny. Sufficient sterile males need to be released in order to achieve an over- 
flooding ratio sufficient to cause a decline in population size. This technique was 
successfully applied for the eradication o f G. austeni from the island o f Zanzibar (Shahid 
and Curtis, 1987).
A range o f applicable techniques is available for the control o f tsetse flies from simple 
technology such as traps, targets, treated cattle and ground spraying to more advanced 
technology such as aerial spraying and the release o f sterile tsetse males. However, the 
control o f tsetse flies only decrease the incidence of human and animal trypanosomiasis, 
and chemotherapy is still the method of choice for controlling the diseases.
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1.2.3 Control of animal trypanosomiasis
Animal trypanosomiasis is an economic burden for Africa, with infection in domestic 
cattle causing a 20% decrease in calving, a 25% decrease in milk production and it is 
estimated that it causes 3 million livestock deaths per year (Seed, 2000). In addition, 
domestic cattle can also act as a reservoir host for T. b. rhodesiense (Hide, 1999). A recent 
HAT outbreak of T. b. rhodesiense in Uganda was directly associated with the import of 
cattle from a HAT endemic area (Fevre et al., 2001). Consequently, the control of animal 
trypanosomiasis is important botli economically and to control HAT.
1.2.3.1 Chemoprophylaxis
Animal trypanosomiasis can be prevented by the use of prophylactic dmgs. The 
prophylactic drugs currently in use for cattle are homidium and Isometamidium. These 
dmgs can provide protection for three months. Prophylactic drugs ai'e particularly useful to 
protect animals at time of constant disease challenge. Chemoprophylaxis is an expensive, 
time consuming and inefficient (due to the problem of dmg resistance to these dmgs) 
solution to the problem of animal trypanosomiasis.
1.2.3.2 Chemotherapy
Treatment o f animal trypanosomiasis relies on three dmgs: homidium, Berenil and 
isometamidium chloride. Isometamedium chloride, a conjugate o f ethidium and pait of the 
Berenil molecule, is used exclusively in veterinary typanosomiasis. All three dmgs are 
used both prophylactically and therapeutically against T. congolense, T. brucei and T, 
vivax. For all major species of trypanosomes (T. congolense, T. vivax and T. evansi) 
resistance to Isometamidium has been reported (Anene et a i, 2001). Multiple resistant 
population o f T. congolense have also been described (Afewerk et aL, 2000).
Cymelarsan, used for the treatment o f trypanosomiasis in camels, has also been shown to 
be very effective against T. b. brucei, T. evansi, and T. equiperdum in buffalo, goats and
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pigs in vitro (Berger and Fairlamb, 1994). Cymelarsan dissociates rapidly into Melarsen 
oxide, thought to be the active form o f the drug (Berger and Fairlamb, 1994),
1.2.3.3 Trypanotolerant cattle
Breeds o f cattle which are tolerant to trypanosomiasis occur in some part o f Africa 
(Murray et a l ,  1984). Although the use o f trypanotolerant cattle in Africa is a way of 
controlling trypanosomiasis in cattle, it is not per se a solution to the problem, since 
trypanotolerant animals still suffer loss o f productivity due to chronic trypanosome 
infection and can succumb to the disease under high challenge. In addition, these animals 
would still be reservoir host for the human infective trypanosomes and so will not reduce 
the incidence in HAT (Fevre et ah, 2001).
1.2.4 Control of Human African Trypanosomiasis
The process of antigenic variation has hindered efforts to develop vaccine against the 
parasite and so chemotherapy has remained the major means o f controlling HAT (Pays, 
1995). There are currently four dmgs available for treating HAT: Suramin, Pentamidine, 
Melarsoprol, and DL-a-difluoromethylornothine (DFMO). The use o f a particular dmg 
depends on the stage o f HAT being treated and relates to the ability o f the dmg to penetrate 
the blood-brain barrier. Suramin and Pentamidine treatment are restricted to the early stage 
of HAT while Melarsoprol and DFMO are lipophilic and thus able to cross the blood brain 
barrier. This characteristic makes them the dmgs of choice for the treatment o f the late 
stage of HAT when the parasite grow in the brain.
With the exception o f DFMO, which was introduced for the treatment of West African 
HAT in 1990, all o f the antitrypanosomal dmgs were discovered more than 40 years ago.
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1.3 Administration, uptake and mode of action of trypanocidal 
drugs
The main dmgs for the treatment of the first stage o f HAT are suramin and Pentamidine, 
which were introduced in 1922 and 1941 respectively. After the parasite has invaded the 
central nervous system (second stage o f HAT), only two drugs are effective, namely 
Melarsoprol introduced in 1949 and DFMO introduced in 1990.
1.3.1 Suramin
Suramin was first introduced for the treatment o f early stages o f HAT in 1922, and is 
especially effective for treating T. b. rhodensiense infections (Wang, 1995). It is also 
effective against T. b. gambiense, T. b. brucei, T. evansi and T, equiperdum (Hawking, 
1963). Suramin is usually administered to patients in five intravenous injections at a 
dosage o f 20 mg/kg body weight once every five to seven days.
The stmcture of Suramin is shown in Figure 1.3. It has been found to bind to albumin and 
low-density lipoprotein (LDL) in semm. Fairlamb & Bowman (1980) demonstrated the 
rapid uptake o f Suramin in the presence o f semm proteins in tiypanosomes. The uptake 
was 18 fold higher than could be explained by fluid endocytosis alone, therefore 
suggesting a high affinity transport system. Evidence for receptor-mediated endocytosis of 
host LDL in both bloodstream and procyclic forms was discovered by Coppens et ah 
(1988) who proposed that Suramin was entering trypanosomes bound to LDL through 
LDL- receptor mediated endocytosis (Coppens et al., 1988). In addition Suramin was 
found to inhibit LDL-binding and uptake by T. brucei in a concentration dependent 
manner, suggesting competition for the LDL-binding site on the LDL-receptor
11
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Figure 1.3; Structure of Suramin, Pentamidine and DFMO. Suramin (A) and 
Pentamidine (B) are used for treatment against early stage tiypanosomiasis. DFMO (C) is 
in use for the treatment of late stage trypanosomiasis.
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(Vansterkenburg et a l, 1993). However, Pal et aL (2002) recently demonstrated that while 
Suramin was transported by receptor-mediated endocytosis in T. brucei^ the LDL-mediated 
endocytosis was only indirectly involved in Suramin uptake. The specific route by which 
Suramin enters the trypanosomes has not yet been identified.
Suramin is an inhibitor of many different dehydrogenases and kinases from mammalian, 
bacterial and fungal sources. In T. brucei. Suramin was found to inhibit dihydro folate 
reductase and thymidine kinase as well as being a potent inhibitor o f many o f the 
glycolytic enzymes in T. brucei (hexokinase (HK), phosphoglucoisomerase (PGI), 
phosphofiaictokinase (PFK), triosephosphate isomerase (TIM), aldolase (ALDO), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), 
glycero-3-phosphate dehydrogenase (GPDH), and glycerol kinase (GK)) (Misset and 
Opperdoes, 1987). It was thus proposed tliat Suramin acted by blocking glycolysis in 
trypanosomes. This theory on the mechanism of antitrypanosomal action o f Suramin is 
contradicted by the fact that all these glycolytic enzymes are confined within single 
membrane bound microbody organelles, termed the glycosome. As it is unlikely that the 
glycosome will take up Suramin by passive diffusion or endocytosis due to its high 
negative charge, the nine glycolytic enzymes would be protected firom Suramin via 
compartraentalisation. However, the genes encoding these enzymes are located in the 
nucleus and the enzymes are synthesised on free ribosomes in the cytoplasm with 
subsequent import into the glycosome within three to five minutes without any proteolytic 
modification. One possible mode o f action o f Suramin could be that the inhibition of 
glycosomal proteins import leading to a gradual decrease of enzyme concentration in the 
glycosome and a slowing down o f energy metabolism (Wang, 1995).
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1.3.2 Pentamidine
The aromatic diamidine Pentamidine (1,5-bis (4’-aminidinophenory) pentane; Figure 1.3) 
introduced in 1937 has been used for decades in the treatment o f HAT, antimony-resistant 
leishmaniasis (Sereno et a l ,  2000). It is effective against the early stage o f T. b. gambiense 
infection and is given at a dose of 4 mg/kg body weight by 7 to 10 intramuscular injections 
daily or on alternative days. Pentamidine is the only drug that has been use for large scale 
prophylaxis (Dukes, 1984).
African trypanosomes accumulate Pentamidine to millimolar concentrations via a high 
affinity transport system which is energy dependent and competitively inhibited by other 
diamidines (Damper and Patton, 1976). The Pentamidine transporter was identified in 1995 
as the P2 adenosine/adenine transporter (Carter and Fairlamb, 1993). Two more 
Pentamidine transporters were recently described, a high-affinity pentamidine transporter 
(HAPTl) and a low affinity Pentamidine transporter (LAPTl) (de Koning, 2001).
The mechanism of Pentamidine antitrypanosomal action is unknown. Pentamidine has 
been shown to inhibit thymidylate synthetase, an enzyme present in various 
trypanosomatids, (Gutteridge, 1969) as well as S- adenosyl-L-methionine decarboxylase 
(Bittoni et a t, 1986), mitochondrial topoisomerase II (Shapiro, 1993), mitochondrial 
membrane potential (Vercesi and Docampo, 1992), dihydrofolate reductase (Waalkes and 
Maluku, 1976), thymidylate synthetase (Kaplan and Myers, 1977) and calcium transport 
(Benaim et a l,  1993). Given this range o f inhibitory activities, it is difficult to define a 
specific selective mode o f action.
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1.3.3 DFMO
DFMO (Figure 1.3) was primarily developed as an anti-tumour proliferation and 
modulation of cell differentiation drug but the clinical trials showed poor results. DFMO 
was first synthesised as a potential suicide inhibitor o f ornithine decarboxylase (ODC),
ODC is the key enzyme in the pathway leading to biosynthesis of polyamines: putrescine, 
spermidine, and spermine, which are essential for the proliferation o f prokaryotic as well 
as eukaryotic cells. DFMO depletes the polyamines putrescine and spermidine fiom T. 
bruceihoih in vitro and in vivo. Subsequently, the DFMO-treated trypanosomes are 
transformed to a non-dividing, short, stumpy form that is apparently incapable o f changing 
its VSG and is eventually killed by the host immune reaction (Bitonti et ah, 1986b).
DFMO is relatively ineffective against T. b. rhodensiense infections. Its inefficiency in 
treating T, b. rhodesiense infections is explained by the short half-life o f ODC and high 
expression levels of ODC in T. b. rhodesiense as compared to T. b. gambiense (Itens et al., 
1995; Itens et at., 1997).
The uptake o f DFMO in bloodstream forms o f T. b. gambiense and T. b. rhodesiense is 
thought to be a combination o f passive and mediated diffusion, depending on the 
extracellular concentration (Bitonti et al., 1986; de Koning, 2001). DFMO can be 
accumulated in tiypanosomes to millimolar levels (de Koning, 2001). DFMO is a 
remarkably safe drug but it requires to be administered intravenously at a large dose o f 400 
mg/kg body weight per day in four equal doses every 6 h for 14 days (Van Nieuwenliove et 
al, 1985).
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1.3.4 Arsenicals
The class o f melaminophenyl arsenical dmgs use for the treatment o f trypanosomiasis 
includes Melarsoprol, Cymelarsan, Trlmelarsan and Melarsen oxide (Figure 1.4).
Melarsoprol is the only arsenical dmg cuirently used for the treatment of HAT and was 
made available in 1949. Cymelarsan is licensed only as a veterinary dmg against 
trypanosomiasis in camels and the other two dmgs have not been licensed. Until 1990, 
Melarsoprol was the only dmg capable of treating late stage T. b. gambiense and T. b. 
rhodesiense infections. It is administered intravenously at a dose of 3.6 mg/kg body weight 
in three to four series of four injections separated by at least one week (WHO). A major 
problem with Melarsoprol is its toxic side effects. The encephalopathic syndrome, which is 
reported to occur in 2-10% of treated cases is fatal in 50-70% of these cases, constitutes the 
most important complication o f Melar*soprol treatment (Keiser and Burri, 2000).
In bloodstream forms o f T brucei, Melarsoprol is rapidly metabolized into Melarsen oxide 
(Keiser and Burri, 2000; Keiser et a l ,  2000). Melarsen oxide was shown to be the active 
metabolite against HAT. Water soluble melaminophenyl arsenicals such as Melarsen oxide 
are transported into tiypanosomes by the P2 adenosine/adenine transporter (Carter and 
Fairlamb, 1993; de Koning and Jarvis, 1999; de Koning, 2001). It is unknown whether the 
lipophilic Melarsoprol is also transported by the same mechanism (de Konmg, 2001). In 
procyclic forms however, Melarsoprol crosses the membrane by passive diffiision (Scott et 
a l, 1997). A summary o f transporters involved in the uptake of trypanocydal diugs 
discovered so fai' in bloodstream trypanosomes is given in Figure 1.5.
Melarsoprol leads to the rapid lysis of trypanosomes, but its mechanism of 
antitrypanosomal action is not well understood. It has been proposed that trivalent
16
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Figure 1.4: Structure of the melaminophenyl arsenical drugs. Cymelarsan (A) and 
Melarsoprol (B) dissociate primarily into Melarsen oxide (C).
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Figure 1.5; Transport of trypanocides in bloodstream forms of 71 brucei. Arsenical 
drugs (Melarsoprol, Cymelarsan, etc.) and diamidines share a common transporter: the P2 
transporter. Reproduced from de Koning (2001).
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arsenicals with two replaceable ligands have a high affinity for intracellular thiols such as 
trypanothione and dihydropoamide plus several enzymes including trypanothione 
reductase (Fairlamb et a l ,  1989), 6-phosphogluconate dehydrogenase (Hanaii et a l,  1996) 
and glycerol-3 phosphate dehydrogenase (Denise et a l,  1999). However, these inhibitory 
effects have not been directly linked to cell lysis. In vivo, Melarsoprol is quickly 
metabolised into Melarsen oxide, which was shown to be an active metabolite (Keiser et 
a l,  2000). Melarsen oxide was first believed to act by blocking glycolysis in trypanosomes 
through inhibition of the pyruvate kinase. However, later studies indicated that the lytic 
effect of Melarsen oxide is not the primary result of inhibiting pyruvate kinase 
(Cunningham et a l,  1994). Thus, while a number of enzyme activities have been shown to 
be inhibited by the arsenicals, the nature of the primary target of these inhibitors is still 
unclear. Whether the basis for their selective action is due to their rapid and specific uptake 
by the P2 transporter followed by inhibition o f a range of enzyme activities or is via some 
other mechanisms still need to be investigated. The rate of entry o f the drug into the CSF is 
related to the lipid solubility o f the unionised molecule. Melarsen oxide and Melarsoprol 
have high lipid solubility. At physiological pH of 7.4, only 0.2% of Melarsoprol is 
unionised, indicating that only a small amount of the drug is available to cross the lipid 
membrane.
1.4 Arsenica! resistance in T. brucei
1.4.1 Definition of drug resistance
Treatment failures with Melarsoprol were reported as early as 1986 (WHO). However, the 
rates o f treatment failure remained at low and constant levels o f 1 to 10% (WHO, 1986; 
Pepin and Milord, 1994). This situation has changed in recent years with reports o f much 
higher rates of treatment failure fi-om northern Uganda and northern Angola. Up to 25% of
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treated patients in Angola and 30% in Uganda were reportedly non-responsive to 
Melarsoprol therapy (Legros et al, 1999, Mato vu et al, 2001). Treatment failure can be 
defined as the “absence or insufficient effect of drug action after administration o f a 
normally effective dose”. It is usually observed as the presence o f trypanosomes in a 
sample from patients within one month of treatment completion or a complete lack of 
clinical response dur ing the course of treatment. Drug resistance, however, was defined in 
1963 by the WHO as the “ability o f a par asite strain to multiply or survive in the presence 
o f concentrations o f a drug that normally destroy parasites of the same species or prevent 
their multiplication. Such resistance may be relative (yielding to increased doses of the 
drug tolerated by the host) or complete (withstanding maximum doses tolerated by the 
host)”.
The difference between the two is fundamental as although it is true that diug-resistance 
will bring about drug failure, it is not necessarily true that drug failure is the result o f drug 
resistance since resistance is only one o f many factors affecting drug failure (Borst and 
Ouellette, 1995).
1.4.2 Biochemical and molecular basis of arsenical resistance in T. 
brucei
Cross-resistance between the diamidines such as Pentamidine and the melaminophenyl 
arsenicals has been reported in laboratory-induced drug resistant strains of T. brucei 
(Fairlamb et a l ,  1992). Cross-resistance between two different classes of drugs generally 
implies an alteration in either a common uptake/efflux mechanism or a common target (or 
both).
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Carter and Fairlamb were the first to demonstrate the transport o f Melarsen oxide via an 
adenosine transporter, later referred to as P2 ti'ansporter, into bloodstream forms of 
trypanosomes (Carter and Fairlamb, 1993). This provided the first basis for the search for 
the molecular mechanism of arsenical resistance in T. brucei. Since this first report, studies 
o f arsenical resistance in T, brucei have mainly centred on this transporter. The gene 
encoding the transporter, TbATl, was cloned in 1999 and a structure for the protein was 
proposed fiom the sequence (Maser et al., 1999). Sequencing of TbATl from a laboratoiy- 
derived arsenical resistant line of T. brucei demonstrated the presence often point 
mutations in the gene, six o f which conferred an amino acid substitutions in the protein 
sequence (Maser et a l, 1999). hi addition, clonmg of the TbATl gene in yeast also 
supported the involvement o f the P2 transporter in resistance to Melarsoprol. The strain of 
Saccharomyces cerevisiae used had no transporter for exogenous adenosine and was 
unable to use it as a purine source. These cells defective in purine biogenesis were 
transformed with TbATl gene and grown on agar containmg adenosine as sole purine 
source. The transformed yeasts were able to grow on adenosine as sole source o f purine. In 
addition, expression of the TbATl gene in yeast rendered the yeast sensitive to 
Melarsoprol. However, the expression of the mutated TbATl gene in yeast did not confer 
sensitivity to Melarsoprol, demonstrating that the mutated gene was not able to mediate the 
transport o f the drug in the cell (Maser et a l ,  1999).
Analysis of the P2 transporter by competitive uptake with adenosine revealed that the P2 
transporter also mediates the transport o f Berenil, Pentamidine, Propamidine and 
Stilbamine in addition to the arsenicals (Figure 1.5) (de Koning, 2001), explaining the 
cross-resistance observed between the diamidmes and melaminophenyl arsenical dmgs 
(Fairlamb et a l,  1992; Frommel and Balber, 1987). The P2 transporter was shown to be
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selective for adenine and adenosine with little afSnity for other purines, but it also 
mediated the transport of diverse structures such as Melarsoprol and Pentamidine (Carter et 
a l, 1995; de Koning and Jarvis, 1999). The paradox of the selectivity o f the P2 transporter 
was resolved with the determination o f its substrate recognition motif. The substrate 
recognition motif o f the P2 transporter was determined by assessing the inhibition of 
adenosine transport by a series of adenosine analogs (Figure 1.6) (de Koning and Jarvis, 
1999; de Koning, 2001). However, preliminaiy analysis of the P2 transporter in 
Melarsoprol resistant T. b. rhodesiense isolated from relapsed patients revealed that only 
50% of the isolates contained the mutated transporter (Mato vu et a l,  2001). In addition, a 
knockout o ï TbATl in T. brucei conferred only a three fold resistance to Melarsoprol, 
which is well below the level of resistance obtained in laboratory-induced lines (Matovu et 
a l, 2003). In addition, two laboratory-induced Cymelarsan resistant lines (247 and 386) 
exhibited the resistance phenotype in procyclic stages (Scott et a l ,  1996) for which P2 
transporter activity cannot be detected (Figure 1.7) (de Koning et a l,  2000). Consequently 
the resistance to Melarsoprol exhibited by these lines cannot be accounted for by mutations 
in the P2 transporter.
The observation that a considerable proportion o f wild type TbATl were found among 
relapsed patients, that only three fold resistance to Melarsoprol was observed in the TbATl 
knockout line and that procyclic forms can exhibit arsenical resistance strongly indicate 
that TbATl is not tlie only gene responsible for conferring arsenical resistance in T. brucei. 
A model whereby the loss of a single transporter could mediate cross-resistance to all 
diamidines and melaminophenyl arsenical drugs and high level arsenical resistance 
appears, in view of these findings, incomplete.
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Figure 1.6: Recognition motif for the P2 transporter. Reproduced from de Koning, 
2001 .
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Figure 1.7: Nucleotide and nucleoside transporter in T, brucei. Reproduced from de 
Koning, 2001.
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1.5 The study of mechanisms of drug resistance
From the preceding discussion it is clear that the field of drug resistance is far fiom fully 
understandood or defining the genes that determine dmg resistance in trypanosomes and 
therefore explaining the mechanisms by which resistance occurs, hi trypanosomes there are 
a range o f techniques that could be applied to investigate the mechanisms o f resistance and 
these are reviewed below.
1.5.1 Genetic tools
1.5.1.1 Classical genetic analysis
While T. brucei multiplies mainly by binary fission, a mating system exists and genetic 
exchange was clearly demonstrated by laboratory co-transmission studies (Sternberg and 
Tait, 1990). There is evidence for segregation o f alleles and recombination between loci 
(Turner et al, 1990). However, it appears that genetic exchange is non-obligatory and the 
frequency at which it occurs in natural population is still unknown (Sternberg et al., 1989). 
The genetic basis o f a phenotype can be determined by the analysis o f the progeny from a 
cross of parental stocks with different phenotype (drug sensitive/ resistant stocks). To 
determine the region o f the genome in which gene or genes associated with the particular 
phenotype is located, a genetic map must have been previously established. This genetic 
map, made using molecular markers, enables linkage analysis to be performed. The co­
segregation o f markers on the genetic map with the phenotype of the progeny of the cross 
determine the location, between two markers, o f the gene or genes of interest. The 
efficiency o f the linkage analysis depends on the resolution of the genetic map. In general 
linkage can be established within several hundr ed kilobases, which might contain several 
genes. Analysis using RNAi or gene knockout is then required to identify the specific gene.
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Genetic maps for chromosome I and II o f T. brucei are available (Hall et ah, 2003; El 
Sayed et al, 2003). A recent study has demonstrated the existence o f crossing over and the 
size of the recombination unit was calculated which suggested that at least one crossover 
will occur per chromosome at meiosis (Tait et ah, 2002). Crosses between naturally 
occurring variation in dmg resistance between parental stocks of 386/247, 386/927 and 
247/927 were produced (Hope et ah, 1999). The linkage analysis of the drug resistance 
phenotype in the progeny from the cross between 247/927 determined the location o f a 
single gene conferring resistance between two closely located markers on chromosome II 
(Dr S. Taylor, personal communication).
The main limiting factor in the study of inheritance patterns o f traits is the available 
phenotypic variation between parasite stocks. In addition, there are difficulties in obtaining 
and cloning large number of hybrid progeny, which determine statistical significance of 
segregation phenotypes.
1.5.1.2 Reverse genetic analysis
Two powerful reverse genetic tecliniques are available for the analysis o f gene function in 
T. brucei. Firstly the use o f gene knockouts based on homologuons recombination and 
secondly RNA interference (RNAi) which allows the knockdown of specific transcripts. 
These techniques are largely used when a specific gene is being studied and can be used to 
define whether the gene is essential or the loss leads to a specific phenotype. RNAi is 
currently being used on a large scale basis to knockdown every identified gene on 
chromosome I. These technique are particularly useful for confirming that an identified 
gene has a particular function.
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RNAi is the process by which gene-specific double stranded RNA (dsRNA) elicits 
degradation of mRNA. This phenomenon occuis post-transcriptionally, which makes it the 
strategy o f choice to down-regulate the expression of repeated genes. The first observation 
o f degradation of mRNA by gene-specific dsRNA in T. brucei was made in 1998 (Ngô et 
al., 1998). RNAi technology has become the method of choice to down-regulate gene 
expression in a variety of organisms. RNAi is particularly well suited for diploid organisms 
such as trypanosomes as transcripts hom  both alleles are down regulated. Placement of 
integrated RNAi constructs under control o f the let repressor system or the T7 promoter 
system provide a powerful method to probe gene function in trypanosomes. RNAi 
technology has been applied in T. brucei to study the fimction of gamma-glutamylcysteine 
synthetase (Huynh et al., 2003), surface protease GP63 (LaCount et al., 2003), gamma 
tubulin (McKean et al., 2003) and farnesyl phosphate synthase (Montalvetti et al., 2003). 
The RNAi technique is simple and efficient, but the induction of mRNA degradation by 
RNAi failed to provide a phenotype in 50% of the cases (Ullu et al., 2002). In addition, 
RNAi technology requires the pre-selection o f genes whose function are o f interest. In the 
case of the mechanism o f Cymelai'san resistance in trypanosomes the selection of genes is 
not obvious as the drug targets and the mode o f action o f the drug are still unknown.
1,5.2 Micro-array expression analysis
One approach to identifying the mechanisms o f drug resistance is by comparative analysis 
of gene expression between drug sensitive and resistant isolates. One of the hypothesis 
assumed in employing this technique is that a change in gene expression causes resistance.
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Micro-array expression analysis is based on the construction of ultra-high density DNA 
micro-arrays on glass microscope slides followed by hybridisation with fluorescently 
labelled cDNA and analysis using a con-focal laser scanner. The advantages of this 
technique are two-fold. Firstly, the micro-arrays allow the simultaneous interrogation of 
thousands of cDNA clones or oligonucleotides with mRNA from various resistant lines of 
parasites at once. Secondly, the use of fluorescently labelled probes and con-focal laser 
microscopy allows partial quantitative determination of the relative expression levels o f 
many genes in a single experiment by comparing different resistant lines (Cells et al.,
2000). A large amount o f data ar e generated by this approach and the analysis o f the data 
can be complex. Reproducibility can be quite low and so for statistical analysis micro­
arrays studies requires the experiment to be repeated several times. In addition, micro­
arrays study the expression o f mRNA level in an organism. One mRNA molecule can give 
rise to anything fiom one to a few dozen gene-products in higher eukaryotes depending 
upon the degree o f post-translational modification, cleavage events and the degree of 
differential exon splicing possible within exon-rich genes. Micro-airay teclmology has 
been applied to the study o f stage specific gene expression in T. brucei (DieM et ah, 2002) 
and T. cruzi (Minning et al., 2003).
1.5.3 Proteomic techniques
1.5.3.1 Definition
The term “proteome” first appeared in literature in July 1995 and refers to the “total 
protein complement o f a genome”. Wasinger et al. (1995) qualified this further by stating 
that “although ‘proteome’ refers to the total complement able to be encoded by a given 
genome, it is unlikely that: 1 - the totality o f this potential for protein expression will be 
realised at any given instant, and 2- the detection threshold of 2 dimensional gel 
electrophoresis (2DE) for low copy number molecules will enable all translated proteins to
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be visualised. Proteome analysis must depend upon experimental design and the need to 
examine several physiological states both in vitro and in v/vn.”
In general, the proteome represents the protein pattern o f an organism, a cell, an organelle, 
or even a body fluid determined quantitatively at a certain moment and under precisely 
defined conditions. Furthermore, the proteome reflects the cunent metabolic status of the 
corresponding cell (or organism) which is determined by manifold interactions of the 
different molecules that are currently still difficult to analyse and by a range of 
environmental parameters. Unlike the genome, the proteome is thus a highly dynamic 
system which is characteristically altered by changes in environmental conditions. 
Analysis of the total protein complement of a genome has only recently become possible 
due to improvements in the reproducibility o f separation technologies in association with 
immobilised pH gradients, the availability o f computer software for the construction of 
polypeptide maps and the comparison of gel separations by advanced image analysis and 
the sensitivity and applicability o f mass spectrometiy to the analysis o f proteins separated 
by two dimensional gel electrophoresis (2DE).
1.5.3.2 Applicability of proteomics study to trypanosomes
Analysis o f the complete sequences fi om chromosome I and II o f T. brucei provides some 
information about the structure and gene content of the chi omosomes. Both chi omosomes 
have a gene-rich core, a region containing a retro-transposon hotspot, VSGs adjacent to 
telomeres and may carry a bloodstream expression site with upstream 50 bp repeats (El- 
Sayed et al., 2003, Hall et al., 2003). Analysis o f these two cliromosomes revealed long 
arrays o f genes located on the same coding strand, each array separated by a strand switch 
region. This arrangement of the genes along the chromosomes is consistent with 
polycistronic transcription o f trypanosome genes (Tschudi and Ullu, 1988), whereby long
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mRNA transcripts o f  multiple genes are processed to individual mRNAs by trans-splicing 
of a 5’ spliced leader and addition of a poly-A tail (Matthews et a l, 1994). Analysis o f the 
strand switch regions revealed a lack of common sequence motifs that could represent 
specific promoters capable o f controlling gene transcription during the development of T. 
brucei. Only two promoters have been identified so fai- in the T. brucei genome. One 
controls the transcription of the VSG genes (Zomerdijk at a l,  1990) the other one controls 
the transcription o f the procyclin gene (Sherman et a l, 1991). With such a gene 
organisation, any control at the level o f  transcription initiation would imply that all genes 
belonging to the same unit aie regulated in the same way. This does not appear to he the 
case. Instead, control o f gene expression in T. brucei is most likely accomplished at the 
post-transcriptional level, by both regulating the levels o f mRNA and the levels and 
activities o f the expressed proteins (post-translational modifications). This view is 
supported by the study o f the regulation of cytochrome c protein hi T. brucei (Tom et al, 
1993). The bloodstream trypanosomes synthesise apocytochrome c protem at levels 
comparable to that o f  procyclic trypanosomes, but protein turnover prevents accumulation 
o f  cytochrome c protein in the bloodstream form. A similar observation applies to 
cytochrome c reductase.
The importance of protein-based analysis is its ability to study post-transcriptional control 
as well as post-translational modifications such as phosphorylation, glycosylation, 
acylation and méthylation. Proteins determine the biological phenotype o f an organism and 
proteins are the primaiy targets for most therapeutic agents. The advantages o f proteomic 
studies are that they give a global picmie o f the changes taking place, whereas previous 
drug resistance studies have concentrated on individual enzymes or protems and not on 
total response (Barett et a t, 2000). Techniques such as 2DE, quantitative computer image
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analysis and protem identification can be use to create a “reference map” of all detectable 
proteins. Such reference maps establish patterns o f normal gene expression in the organism 
and allow the examination o f some post-translational protein modifications which are 
functionally important for many proteins. In addition, comparative maps can be established 
by analyzing variants o f the wild type and so identify differences associated with a mutant 
or a different physiological condition. It is possible to screen proteins systematically fi'om 
reference maps to establish their identities (Wilkins et ai, 1996).
Very few proteomic studies have been performed on tiypanosomes. Three proteomic 
studies were performed in the 1980s on T. brucei using carrier ampholytes for isoelectric 
focussing in the first dimension. These were used to detect difference in VSG expression 
between cloned populations (Pearson et a/., 1981) or to detect differences in protein 
expression between subspecies (Anderson et al., 1985; Pearson and Jenni, 1989). The use 
o f carrier ampholytes meant that the reproducibility of the gels was difficult. In addition, 
no easy/fast methods were available to identify the differentially expressed proteins. The 
availability o f T. brucei genome sequences and of new technologies, for isoelectric 
focussing and identification of protein separated by 2DE using mass spectrometry 
methods, have removed most of the limitations o f the proteomic studies. Recently, a 
protocol was developed for the extraction and separation of proteins from T. brucei using 
IPG tecluiology (van Deursen et ah, 2003). It is expected that the new technologies will 
spark an increase in research activity concerned with the analysis o f the T. brucei 
proteome.
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1,6. Aim
The aim of this project is to use proteomics to understand the mechanisms of arsenical 
drug resistance in T. brucei parasites. This is a particularly important area, given that there 
are only four drugs available for the treatment of HAT, Further, resistance to Melarsoprol 
treatment, the drug of first choice for late stage trypanosomiasis, has been reported in many 
parts o f Africa. One mechanism by which drug resistance to Melarsoprol can be generated 
has been described and involves the alteration of the adenosine P2 transporter. However, 
there is preliminary evidence suggesting that other mechanisms are very likely to be 
involved.
Isogenic lines of parasites that are sensitive or resistant to Cymelarsan (a close analogue of 
Melarsoprol) have been described previously (Scott et al., 1996,1997). Comparison o f the 
proteins expressed by each o f these lines can be made by 2DE in order to identify specific 
polypeptide alterations associated with the resistant phenotype. The identity o f the proteins 
showing differences can then be determined using mass spectrometiy followed by the 
screening of gene sequence databases.
The specific objectives o f the project are:
■ To find the best solubilisation method for proteins firom trypanosomes to maximise 
sensitivity and reliability o f proteomic analysis
■ To construct a partial proteome map o f T. brucei
■ To identify changes in the polypeptide profile of T. brucei that are associated with 
arsenical resistance
■ To characterise the polyptetides associated with Cymelarsan resistance
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To conduct downstream analyses o f any proteins identified associated with drug 
resistance, with the aim o f developing testable hypothesis o f the mechanism of arsenical 
resistance in T. brucei
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Chapter II 
The development of proteomic techniques for T. brucei
2.1 Introduction
Two-dimensional gel electrophoresis (2DE) has come into widespread use since the 
publication, in the early seventies, o f methods combining isoelectric focussing (lEF) in the 
first dimension with sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) in the second dimension (Ames and Nikaido, 1976). In recent years, the technique 
o f 2DE was improved by the introduction o f immobilised pH gradients (IPG) for the 
separation o f proteins by lEF to replace the use of carrier ampholytes. Immobilised pH 
gradient gels are made by a small number o f defined chemicals (acrylamido buffers) which 
are covalently linked to a polyacrylamide matrix. These allow true steady-state focussing, 
which greatly increases the reproducibility o f the technique.
The protocol for 2DE using immobilised pH gradients is well developed and has recently 
been reviewed (Gorg et al, 2000). However, sample preparation, i.e. the extraction and 
solubilisation o f proteins in a solution compatible with 2DE, still requires to be determined 
empirically for each organism or cell fraction under study. For efficient protein 
solubilisation and high resolution on 2D gels it is necessary to acliieve complete disruption 
of molecular interactions, to obtain single polypeptides, and maintain tliis state throughout 
the separation process. Many protocols have been developed to achieve this aim. Table 2.1 
illustrates the evolution o f sample preparation methods for proteins fiom protozoan 
parasites by 2DE. It is now generally accepted that a combination o f chaotropes (i.e. urea 
and thiourea) and zwitterionic amphiphilic compounds (e.g. CHAPS or SB3-10)
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Sample lEF
method
Solubilisation method Detection Reference
T. brucei CA-IEF 0.25% NP-40, 2 mM PMSF lodinated
lectins
Pearson et al, 
1981
L.
tropica
CA-IEF 0.5% Triton XIOO, 20 iiiM EDTA, 2 
mM PMSF, 10 mM lodoacetamide
labelling Handman et al., 
1983
T, brucei CA-IEF 9 M urea, 5% 2-mercapto ethanol, 
4% Nonidet P-40, 2% ampholites
labelling Anderson et al., 
1985
T. brucei CA-IEF 9 M urea, 2% 2-mercaptoethanol, 
4% Nonidet P-40, 2% ampholites
^^ S labelling Pearson and Jenni, 
1989
T. gondii CA-IEF 9.8 M urea, 0.3% SDS, 3% NP 40, 
2% ampholites
^H labelling Achbarou et al., 
1991
T. gondii IPG-IEF 7 M urea, 2 M thiourea, 4% 
CHAPS, 1% DTT, 2% IPG buffer, 
0.05% Triton X-100
Coomassie 
blue staining
Dlugonska et al., 
2001; Nischik et 
al., 2001,
T. gondii IPG-IEF 8 M urea, 2% CHAPS, 22 mM DTT, 
0.5% IPG buffer.
Silver and 
Coomassie 
blue staining
Cohen et al, 2002
L
infantum
IPG-IEF 7 M urea, 2 M thiourea, 4% 
CHAPS, 40 mM Tris base, 1 mM 
PMSF
Silver staining El Fakhry et ai, 
2002
T, brucei IPG-IEF 9 M urea, 2 M thiourea, 2% 
CHAPS, 65 mM DTT, 0.5% IPG 
buffer, cocktail of protease 
inhibitors
Silver staining Van Deursen et al., 
2003
Table 2.1; Development of solubilisation methodology for 2DE analysis of parasitic 
proteins. Selected examples from the literature to illustrate the evolution o f solubilisation 
methodology and 2DE analysis. The use o f IPG-IEF was a significant milestone in the 
analysis o f parasitic proteins by 2DE.
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in the extraction buffer are essential to solubilise most proteins from a wide range of 
organisms (Rabilloudc^ a/., 1997, Rabilloud, 1998).
The limitations o f 2DE separation are well documented and is particularly evident for 
membrane proteins (Santoni et a l ,  2000a; Santoni et aL, 2000b). The major obstacle o f 
global 2DE separation remains the solubilisation of all the proteins fr om a sample with one 
sample preparation method. There ar e three reasons for this obstacle: fii'st, many 
hydrophobic proteins are not solubilised in the non-detergent isoelectric focusing sample 
buffer (Santoni et ah, 2000b), seeond, solubilised proteins are prone to precipitation at 
their isoelectric point (Adessi et al, 1997) and third, hydrophobic proteins transfer 
inefficiently to the second dimensional gel (Wilkins et ah, 1998). The limited dynamic 
range of protein visualisation is also an issue because membrane proteins aie typically 
lower in abundance compared with most soluble proteins. In addition, membrane proteins 
are heterogeneous due to the differential glycosylation o f extracellular domains, and this 
results in membrane proteins focusing over a wide pH range durmg lEF, producing streaks 
on the 2D gels.
Sample preparation is the first important step of every proteome analysis. In this chapter, a 
comparison o f three protocols for the extraction and solubilisation of proteins fr om T. 
brucei was made. The protocols were based on a recently published protocol for protein 
extraction fr om T. brucei (van Deuisen et a l , 2003), which uses a combination of 
chaotropes, zwitterionic amphiphilic compounds as well as a cocktail o f protease 
inhibitors. Protein extracts were separated on 2D gels and compared using three criteria: 
the resolution of the protein spots, the number o f protein spots extracted and separated 
which could be visualised and the distribution o f the protein spots at low/high molecular
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weight/pl. The reproducibility o f the extraction protocol and the solubilisation of 
membrane proteins using the selected protocol were also assessed.
2,2 Materials and Methods
2.2.1 Commonly used reagents
All equipment and reagents for lEF and SDS electrophoresis (IPGphor, Multiphor II 
horizontal electrophoresis unit, Hoefer Dalt multiple vertical electrophoresis unit, EPS 
3500 XL power supply, Multitemp II thermostatic circular, ImageMaster 2Delite V3.01 
softwai’e, Typhoon scanner 9400, Labscan, Immobiline DryStrip, IPG buffers, TEMED, 
CHAPS, DTT, APS, urea, glycine, Tris, ECL kit, Hybond-C nitrocellulose membrane and 
Protein Silver Staining Kit) were purchased from Amersham Bio sciences. TPCK, TLCK, 
EDTA, EGTA, Leupeptin, Pepstatin A, Coomassie Brilliant blue G250 and Gentamycin 
were purchased from Sigma. SDM 79 culture medium and foetal calf serum were 
purehased from GibeoBRL. The Sypro ruby stain and 30% polyacrylamide solutions were 
purchased from BioRad.
2.2.2 In vitro culture of procyclic trypanosomes
For this study, two laboratory stocks o f J! brucei (TREU 927 line and STIB 386 line) were 
used. The lines will be referred to as 927 and 386. The lines were grown in mice from a 
cryopreserved stabilate before being transformed into procyclic forms by transfer of 
parasites to Semi Defined Medium 79 (SDM79) with 3 M cis-asconitate (Brun and 
Schonenberger, 1981).
Procyelic trypanosomes were grown in suspension culture either in T-25 or T-75 culture 
flasks (Falcon, UK). The culture medium was SDM79 supplemented with 10% heat
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inactivated (56°C, 30 min) foetal calf serum and 0.2 mg Gentamycin, referred to as 
complete SDM79 (Brun and Schonenberger, 1979), Flasks were incubated at 25 °C. 
Trypanosomes from 5 ml o f procyclic culture at 5x10^ trypanosomes/ml were concentrated 
by centrifuging at 12,000 g for 3 min. Stabilates were made by re-suspending the 
trypanosomes in 0.5 ml o f complete SDM79 medium and 0.5 ml o f fr eezing medium (10% 
glycerol in heat inactivated foetal calf serum). The trypanosomes were then transferred into 
freezing vials and cooled in a cotton wool lined polyester container at ~70°C for 6 h prior to 
transfer to liquid nitrogen.
2.2.3 SDS-PAGE mini gels
SDS-PAGE mini gels were used to assess the quality and quantity o f proteins extracted 
using the solubilisation protocols. These were also used as the second dimension for 2DE 
analysis with 7 cm IPG strips.
Polyacrylamide gels (12%) were made in 0.375 M Tris-HCl pH 8.8, 1% (w/v) SDS, 1% 
(w/v) ammonium persulfate, 5 pi TEMED, using a 30% polyacrylamide mix.
For the quantification of protein extracts, a stacking gel was added onto the 12% gel. The 
stacking gel consisted of a 4% polyacrylamide gel in 0.125 M Tris-HCl, pH 6.8.
The samples were prepared as follows: 10 pi o f the protein extract was mixed with 10 pi of 
SDS loading buffer (62.5 mM Tris-HCl, pH 6.8,10% glycerol, 2% (w/v) SDS, 0.4 ml 2- 
mercaptoethanol, 0.05% (w/v) bromophenol blue), boiled for 1 min and then chilled on ice 
prior to loading onto the SDS-PAGE gel. Separation was performed by electrophoresis at 
110 V for 2 h. Gels stained with Coomassie Brilliant blue were incubated in a Coomassie 
staining solution (0.5 g Coomassie Brilliant blue G 250, 100 ml acetic acid, 125 ml iso­
propanol and ddHiO up to 1 L) overnight. Gels were destained by multiple washes in a 
solution o f 10% acetic acid/ 20% methanol until background staining had disappeared. Gel 
images were acquired using an AmershamPharmacia Biotech Labscan. Images o f the gels
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were acquired at 300 dots per inch using Labscan sv3.0 software on an Umax flatbed 
scanner with integrated transparency adapter.
2.2.4 Sample preparation for 2DE
A published protocol (PI, van Deursen et al., 2003) for the extraction and solubilisation of 
proteins from T. brucei was compared with two modified protocols (P2 and P3). Procyclic 
form trypanosomes (1x10^ tiypanosomes/ml) were concentrated by centrifuging for 8 min 
at 12,000 g in a centrifuge tube and the pellet was transferred into an Eppendorf tube. The 
pellet was washed twice in 500 pi o f phosphate buffered saline with 1% glucose (PSG), pH 
7.4. Trypanosomes were resuspended and lysed in 350 pi o f lysis/rehydration buffer 
consisting of 9 M urea, 2 M thiourea, 2% CHAPS, 65 mM DTT, 0.5% IPG buffer and a 
trace of bromophenol blue. 35 pi of protease inhibitor cocktail 1 (1 mM EDTA, 1 mM 
EGTA, 1 pg/ml Pepstatin A, 10 pg/ml Leupeptin, 100 pg/ml TPCK, 50 pg/ml TLCK) was 
added to the tiypanosomes suspension. The trypanosomes were then incubated for 1 h at 
room temperature with the tubes being vortexed every 10 min, and the resulting lysate was 
stored at -20°C (protocol PI) (van Deursen et al, 2003). In the first variant o f this protocol, 
a nuclease mixture (2,000 units/ml DNAase 1,750 units/ml RNAase A, 50 mM MgCb, 0.5 
M Tris pH 8.0) was added to the sample at the same time as the lysis/rehydration buffer. 
The tubes were incubated on iee for 10 min before the addition o f the protease inhibitor 
cocktail 1 and then incubated for 1 h at room temperature with voitexing every 10 min 
(protocol P2). In the second variant, a commercially available protease inhibitor cocktail 
(“COMPLETE” protease inhibitor coektail Tablets (Roche) complemented with 10 pi o f a 
EDTA, EGTA and PMSF solution) was used (protocol P3) instead of cocktail 1. This 
cocktail was added immediately to the lysis/rehydration buffer. No nucleases mixture was 
used in this protocol. The tubes were incubated 1 h at room temperature as described for
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Protocol PI Protocol P2 Protocol P3
Lysis/rehydration buffer 350 pi 350 pi 350 pi
Nucleases mixture 10 pi
Proteinase inhibitor cocktail 1 35 pi 35 pi
Proteinase inhibitor cocktail 2 35 pi
Table 2.2: Summary of protocol PI, P2 and P3. The volumes given in the table 
correspond to the volumes of reagents used for the extraction o f proteins from 1x10® 
trypanosomes to be loaded onto a 18 cm 2D gels.
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the other protocols. A summary o f the three protocols is given in Table 2.2. The lysates 
were centrifuged for 5 min at 12,000 g to remove insoluble material and stored at -20°C.
2.2.5 Two-dimensional gel electrophoresis
Extracts were run m the fir st dimension using IPG strips rehydrated with the supernatant of 
proteins extracted in lysis/rehydration buffer. The volume of the protein extract used for 
the rehydration of the strip depended on the size of the IPG strip: 125 pi was used on 7 cm 
IPG strips and 350 pi was used on 18 em IPG strips. Rehydratation and lEF were carried 
out on an IPGphore at 20°C and using 50 pA/strip. Rehydratation was performed at 30 V 
for 15 h, followed by lEF at 500 V for 500 V/h, 1,000 V for 1,000 V/li, 8,000 V for 3,975 
V/h by gradient and a final stage at 8,000 V/h for 4 h (7 cm gels) or 6 h (18 cm gels).
For the separation in the second dimension, the rehydrated IPG strip was first equilibrated 
for 15 min by rocking in a solution o f 50 mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol,
2% SDS and 100 mg o f DTT to reduce the proteins, and then for 15 min in a solution o f 50 
mM Tris-HCl pH 8.8, 6M urea, 30% glycerol, 2% SDS and 250 mg o f a-Iodoacetamide 
(Calbiochem) in order to alkalynate the cysteine residues. The IPG strip was then rinsed in 
electrophoresis buffer before being embedded on a 12% SDS-PAGE gel with 0.5% (w/v) 
agarose. Electrophoresis buffer consisted o f 25 mM Tris base, 192 mM glycine and 0.1% 
SDS. Gels were run at 110 V for 2 h (7 cm gels) or 110 V for 24 h (18 cm gels) at 15°C.
2.2.6 2D gel staining and image acquisition
The gels were stained either in Coomassie Brilliant blue, silver or Sypro ruby (BioRad). 
Staining with Coomassie Brilliant blue was performed as described for SDS-PAGE gels. 
Silver staming was performed using the Protein Silver Staining Kit and the automatic gel 
Stainers according to the manufacturer’s instructions. Sypro ruby staining of 2D gels was
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performed following the manufacturer’s (BioRad) instructions. The gels stained with 
Coomassie Brilliant blue or silver were imaged as described previously for SDS-PAGE 
mini gels. Images from gels stained with the fluorescent dye, Sypro ruby, were acquired 
using a Typhon scanner 9400 (variable mode imager) under the following settings: 
emission filter set at 560 LP green/purple, PMT= 550, laser = green 532, sensitivity 
normal, pixel size ~ 100 microns (Gorg et ah, 2000).
2.2.7 Western blotting
Following SDS-PAGE analysis, separated proteins were transferred to Hybond-C 
nitrocellulose membrane by electroblotting in transfer buffer (20 mM Tris, 225 mM 
Glycine) using a BioRad mini transblot cell, according to the manufacturer’s instructions. 
Proteins were transferred at 110 V for 1 h 30 min. The membrane was stained with 
Ponceau S to allow rapid assessment of protein transfer to the nitrocellulose membrane.
The nitrocellulose membrane was then placed in blocking solution consisting o f 5% 
skimmed milk in TBS-Tween (0.02 M Tris, 0.137 M NaCl pH 7.6, 0.05% Tween 20) and 
incubated overnight at 4°C. The nitrocellulose membrane was washed for 10 min in TBS- 
Tween at room temperature three times and then incubated for 1 h 30 min in the primary 
antibody diluted in TBS-Tween. Two primary antibodies raised against T. brucei Rab2 and 
Rabl 1 proteins were used (gift from Dr M. Field, Imperial College London). The 
membrane was washed for 10 min in TBS-Tween tluee times to remove any unbound 
antibody, secondary antibody, horseradish peroxidase-conjugated anti-rabbit IgG 
(Diagnostics Scotland, 1:1,000 dilution) in TBS-Tween, was added and incubated for 1 h 
30 nun at room temperature. The membrane was washed for 10 min in TBS-Tween three 
times. The bound conjugated antibody was detected using an ECL kit and incubation for 1 
min. The surplus solution was drained fr om the membrane wliich was then exposed to the 
autoradiographic films from 1 to 10 min as required (Kaufinann et al., 2001).
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Autoradiographs were developed using a film processor (X-Ograph imaging system 
compact X4) according to the manufacturer’s instructions.
2.3 Results
2.3.1 Assessment of the three sample preparation protocols
The three sample preparation protoeols developed for the extraction and solubilisation of 
proteins from T. brucei were compared using 1x10^ procyclic forms trypanosomes o f stock 
927. The concentration o f protein extracted using each protocol could not be assessed with 
either a Bradford technique (e.g. Coomassie Plus Protein Assay from Pierce) or an assay 
based on the biuret reaction (e.g. BCA Protein Assay from Pierce) because of the presence 
o f high concentrations o f urea, thiourea and DTT reagents in the lysis/rehydration buffer 
(data not shown). Instead, 12% SDS-PAGE mini gels were run to assess the relative 
concentration and quality of protein extracted (Figure 2.1). Limited differences were 
observed between the proteins extracts visualised on the SDS-PAGE gel, but protocol P3 
gave a higher number of protein bands with an especially good representation o f those at 
high molecular weights.
In order to further assess the quality o f the proteins extracted using the tliree protocols, the 
extracts were separated on 18 cm pH 3-10 non-linear (nl) IPG strips in the first dimension 
followed by 12% polyacrylamide gels in the second dimension. The gels were stained with 
silver, scanned and analysed using the ImageMaster 2DEHte software (Figure 2.2A). Only 
303 protein spots were detected on the 2D gel run with protein extracted using protocol PL 
The protein spots were concentrated mainly between pH 4 and 7 and very few were 
detected at more basic pH. Detection of spots using ImageMaster 2DElite software on this
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Figure 2.1: SDS-PAGE analysis of proteins extracted using protocols PI, P2 and P3.
Proteins from 1x10* procyclic trypanosomes were extracted. The extracts were run on a 
17% SDS-PAGE gel to assess the quantity and quality o f the extracts. The gel was stained 
with Coomassie Brilliant blue. Lane 1 : broad range molecular weight marker (catalogue 
number C3437, Sigma).
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P3: 440 protein spots
Figure 2.2: 2DE separation of proteins extracted using protocol PI, P2 and P3.
Proteins were extracted from 1x10* trypanosomes, separated on broad pH lEF (pH 3-lOnL) 
2D gels and silver stained. The gels were analysed using ImageMaster 2DElite software to 
determine the number o f protein spots separated.
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gel was difficult because of the poor resolution of high molecular weight spots. 468 and 
440 protein spots were detected on silver stained 2D gels of proteins extracted using 
protocols P2 and P3 respectively (Figure 2.2B and C). The resolution on these gels was 
much higher than for protocol PI. A good representation o f low and high molecular 
weight protein spots as well as protein spots located at acidic and basic pH was observed 
on these 2D gels. The 2D pattern o f proteins extracted using protocol P3 showed horizontal 
streaking on the gel in the area o f high molecular weight proteins. This prevented the 
complete separ ation of the protein spots located at this region o f the gel. No streaking was 
observed on 2D gel run with proteins extracted using protocol P2.
Based on theses results, protocol P2, combining the lysis/rehydiation buffer with nucleases 
and protease inhibitors, was the most efficient sample preparation for 2DE analysis o f T. 
brucei proteins. For all subsequent analysis, protocol P2 was chosen since the greater 
number of spots were obtained and were separated with the highest resolution using this 
sample preparation protocol.
2.3.2 Assessment of the reproducibility of protocol P2
Three independent extractions were undertaken using protocol F2 on different days from 
different cultures of T. brucei 927. The samples were sepaiated by 2DE (pH 4-7) on 18 cm 
gels. The gels were silver stained and analysed (Figure 2.3). The 2D pattern on the gels 
was highly reproducible. The intensity o f staining of spots also seemed to vary very little 
between the different extractions.
Proteins from tlri ee different concentrations o f trypanosomes (1x10^, 1x10* and 1x10^) 
were extracted using protocol P2 and separated by 2DE (pH 3-lOnl) to assess the optimal
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Figure 2.3: 2DE separation of three independent protein extracts using protocol P2.
The reproducibility o f the sample preparation using protocol P2 was assessed by running 
three independent protein extracts on pH 4-7 2D gels.
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protein concentration for running over 18 cm 2D gels. The gels were silver stained and 
analysed with the 2DElite software (data not shown). At a concentration o f 1x10^ 
trypanosomes (about 4 mg of proteins) horizontal streaking due to protein precipitation 
was observed, preventing the resolution of the spots. The highest number of protein spots 
with the best resolution were obtained from extracting proteins from 1x10* tiypanosomes, 
corresponding to about 0.7 mg of proteins, and this concentration was loaded onto gels to 
be silver stained for the rest o f the project.
2.3.3 Comparison of staining techniques for the detection of proteins
One of the major limitations o f the 2DE technique is the visualisation of the proteins once 
they have been separated on 2D gels. Unlike genomics, proteomics has no equivalent of 
amplifieation by PCR and thus sensitivity o f the staining technique is a critical issue.
Three protein stains, Coomassie Brilliant blue, silver and Sypro ruby, were compared for 
their sensitivity in detecting proteins separated by 2DE.
Protems were extracted from procyclic trypanosomes using protocol P2, separated on three 
18 cm 2D gels, pH 4-7 and the 2D gels were stained with either Coomassie Brilliant blue, 
silver or Sypro ruby (Figure 2.4). Image analysis o f these gels enabled the detection o f 909 
protein spots on the silver stained gel, 605 protein spots on the Sypro ruby stained gel but 
only 203 protein spots on the Coomassie Brilliant blue stained gel. Silver staining was the 
most sensitive o f the three stains used in this experiment. The developing of the silver 
stained gels, using the automatic gel stainer, gave inconsistent results (data not shown) 
possibly due to variation in water temperature.
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A)
Coomassie: 203 protein spots
B)
Silver: 909 protein spots
Sypro ruby: 605 protein spots
Figure 2.4: A comparison of protein stains. Solubilised proteins from procyclic 
trypanosomes (1x10*) extracted using protocol P2 were loaded onto pH 4-7 gels. The gel 
images were analysed using the ImageMaster 2DElite software.
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2.3.4 Assessment of the extraction of a membrane proteins using 
protocol P2
Membrane proteins are among the most difficult proteins to solubilise during sample 
preparation. This characteristic may exclude membrane proteins from the lEF step of 2D 
gels. Western blot analysis was used to assess the solubilisation and separation of two 
known T. brucei membrane proteins, Rab2 and Rabl 1, (Field et al., 1999, Pal et al., 2003) 
using protocol P2 and their separation by both one and two dimensional gel 
electrophoresis.
Proteins were separated on one dimensional SDS-PAGE gels and Western blotted using 
antibodies against the Rab2 and Rabl 1 membrane proteins of T. brucei. In addition, 
proteins were extracted directly from cells by boiling in SDS-PAGE loading buffer. This 
highly denatur ing envir onment should extract the membrane proteins, and so this extract 
was used as a positive control. These extracts were rim in parallel on SDS-PAGE gels. 
Coomassie Brilliant blue staining o f the gel showed the increased number of protein 
extracted by boiling the trypanosome pellet in SDS loading buffer as compared with 
protocol P2 (Figure 2.5). More specifically, high molecular weight proteins were under 
represented in the protein extracts fr om protocol P2.
The Rab2 protein was extracted from procyclic trypanosomes by both extraction 
techniques as shown by Western blot analysis (Figure 2.6A). Western blot analysis with 
antibodies against the T. brucei Rabl 1 protein was also performed in a similar experiment 
(Figure 2.6B). No pre-immune serum was available as a control for either antiserum but 
the absence of binding with anti Rabl 1 allowed the results to be used as a negative control 
for Rab2.
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Figure 2.5: SDS-PAGE gel of protein extracted using protocol P2. Coomassie Brilliant 
blue stained SDS-PAGE gel o f protein extracted from line 386. Proteins were extracted by 
dissolving 1x10* trypanosomes in SDS loading buffer (lane 2) or using protocol P2 
developed for 2DE analysis (lane 3 and 4).
A) B) C)
386 386
pH 3 pH 10
Figure 2.6: Western blot analysis of Rab2 and R abll extracted from T, brucei and 
separated by SDS-PAGE gel and 2DE. Proteins were extracted from procyclic forms by 
either boiling the trypanosome pellet in SDS loading buffer (lane 1) or using protocol P2 
(lane 2) developed for 2DE sample preparation. Western blot analysis was performed using 
affinity-purified rabbit TbRab2 antiserum (A) and TbRabl 1 antiserum (B) (gift from Dr 
M. Field, Imperial College London). Whole cell extract from procyclic T. brucei 386 was 
separated by 2DE on a 7 cm pH 3-lOnl strip. Western blot analysis was performed using 
affinity-purified rabbit TbRab2 antiserum (C).
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To determine whether the Rab2 protein could be detected on a 2D gel, a 7 cm 2D gel (pH 
3-1 Onl) was run with protein extracted using protocol P2 and analysed by Western blot 
(Figure 2.6C). The protein spots detected with the anti-Rab2 antibody were resolved as a 
horizontal streak, from which three protein spots located at similar molecular weight and 
slightly different pi could be detected within the streak (Figure 2.6C). This demonstrated 
that the Rab2 protein entered the IPG strip during the lEF separation step, were partially 
separated by lEF and transferred in the SDS-PAGE gel.
These results would suggest that a combination of chaotropes, zwitterionic amphiphilic 
compounds and DTT in the sample preparation buffer enables the extraction o f at least 
some membrane protems and their separation by 2DE.
2.4 Discussion
The “ideal” sample preparation would requir e extracting all the protein components, 
including hydrophobic membrane proteins, proteins with extreme pi a well as low copy 
number proteins in the presence o f the most abundant proteins. Disruption o f hydrogen 
bonds by chaotropes, prevention of hydrophobic interactions by surfactants and destruction 
o f intramolecular and intermolecular disulfide bonds by reducing agents are essential in 
order to obtain a high level of protein extraction and therefore the detection of a maximum 
number o f protein spots by 2DE and to avoid the presence o f multiple proteins per spot 
(Rabilloud, 1998; Mo Hoy, 2000; Lanne et al., 2001). Inclusion o f a cocktail o f proteinase 
inhibitors will minimise proteolytic activity and so minimise the generation o f multiple 
different derivatives of each protein.
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To achieve this aim, protocols have been developed which include the use o f a 
combination o f urea and thiourea (chaotropes) with CHAPS (surfactant), DTT (reducing 
agent) and a cocktail o f protease inhibitors. The addition o f nucleases to the 
lysis/rehydration solution caused an increase in the number o f protein spots and a higher 
resolution of these spots on 2D gels.
The sample preparation protocol needs to be as simple as possible in order to minimise 
sample variability. In the P2 protocol developed here, all the reagents were added to the 
trypanosome pellet in one step and the lysis occurred at room temperature. This gave very 
high reproducibility o f 2D patterns from independent extractions.
Global protein expression studies using silver stained pH 4-7 gels demonstrated a variation 
in the number o f resolved protein spots from 630 spots (Cohen et al., 2002) to about 1000 
spots (van Deursen et al., 2003). Using the P2 protocol developed in this study 909 protein 
spots could be detected by silver staining o f pH 4-7 gels., which ranks the P2 
solubilisation protocol in the higher range o f the protocols used for global expression 
profiling.
The silver stain was more sensitive for protein detection on 2D gels than either Coomassie 
Brilliant blue or Sypro ruby. However, silver staining has several drawbacks for 2DE 
analysis such as a poor reproducibility, a limited dynamic range and the fact that certain 
proteins stain poorly, negatively or not at all (Tauber et al., 2001). In addition, low 
detection limits often occur in mass spectrometry because the stain modifies cysteine 
residues and the glutaraldehyde and formaldehyde used in the procedure alkylate protein 
amino groups (Patton, 2000). The fluorescent stain, Sypro ruby, was slightly less sensitive
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(about 66% of the protein spots detected by silver were detected by Sypro ruby), but was 
more reproducible and easier to perform. The detection limit of the Sypro ruby dye is in 
the range of 1-2 ng of protein per spot, and the linear range is over tliree orders of 
magnitude (Gorg et a l, 2000). Consequently Sypro ruby and Coomassie Brilliant blue 
were the preferred detection techniques for proteomic analysis o f 71 brucei. Sypro ruby 
being a fluorescent stain rendered the excision o f the protein spots of interest from the 2D 
gels difficult and requires special equipment such as the Amersham Ettan robotic 
workstation, which was not available at the beginning of this study. Consequently, 
Coomassie Brilliant Blue staining was used at first to detect highly abundant differentially 
expressed proteins and Sypro ruby was used in the second pass to determine differentially 
expressed low abundance proteins.
Two antibodies against Rab proteins were used on Western blot analysis to assess the 
extraction o f membrane proteins using protocol P2 and the of these proteins separation by 
2DE. Rab proteins are small GTPases involved m the endocytosis and exocytosis transport 
in trypanosomes. They control the direction and timing o f vesicle fusion dur ing 
intracellular trafficking between membraneous compartments. Rab proteins are not 
transmembrane proteins, instead they are peripheral proteins thought to be embedded in the 
membrane through their isoprene moieties. Rab2 is restricted to endoplasmic reticulum 
(ER) exit sites and ER-Golgi intermediate compartments (Field et a l,  1999) while Rabl 1 
is located in the endosomal system and co-localises with internalised anti-VSG antibody 
and Transferrin (Pal et a l, 2003). The Rab2 protein was shown to be extracted by protocol 
P2 and to separate by 2DE. No detection o f Rabl 1 protein could be obtained in either the 
sample extracted by protocol P2 or the sample obtained by boiling the trypanosome pellet 
in SDS buffer. Rab2 is known to be expressed at similar levels in procyclic and
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bloodstream forms of T, brucei whereas the Rabl 1 protein is strongly up regulated in 
bloodstream trypanosomes (Field and Field, 1997; Pal et ah, 2003). As the samples used in 
this study were extracted from procyclic trypanosomes, the level o f Rabl 1 proteins might 
have been too low to be detected. This experiment was performed to assess the extraction 
o f membrane proteins by the solubilisation protocol developed. As Rab proteins are 
peripheral protems, it is possible that the Rab2 protein detected in the 2DE extract was due 
to the detachment o f the Rab protein from its isoprene moiety. Transmembrane proteins are 
the most diffrcult membrane protems to solubilise as they contain hydrophobic regions that 
enable part of the protein to reside within the membrane. Extraction o f transmembrane 
protein from T. brucei could be performed using anti-cystein-rich transmembrane protein 
(anti-CRAM) antibodies (Liu et al., 2000). CRAM protein is located at the flagellar pocket 
and is involved in the endocytosis pathways and has been shown to be expressed in 
procyclic forms o f trypanosomes (Liu et a l, 2000). As such this protein would be a good 
test to determine the extraction of transmembrane proteins by protocol P2.
The main aim o f the work described in this chapter was to develop a simple, complete and 
reproducible method for sample preparation fr om T. brucei. This was achieved by 
comparing the proteins extracted using three different protocols followed by analysis on 
SDS-PAGE gels and 2D gels. Sample preparation P2 was shown to be simple, 
reproducible and robust, and it enabled the extraction of at least some membrane proteins, 
so that 2D gels o f T. brucei proteins can now be run reproducibly. The protein spots of 
interest can then be analysed by mass spectrometiy techniques to generate information 
about the protein spots. The mass spectrometry data can then be used for identification of 
the protein spot as described in the next chapter.
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Chapter III 
Assessment of algorithms for protein identification from 
peptide mass fingerprint data
3.1 Introduction
111 the previous chapter a simple, efficient and reproducible sample preparation method was 
developed for 2DE analysis o f protein extracted from procyclic forms o f T. brucei. The 
next step, after separation of protems by 2DE, is the identification o f the proteins o f 
interest by mass spectrometry (MS).
Various mass spectrometry techniques are available (peptide mass fingerprint, peptide 
sequence tags) for the identification of protein spots from 2D gels. The simplest and fastest 
method is peptide mass fingerprinting (PME) which can be powerful when combined with 
a protein sequence database. A peptide mass fmgerprint consists o f the mass of each 
peptide generated from digestion o f a protein with a specific protease as measured by mass 
spectrometry. A peptide mass fingerprint provides no inherent sequence information. The 
commonly used enzyme for digestion of proteins is trypsin which specifically cleaves the 
peptide bond at the C-terminus o f arginine and lysine residues, except if they are followed 
by a proline. Peptide mass fingerprints are generated by Matrix-Assisted-Laser- 
Desorption-Ionsation Time-Of-Flight (MALDI-TOF) mass spectrometry. The use of 
peptide mass fingerprints generated from mass spectrometry for protein identification was 
first demonstrated in 1993 for cytochrome c from dog and pigeon, a GTP-binding protein 
from humans, an uteroferrin from pig, the human sex steroid binding protein and a 
thermostable DNA polymerase (Yates et a l, 1993).
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Search engines have been developed to enable the rapid searches o f protein and nucleotide 
sequence databases with PMF data. Three common steps are involved for all search 
engines: firstly, each protein in the database is digested in-silico based on the specificity o f 
the enzyme and the masses o f the resulting peptides are calculated enabling the 
construction o f a theoretical peptide mass fingerprint; secondly, the experimentally 
determined peptide mass fingerprint is compared with the theoretical peptide mass 
fingerprint and a score is calculated which reflects the accuracy of the match between the 
experimental and theoretical peptide masses; thirdly, the protein sequences in the database 
are sorted according to their score and the protein sequence with the best score is selected 
(Fenyo, 2000).
All search engines developed for protein identification by PMF are based purely on a 
statistical approach. With the increased use o f proteomic analysis, several types of search 
engine for protein identification by PMF have been developed and made available on the 
Internet (Table 3.1). All aie based on the same principle: the comparison of a peptide mass 
fingerprint generated fr om a protein with the theoretical peptide mass fingerprint of all 
available proteins in a database (Fenyo, 2000), Each new generation o f search engine has 
been improved by increasing the sensitivity and specificity o f the protein identification.
The sensitivity o f a search engine can be defined as its ability to detect a match in the 
database, whereas its specificity is the ability to distinguish random Ifom real matches. The 
main improvement made to these search engines in recent years has been the addition o f 
algorithms for evaluating the search results. The most important aspect of the search 
algorithm is the need to distinguish a correct identification Ifom a random match: i.e. 
specificity.
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Name Internet location
PepSea http://pepsea.protana.com/PA_PepSeaForm.html
Peptldent/Multildent http://www.expasy.ch/tools/peptident.html
MS-Fit http://prospector.ncsf.edU/ucsfhtml3.2/msfit.htm
ProFound http://www.proteometrics.com/prowl-cgi/ProFound.exe
MASCOT® http://www.matrixscience.com/cgi/searchform.pl?SEARCH=PMF
Table 3.1: List of search engine available for protein identification from peptide mass 
fingerprint data.
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The only comparison of the various algorithms for the identification of protein using PMF 
data found in the literature was performed in-silico, using theoretical protein sequences 
from NCBInr cleaved using trypsin cleavage rules to obtain a random peptide 
monoisotopic mass pool (Tang et al., 2000). This study was performed on three search 
engines (MS-Fit, ProFound and MASCOT®) and demonstrated a wide variation between 
the sensitivity and specificity o f the search engines. This comparison does not appear to 
have been performed on real proteins separated by 2DE, digested with tiypsin and analysed 
by MS.
In this study, 126 peptide mass fingerprints, generated by MALDI-TOF MS from T. brucei 
proteins separated by 2DE, were used to evaluate the specificity o f three publicly available 
search engines. The MS-Fit, MASCOT® and ProFound sear ch engines were used to search 
the National Centre for Biotechnology Information protein database (NCBIni). The 
evaluation of the sensitivity and specificity o f the three search engines for the identification 
o f proteins from T. brucei was performed by comparing the results obtained for each 
peptide mass fingerprint.
3.2 Materials and Methods
3.2.1 Commonly used reagents
Ammonium bicarbonate, TFA, CHCA and acetonitrile were purchased from Sigma. 
Tiypsin was purchased from Promega. The ZipTip^^ pipette tips were purchased from 
Millpore.
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3.2.2 Protein extraction, 2DE and staining
Proteins were extracted firom 2x10* procyclic trypanosomes from line 927 according to 
protocol P2 developed in chapter 2. The proteins were separated by 2DE and stained using 
Coomassie Brilliant blue followmg the protocols described in chapter 2.
3.2.3 In-gel trypsin digestion and mass spectrometry
Gel pieces were excised from the gel using a scalpel and transferred into an Eppendorf 
tube. The gel pieces were washed for 1 h 30 min in 100 mM ammonium bicarbonate, 1 h 
30 min in 50% acetonitrile/100 mM ammonium bicarbonate, then 10 min in 100% 
acetonitrile and then dried in a vacuum centrifuge. The gel pieces were rehydrated with 0.2 
jLig o f trypsin in 25 mM ammonium bicarbonate for 15 min. In-gel digestion was carried 
out overnight at 37°C, on a horizontal shaker at 1,000 g (Heilman et aL, 1994).
The resulting peptides were desalted and concentrated using ZipTip™ pipette tips 
containing Cig reverse phase media. The samples were acidified by addition o f 3 pi of 3% 
trifluoroacetic acid (TFA) prior to desalting. The ZipTip^'^ was equilibrated in 50% 
acetonitrile by aspirating 10 pi mto the tip twice and then washing twice with 10 pi of
0.1% TFA. Peptides were then bound to the reverse phase and washed twice with 0.1% 
TFA. Peptides were eluted in 2 pi o f 50% acetonitrile/ 0.1% TFA (Erdjument-Bromage et 
aL, 1998, Lamer and Jungblut, 2001).
The concentrated desalted sample (0.5 pi) was mixed with 0.5 pi o f matrix solution (10 
mg/ml a-cyano-4-hydroxycinamic acid (CHCA) in 50% acetonitrile/ 0.1% TFA), spotted 
onto a stainless steel plated MALDI sample stage, and allowed to air-dry for 30 min. 
Spectra were acquired using the Perspective Biosystems Voyager-DE instrument in
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reflector/delayed extraction mode. Peptides are co-crystallised with the matrix, a small 
weakly acidic molecule, which absorbs the energy from the laser and emits energy as heat. 
This results in the desorption o f samples which are then accelerated into the vacuum. Since 
all ions are accelerated from a fixed point with the same potential, they will drift according 
to their mass to charge ratio. Calibration was achieved usmg the porcine trypsin auto­
digestion peptides at 842.510 and 2211.1046 Da [M+H]" .^ Composite spectra consisting of 
200 laser shots were acquired for each protein spot.
3.2.4 Protein identification search engines
3.2.4.1 First generation algorithm: MOWSE
The first generation o f algorithms developed for the use o f PMF for protein identification 
were based on the simplest and most obvious scoring method, which is to count the 
number o f measured peptide masses that correspond to calculated peptide masses in the 
theoretical peptide mass fingerprint of each protein in the database (Pappin et al., 1993). 
This is referred to as the MOleculai’ Weight SEarch (MOWSE) score. The greater the 
number of experimental peptides matching the theoretical data, the higher the likelihood of 
the protein in the database being the protein excised fr om the gel. This technique was 
shown to work well for high-quality experimental data. However, it has the disadvantage 
that it usually gives higher scores to larger proteins as these have a larger number of 
proteolytic peptides and so the probability o f random matching is higher. This is referred to 
as the protein size effect.
3.2.4.2 Second generation algorithm: the MS-Fit search engine
The MOWSE score implemented in the MS-Fit search engine
f http : //pro spector.ucsf edu/ucsfhtml4.0/msfit. html is based on the simple scoring method 
described above. However, the MOWSE score has been improved to compensate for the
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protein size effect and also to take into account the relative abundance of the peptides in 
the database when calculating the score, that is, the probability o f getting a random match 
to a larger peptide is lower and therefore a match will contribute to a liigher degree to the 
score (Fenyo, 2000). From the literature, MS-Fit is the search engine most often employed 
for protein identification using PMF data, however, the scoring system employed by MS- 
Fit is un-reliable due to a poor scoring system and so many authors have developed their 
own criteria. The criteria selected for this study for the unambiguous identification of T. 
brucei protein spots using the MS-Fit search engine were as follows:
a) At least five peptides from the measured peptide mass fingerprint must match those 
o f the theoretical peptide mass fingerprint o f the protein in the database
b) The size o f the peptides masses matching the theoretical peptide mass fingerprint 
should cover at least 15% of the protein
c) The accuracy o f the matching peptides should be equal to or less than 50 ppm 
(differences between the measured peptide and the theoretical peptide should be 
lower than 50 ppm) (Mami et ah, 2001).
These three criteria were applied to the MS-Fit search results and used as an alternative to 
the MS-Fit scoring system to determine protein identification. They were considered to 
provide high stringency thresholds limits for unambiguous protein identification.
3.2.4 3 Third generation algorithms: the MASCOT® and the ProFound search 
engines
The MASCOT® search engine
The MASCOT® search engine (http://www.matrixscience.com) is based on a modified 
MOWSE algorithm using a probability based scoring system. The probability that the 
observed match between the experimental data and a protein sequence is random is
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calculated for each protein sequence in the database. The proteins are classified with 
increasing probability of being a random match to the experimental data. In addition, the 
probability that a match would be significant is calculated by the search engine. This 
probability is based on the size o f the database and the firequency o f each peptide mass in 
the database. The MASCOT® search engine guidelines state that if the probability based 
score is higher than the database’s probability (p) then the match is significant within 95% 
confidence limits. The scores are expressed as -~10*log(P), where P is the probability that 
the observed match is a random event (Perkins et aL, 1999). The results are displayed as a 
histogram showing the distribution o f the scores and the 95% confidence limit (p).
The ProFound search engine
The ProFound (http://129.85.19.192/profound_bin/WebProFound.exe) search engine also 
contains a probability based scoring system. The probability o f the match being the best 
match is calculated based on Bayesian theory (Tang et aL, 2000). This probability takes 
into account available information about each individual protein sequence in the database 
(e.g. molecular weight, pi) and allows for the incorporation o f additional experimental 
information (e.g. amino acid composition or sequence information). In addition, empiiical 
information about patterns observed for the distribution of proteolytic peptides along the 
protein sequence is included in the algorithm (Tang et aL, 2000).
Database searches by the ProFound search engine can be divided into four steps:
1) assignment o f mono-isotopic masses to the raw data
2) peptide mass search against the database
3) Bayesian probability calculation (P value)
4) significance testing o f the results (Z score)
Bayesian probability increases with increasing number o f peptide matches, increasing mass 
accuracy and decreasing number o f digested fragments. The Bayesian probability gives a
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measure of confidence that the protein selected by the algorithm fi*om the database is the 
sample protein (Zang et aL, 1995).
The ProFound search engine also incorporates an algorithm that estimates the significance 
of the match (Z score) for each candidate protein. Significance testing is achieved through 
calculation o f a score frequency function for random matches. This is derived fr om 
statistical analysis o f the database being searched using random selections o f peptide 
masses from different proteins that are then grouped as synthetic proteins and used in a 
peptide mass search of the database. Therefore the Z score gives an indication o f how 
significantly different the identified protein is compared to a random mass match in the 
database (Ericksson et al., 2000). A Z score >1.65 indicates that the candidate protein in 
the database is unlikely (within 95% confidence) to be a random match (Zang et aL, 2000). 
Based on the properties of this search engine, the protein with the highest P value and Z 
score is identified as the most likely candidate protein.
3.3 Results
Peptide mass fingerprints of T. brucei proteins sepaiated by 2DE were generated by 
MALDI-TOF MS. These were analysed using three seai'ch engines: MS-Fit 
(ProteinProspector), MASCOT® (MatrixScience) and ProFound (Rockefeller). The three 
search engines were used to compare experimental peptide mass fingerprints against 
theoretical peptide mass fingerprints generated from all available protein sequences in the 
NCBInr database. Search parameters were selected to accommodate the thi'ee search 
engines and the same parameters were used throughout the searches (Table 3.2). The data 
entry form for each search engine were very similar. The entry form o f the MASCOT® 
search engine is given as an example (Figure 3.1). Note that all search engines for protein
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Parameter Selected option
Database NCBInr
Enzyme Trypsin
Protein mass range 0 to 3000 KDa
Tolerance 50 ppm
Missed cleavage 1
Fixed modification Carboxymethylation
Variable modification Oxidation o f methionine
Charge state MH*
Table 3.2: Parameters selected for database searches using MS data. These parameters 
were used with MS-Fit, MASCOT® and ProFound search engines.
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identification using PMF data will give a “best match” candidate even if all the matching 
peptides are random matches. It is essential to distinguish between a significant match and 
a best match. This can be achieved by evaluating the specificity o f the algorithms used in 
the search engines.
3.3.1 Searching the NCBInr database with MS-Fit, MASCOT® and 
ProFound search engines
126 peptides mass fingerprints were generated by MADLI-TOF MS from T. brucei 
proteins separated by 2DE. These were searched against the NCBInr database using three 
search engines: MS-Fit, MASCOT® and ProFound.
3.3.1.1 The MS-Fit search engine
In total, 37 protein spots were identified using the thi'ee criteria described in Materials and 
Methods. These proteins had a corresponding MOWSE score ranging from 10"^  ^to 10’*'^ ° 
(Table 3.3). However, 13 additional protein spots with a MOWSE score higher than 10^  ^
did not reach the threshold limits fixed by the three criteria for unambiguous identification,
i.e. percentage of coverage < 15% (data not shown). This confirmed that the MOWSE 
score implemented in MS-Fit could not be used on its own with confidence for 
unambiguous protein identification by PMF. In total, 30% of the peptide mass fingerprints 
searched using the MS-Fit search engine (37 out of 126) reached the threshold limits set by 
the three criteria and were considered to be identified.
3.3.1.2 The MASCOT® search engine
The MASCOT® search engine’s guidelines state that a protein score above the database 
score (p) would give an unambiguous identification within 95% confidence limits. This 
guideline was applied to the identification o f the proteins from T. brucei and enabled the
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identification of 16 protein spots, corresponding to 12.7% of the total peptide mass 
fingerprints analysed (Table 3.3).
3.3.1.3 The ProFound search engine
The ProFound search engine is implemented with a probability scoring system (P) and a 
significance testing system (Z). The threshold values given by the ProFound search engine 
for identification are a P value o f 1 and a Z score above 1.65. These threshold values 
corresponded to an identification within the 95% confidence limits. These threshold values 
were used for the identification o f T. brucei protein spots separated by 2DE and enabled 
the identification of 19 spots (Table 3.3). This represented 15% of the total protein spots 
analysed.
3.3.2 Comparison of the results obtained from the three search 
engines
An analysis o f the specificity o f algorithms implemented in the search engines can be made 
by submitting the same search to multiple search engines and comparing the results. This 
analysis was undertaken with the tlii'ee seaich engines using peptide mass fingerprints 
generated fiom T. brucei protein spots separated by 2DE.
As the MS-Fit search engine had no reliable scoring system implemented in the search 
engine, the three criteria employed as thieshold for unambiguous protem identification for 
the MS-Fit search engine were applied to the MASCOT® and the ProFound search engines. 
The best score obtained for the peptide mass fingerprints reaching the thresholds limits set 
by the tliree criteria were compared for each search engine. Using the three criteria, 29.4% 
of the peptide mass fingerprmts analysed (37 out of 126) were identified using the MS-Fit 
search engine, but only 27.7% (35 out o f 126) were identified using the MASCOT® search
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engine and 21.4% (35 out of 126) were identified using the ProFound search engine (Table
3.4). A comparison of the three criteria used for identification showed that the differences 
in the results between the search engines were due to the percentage o f coverage o f the 
protein in the database (Table 3.3). The percentage was calculated directly by the search 
engines. For the same protein, the percentage of coverage varied from 1 to 5% between 
search engines. As a threshold o f 15% coverage was needed for unambiguous 
identification, any difference in coverage calculated by the search engines meant that a 
protein accepted as unambiguously identified by one search engine was not identified with 
another. This demonstrated how critical the tlireshold limits set by the user became when 
there is no probability based scoring system used in the search engine. All search engines 
agreed on the name and NCBI accession number (gi number) o f the best score for each 
peptide mass fingerprint searched, demonstrating that the thi'ee search engines had similar 
sensitivity.
When the probability based scoring system o f the MASCOT® and the ProFound search 
engines was used to determine unambiguous identification only 15.8% (20 protein spots) 
and 12.7% (16 protein spots) were unambiguously identified respectively. The probability 
based search engines had a higher specificity than the three criteria used with the MS-Fit 
search engine.
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MS-
Fit
ProFound MASCOT®
Number o f protein identified based on the scoring 
system of the search engine
N/A 20 16
Number of protein identified using the criteria of mass 
accuracy, number of matching peptides and coverage 
o f the protein
37 35 35
Table 3.4: Summary of comparison of the results from the MS-Fit, MASCOT® and 
ProFound search engines. Results were obtained searching the NCBInr database with the 
126 peptide mass fingerprints. The number o f proteins identified by the three search 
engines using the scoring system and the three criteria described in the text are shown. N/A 
non-applicable.
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3.4 Discussion
The sensitivity and specificity o f the search engine together with human judgment are the 
tliree key factors in the identification of proteins by mass spectrometry. The sensitivity o f a 
search engine relates to its ability to detect a match in a given database while the 
specificity relates to its ability to determine whether the match is significant (random 
match versus real match). Three search engines were compared for their sensitivity and 
specificity in protein identification by PMF. The MS-Fit seai ch engine was one of the first 
developed to search databases with peptide mass fingerprints. A high score with the MS- 
Fit search engine (10^^) did not always correspond to an unambiguous identification with 
the MASCOT® and the ProFound search engines. The low specificity o f the MS-Fit 
scoring system means that the user needs to rely on judgment to accept or reject the best 
score as reflecting an unambiguous protein identification.
The MS-Fit search engine has been the favoured search engine for protein identification by 
PMF in many proteomic studies. The criteria used as threshold limits for protein spot 
identification employed varied remarkably, fi*om the simplest criteria o f five peptides 
matching to the protein in the database (McAtee et aL, 2001), through a minimum of 30% 
coverage (Jungblut et aL, 1999) up to a combination of criteria such as four peptides 
matching with an accuracy o f at least 40 ppm (Smolka et aL, 2003). Basing the 
identification on the percentage of protein covered by the measured peptides biases the 
identification process towards small proteins, whereas an identification process based 
solely on five peptides matching a protein biases the identification towards large proteins.
The selection o f criteria for unambiguous identification o f proteins can be difficult. The 
accuracy obtained in the measurement o f peptide masses strongly influences the specificity
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of the search. Investigation o f the role o f accurate mass measurement in protein 
identification strategies demonstrated that random matches could occur for proteins 
matching as many as 15/23 peptides while using a range of 1,000 to 2,000 ppm (Clauser et 
aL, 1999). When dropping the mass accuracies in the range of 100 to 500 ppm, the level of 
random matches appeared to fall to 7/23 or 8/23 peptides respectively. Once the accuracy 
level reaches 50 ppm, currently possible with MALDI-TOF in reflector mode using 
internal calibration, the level o f random matches dropped to 6/23 peptides (Clauser et aL, 
1999). Recent calculations for proteins expressed by the genomes of Escherichia coli and 
Saccharomyces cerevisia indicate that at 0.1 ppm mass accur acy, 96% of the proteins will 
generate tryptic peptides with one or more unique masses (Figure 3.2). The remaining 4% 
correspond to gene products that are largely duplicates of other proteins (Bruce et aL,
1999). However, this level o f mass accirracy is not achievable with MALDI-TOF MS. 
Consequently, a combination o f criteria including the accuracy o f the peptide match (50 
ppm), the number of tryptic peptides matching (5) and in addition a limit of the coverage 
obtained from the proteins (15%) were used as threshold limits with the MS-Fit search 
engine for unambiguous identification o f proteins (Mann et aL, 2001). However, even 
these stringent criteria were shown to be too relaxed compared to the probability-based 
scoring systems o f the ProFound and the MASCOT® search engines. This demonstrated 
the importance o f the implementation o f a probability-based scoring system, removing the 
“human” factor for protein identification. The advantage of a probability based scoring is 
that a simple rule can be used to judge whether a result is significant or not. The addition 
o f a scoring system determining the probability o f the best match being a significant match 
is essential. It should be kept in mind that the significance testing can never definitely 
prove whether a result is true or false. The significance level is just the calculated risk of 
obtaining a false result.
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Figure 3.2: Importance of mass accuracy in protein identification. Graphical 
representation of all possible unique peptide molecular weights, after trypsin digestion, of 
all yeast proteins in the NCBI at a mass accuracy of 0.1, 1.0 and 10 ppm (reproduced from 
Goodlett et al., 2000).
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All search engines are based on the assumption that the protein being analysed is present in 
the database. However, this assumption is not always true. Consequently, it should be kept 
in mind that peptide mass fmgerprint can only provide the statistically most probable 
identification, taking into account the state of the database at the time of the search. Even 
with the most sensitive and selective search algorithm, if the protein sequence is not 
present in the database then the algorithm’s best score will at best be a closely related 
protein or a random match.
A comparison of the algorithm used in MS-Fit, MASCOT® and ProFound search engines, 
performed in silico, on four proteins sequences taken from NCBI database demonstrated 
that the algorithm employed by the ProFound was more specific than that used by the 
MASCOT® which in turn was more specific than the MS-Fit search engme (Tang et aL,
2000). The specificity o f the ProFound search engine was also shown in this paper to be 
more consistent over a wider range o f protein molecular weight (50 to 200 kDa) than the 
MASCOT® search engine which was only reliable up to 100 kDa. Trypsin digestion of 
protein spots is expected to give rise to peptide fr agments o f between 800 and 2,500 amino 
acids, depending on the distribution o f the recognition sequence for tiypsm in proteins 
(Aebersold and Goodlett, 2001). Consequently the limitation o f the specificity o f the 
MASCOT® search engine for large masses should not affect its efficiency for protein 
identification by PMF.
The MASCOT® search engine was shown to be both sensitive and specific for the 
identification o f proteins from T. brucei. In addition the search engine is simple to use and 
the output of the results easy to interpret. The MASCOT® search engine can also be used 
for searching databases with Tandem mass spectrometry data. As MALDI-TOF and
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Tandem mass spectrometry will both be used in the proteomic study o f the mechanism of 
Cymelarsan resistance in T. brucei the MASCOT® search engine was selected for the rest 
of the proteomic analysis. Other limitations, independent of the search engines (i.e. 
database, post-translational modifications) in the identification of protein spots by mass 
spectrometry will be discussed in the next chapter.
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Chapter IV 
A proteome map of T. brucei
4.1 Introduction
The first step in proteomic analysis is the extraction and separation o f proteins from 
trypanosomes by 2DE (chapter 2). Individually separated proteins are excised from the gel 
and digested with a sequence specific protease (e.g. trypsin). The masses o f the proteolytic 
peptides are measured by mass spectrometry. A search engine is then used to search a 
database with the data obtained by mass spectrometry (refer to chapter 3). Many types of 
search engines are available. A comparison of algorithms implemented in three search 
engines (MS-Fit, ProFound and MASCOT®) demonstrated the sensitivity and selectivity of 
the MASCOT® search engine (chapter 3). The MASCOT® search engine was purchased 
from MatrixScience and adapted to search the NCBIni' database and a local T. brucei 
database.
Proteomic expression profiling of protozoan parasites was rare, until recently, mamly due 
to the lack o f genome sequences for parasites in general The limited availability of 
genome sequence meant that proteins o f interest separated by 2DE might not be 
represented in the database and consequently the protein spots could not be identified using 
mass spectrometry data. However, the situation is rapidly changing with the publication of 
the Plasmodium falciparum  genome sequence (Gardner et aL, 2002) and full genome 
sequencing projects are underway for T. brucei, T. vivax, T. congolense, Leishmania 
major, Leishmania infantum. Toxoplasma gondii, Babesia bovis, Theileria parva.
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Theileria annulata and a further six plasmodium species
rhttp://www.sanger.ac.ul<7Proiects/Protozoa and http://wwvvtigr.org/tdb/parasites/ ).
The haploid genome size o f T. brucei is about 3.5x10^ base pairs with 11 homologous 
chromosome pairs and additional intermediate and mini-cliromosomes o f uncertain ploidy 
(El-Sayed et aL, 2000). The 11 megabase chromosomes are thought to contain most, 
perhaps all, the housekeeping genes and so were targeted by the Sanger and the TIGR 
centres for the sequencing o f the T. brucei genome, using the 927 stock. The TIGR centre 
was allocated the sequencing of chromosomes II to VIII while the Sanger centre was in 
charge o f the sequencing of chromosomes I, IX, X and XI. The methods employed by each 
centre for the sequencing o f the chromosome are different. At the Sanger centre, 
chromosomes were separated by pulsed field gel electrophoresis, excised from the gel and 
sheared into 2-4 kb fragments which were inserted into a plasmid vector. The clones were 
then randomly end-sequenced, producing a 8-1 Ox coverage o f the chromosome. This 
technique is called whole chromosome shotgun sequencing. The TIGR centre produced a 
large number o f BAG clones (bacterial artificial chromosome vector pBACe3.6, average 
insert size of 145 kb) and end-sequenced them. Chromosome specific BACs were selected 
using cDNA markers specific to the target chromosome, subcloned mto plasmid and then 
sequenced to completion. Then the database of end-sequences was then searched to 
retrieve BAG clones that overlap by only 5 to 10 kb, and these are then sequence to 
completion. To date, the sequences o f two of the 11 chromosomes have been completed 
and armotated (data are available on the Internet at http://www.tigr.org/tdb/mdb/tbdb/ and 
http://www.sanger.ac.uk/Projects/T_brucei/) (Table 4.1).
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Sequencing centre Chromosome Size (Mb) Status
Sanger I 1.15/1.2 Complete
TIGR II 1.25/1.3 Complete
TIGR III 1.62/1.75 In progress
TIGR IV 1.62/1.75 In progress
TIGR V 1.68/1.75 In progress
TIGR VI 1.7/2.0 In progress
TIGR VII 2.1/2.1 In progress
TIGR VIII 2.1/2.2 In progress
Sanger IX 3.3/3.5 In annotation
Sanger X 4.4/4.4 Finishing
Sanger XI S.2/5.2 In shotgun
Table 4.1: Genome sequencing project for T. brucei. Status o f the genome sequencing 
project for T. brucei TREU 927 Hne, dated 26'"' June 2003 (reproduced from 
http//:www.sanger.ac.uk/Projects/T_brucei/progress.shtmi). The local T. brucei database 
was made of translated sequences from the available nucleotide sequences from the 11 
chromosomes. The size o f the chromosomes was estimated by pulsed field gel 
electrophoresis.
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In addition, expressed sequence tags (ESTs) made from the sequencing of randomly 
selected complementary DNA (cDNA) are also available from EST discovery projects. 
There are over 5,000 ESTs from T. brucei deposited in Genbank, each with a unique 
accession number, which represent 3,113 unique sequences (Djikeng et «/.,1998; El Sayed 
et a l, 1995). This sequence information, provided both by the sequencing centres and the 
EST projects, is essential for the identification of proteins extracted from T. brucei and 
analysed by proteomic techniques.
It is estimated that the trypanosome genome contains approximately 8,000 genes based on 
sequence from chromosome I and II (Hall et a l, 2003; El-Sayed et a l ,  2003), and while 
numerous post-translational modifications are known to exist in this organism, the genes iu 
general have no introns, with the exception of the PAP gene (Mafr et a l, 2000). In 
addition, RNA editing in trypanosomes has been shown to be extensive for mitochondrial 
mRNAs which are encoded maxicircles (Madison-Antenucci et a l,  2002) but almost non­
existent, except for the addition of the spHced leader sequence at the 5’end by trans- 
splicing, for mRNAs encoded from the 11 chromosomes. Thus unlike in higher eukaryotes, 
the proteome o f trypanosome should not contain a drastically higher number o f proteins 
than genes.
While the current data support the view that intron and alternative splicing do not occur in 
T. brucei and the main factor generating multiple protein product fr om single genes is 
likely to be post-translational modification, tliis has yet to be experimentally tested. In 
order to test the limitations o f the incomplete genome sequence with regard to full 
proteomic analysis of T. brucei, a small scale proteome map was constructed. In addition,
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the question of the level of post-translational modification of proteins and the relationship 
between polypeptide profile and gene number were also addressed.
4.2 Materials and Methods
4.2.1 Protein extraction, 2DE and staining
Whole soluble proteins were extracted from 2x10^ procyclic forms of the reference line 
927 using protocol P2 as described in chapter 2. Protein extracts were separated by 2DE 
poly-acrylamide gels using broad pH ranges (pH 4-7 and 6-11) and stained with 
Coomassie Brilliant blue as described m chapter 2.
4.2.2 In-gel trypsin digestion and mass spectrometry
Protein spots were excised from the gel, digested with trypsin and PMF were acquired 
using the MALDI-TOF MS as described in chapter 3.
4.2.3 Database searches using the MASCOT® search engine
The “all taxa” category o f the NCBInr database and a local T. brucei database were 
searched using the MASCOT® search engine. The parameters selected for the searches are 
described in chapter 3 (Table 3.2).
4.2.3.1 The NCBInr database
This database contains the translated protein sequences from the entire collection of 
annotated DNA sequenees kept at GenBank, and also protein sequences in the Protein Data 
Bank (PDB), SWISS-PROT and Protein Information Resource (PIR) databases, covering 
most of the publicly available data.
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4.2.3.2 The local T. brucei databases
The local T. brucei database was constructed by downloading all available sequence 
information from ftp sites o f the Sanger and the TIGR centres. Two databases were made: 
a nucleotide sequence database (Pawel nt) and a peptide sequence database (Pawel aa). 
P aw eln t database consisted o f a conglomerate o f three nucleotide databases:
1“ A genomic database from the TIGR centre contaming 60 very long contigs from 
chromosomes II-IX. These were arbitrarily cut into 222 fr agments o f manageable 
sizes for the MASCOT® search engine, comprising fragments of up to 50 kb in 
length with 600 bp overlap between fragments.
2- Sanger nucleotide genomic data from chromosomes I, IX, X and XI. Chromosome 
I consisted o f one contig which was cut into 22 fr agments, chr omosome IX 
comprised 257 contigs and were cut into 317 fragments, chromosome X contained 
427 contigs which were cut into 485 fragments and chromosome XI consisted of 
896 contigs.
3- T. brucei GSS/EST clusters from the Sanger centre containing 20,493 sequences. 
Pawel aa conesponds to the predicted putative genes from genomic data described in 1 
and 2. This corresponds to 6,920 sequences fr om chromosome II-IX from TIGR, 509 
sequences fr om chromosome I, 2,348 sequences fr om chromosome IX, 10,590 sequences 
from chromosome X and 2,568 sequences from chromosome XI from the Sanger centre. In 
total, Pawel aa contained 22,935 sequences as updated on the 21/06/2003. These databases 
were downloaded and adapted for searches with the MASCOT® search engine by Dr Pawel 
Herzyk (University of Glasgow).
80
Chapter IV: A proteome map o f T brucei
4.3 Results
4.3.1 Efficiency of peptide mass fingerprinting
In order to produce a proteomic map of the procyclic form of the reference line 927 whole 
soluble cell extracts were separated on pH 4-7 and pH 6-11 2D gels (Figure 4.1). A total o f 
203 protein spots were detected on pH 4-7 gel and 74 protein spots on pH 6-11 gel. From 
these 2D gels, 126 protein spots were excised (91 protein spots from pH 4-7 gel and 35 
protein spots fr om pH 6-11 gel), in-gel digested with trypsin and peptide mass fingerprints 
were acqufred using MALDI-TOF. The peptide mass fingeiprints were searched against 
the NCBIni’ and the local T. brucei database using the MASCOT® search engine, enabling 
the identification of 51 protein spots. The list o f peptide masses obtained for each protein 
spot and used to search the databases is given in Appendix I.
In total, 40.5% of the peptide mass fingerprints obtained using MALDI-TOF (51 out of 
126 protein spots) were matehed to a protein in either the NCBIm* database or the local T. 
brucei databases (Table 4.2), The criteria for identification with the MASCOT® search 
engine were that the protein score had to be higher than the database score (p). From the 51 
protein spots identified, 17 peptide mass fingerprints matched onto a T. brucei entry in the 
NCBInr database. In addition, 24 peptide mass fingerprints matched only to proteins in the 
local T. brucei database. Most of the proteins in the local T. brucei database are not 
annotated so a BLASTp search was performed agamst the NCBInr database to identify 
homologous sequences. From the 24 proteins identified in the local database, seven 
sequences had no homologues in the NCBInr database; these are referred to as hypothetical 
proteins in Table 4.2. Detailed results from the MASCOT® search engine for each protein 
spot analysed by PMF are given in Appendix II.
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Figure 4.1: Proteome map of T. brucei. Coomassie Brilliant blue stained gel o f whole 
cell extract from T. brucei line 927 separated by 2DE on pH 4-7 and pH 6-11. The proteins 
from which peptide mass fingerprints were generated and an identification was obtained by 
searching the NCBInr database and the local T. brucei database are indicated by an arrow.
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Sample Protein ppm Score P Coverage Peptide
86 beta tubulin 25 139 72 27% 11
89 Blast HSR 60 25 69 56 17% 9
90 Blast: HSR 70 17 112 56 21% 11
92 Blast: HSR 70 25 102 56 16% 10
93 Tubulin alpha chain 34 74 72 33% 11
97 Raraflagellar rod protein 27 65 72 17% 7
101 Blast: dihydroiipoamide S acetyltransferase 20 76 55 19% 7
104 Hypothetical 30 56 55 34% 5
105 Blast: HSP70 21 79 56 14% 9
112 Putative phospatidylinositol 4 phosphate 5 kinase 20 63 50 19% 6
114 beta tubulin 16 155 72 42% 12
115 Elongation factor 2 30 90 56 17% 10
117 Blast: Elongation factor 2 20 120 56 15% 12
118 Blast: alpha tubulin 15 73 56 23% 7
123 Blast: Elongation factor 2 30 66 55 10% 9
127 guanine nucleotide binding 17 153 72 42% 12
129 pyridoxine/pyridoxal kinase 14 86 72 26% 8
131 Blast: cytochrome C oxidase subunit IV 20 67 56 21%
132 HSR83 18 66 56 24% 7
133 Tubulin alpha chain 22 93 72 24% 8
136 Enoiase 22 75 72 22% 7
140 beta tubulin 11 59 56 18% 6
145 Alpha tubulin 25 65 56 20% 7
153 Blast; elongation 1 beta 22 76 56 28% 6
154 Blast: elongation 1 beta 21 64 56 31% 5
155 Rroteasome subunit 24 76 72 36% 6
158 Heat shock 70KD protein 4 26 91 72 15% 9
163 Heat shock 70KD protein 4 11 73 72 17% 9
168^ BIR/GRR78 22 81 72 16% 9
170 Hypothetical 30 71 55 36% 6
172 Adenylate kinase 24 105 56 39% 8
173 ATRase beta subunit 19 78 72 24% 9
174 Putative DnaJ protein 30 111 50 35% 10
175 Blast: translation elongation factor 1 alpha 19 58 56 11% 5
176 Elongation factor 1 alpha 11 72 72 19% 6
179 Blast: translation elongation factor 1 alpha 22 67 56 19% 6
180 Hypothetical 25 67 56 22% 6
181 Blast: translation elongation factor 1 alpha 24 57 56 17% 5
182 Hypothetical 20 55 55 19% 5
183 Hypothetical 30 60 55 20% 6
184 Hypothetical 30 123 50 22% 11
185 Putative sucinyl CoA synthetase 25 56 50 25% 5
187 Melate dehydrogenase 25 79 72 29% 7
189 Hypothetical 20 60 55 14% 7
190 Blast: Malate dehydrogenase 50 100 55 29% 7
191 Blast: Malate dehydrogenase 30 97 55 34% 7
195 Glyceraldehyde 3 phosphate dehydrogenase 14 58 56 21% 6
203 Tubulin alpha chain 24 113 72 30% 11
206 Blast: pyruvate dehydrogenase 50 76 55 48% 5
209 guanine nucleotide binding 20 131 72 40% 10
Table 4.2: List of protein spot identified by the MASCOT® search engine. Mass 
fingerprints were obtained by MALDI-TOF MS. Peptide mass fingerprint were searched 
against NCBInr and the local T. brucei database using the MASCOT® search engine. The 
table indicates the acciuacy o f the match (ppm), the score of the protein, the database score 
(p), the coverage of the protein by the identified peptides, and the number o f peptides from 
the fingerprint that match on the protein. The search was last carried out on the 
25/06/2003. Non-annotated ORF from the local T. brucei database were identified by blast 
against the NCBI database to homologues in other species.
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The majority of proteins separated by 2DE and visualised by Coomassie staining were not 
identified. From all the protein spots processed, 10.13% were identified as enzymes, 
followed by 7.14% identified as structmal proteins, 7.14% identified as elongation factors 
and 9.52% classified as others and comtaining the hypothetical proteins (Figme 4.2).
4.3.2 Relationship of polypeptide profile complexity to gene number in 
T. brucei
An iso form is defined in the Dictionary o f Cell Biology as a protein having the same 
function and similar* (or identical) sequence but the product of a different gene and usually 
tissue specific (Lackie and Dow, 1995). For the purpose of this thesis, we will limit the 
definition o f an iso form to a protein product of one or different genes with identical DNA 
sequences. Consequently, any iso form observed on a 2DE will be the results o f a post- 
translational modification by either the covalent addition of a small adduct or by 
proteolytic processing.
The identification of protein spots by MALDI-TOF analysis showed a large proportion of 
a (5 spots) and (3 (3 spots) tubulins on the proteome map. So far, the genome sequencing 
project o f T. brucei has identified 13 a tubulin genes and 14 |3 tubulin genes on one 
homologue and 9 a  tubulin genes and 10 p tubulin genes on the other homologue of 
chromosome I (Hall et a l,  2003). Alignment of all the sequences o f a  tubulin genes and p 
tubulin genes found in the GeneDB database has shown that all a tubulin genes are 
identical and all P tubulin genes are identical to each other (data not shown). Consequently 
the tubulins spots identified from the proteome map are isoforms. The a and P tubulins 
spots identified are located at very different places on the proteome map, indicating that 
these isoforms are possibly the results o f modification by proteolytic processing.
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Figure 4.2: Pie chart representation of classes of protein identified. The class other 
contains the “hypothetical” proteins (4.76%) from the local T. brucei database for which 
no homologues where found in the NCBI database.
90 92
•/• • •
Figure 4.3: 2DE pattern of post-translationally modified proteins. Zoom view o f a part 
of the 2D gel (pH 4-7) showing the characteristic pattern of iso forms with similar 
molecular weight but slight variations in pi. Samples 90 and 92 were both identified as 
heat shock protein 70, transcript product o f the same ORF (score: 112 and 102 
respectively).
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The HSP70 protein spots (spot 90 and 92) identified on the proteome map are also 
isoforms as they are products o f the same gene. The HSP70 gene family is large but also 
very diverse which enabled the differentiation o f the gene products by MALDI-TOF 
analysis, as illustrated in Figure 4.3. Protein spots 90 and 92 are located at similar apparent 
molecular weight but with different p i (Figure 4.4), indicating that the isoform are 
probably the results o f post-translational modification by covalent addition of a small 
adduct. This suggests that the HSP70 protein is regulated at the post-transcriptlonal level in 
T. brucei.
In some cases however the MALDI-TOF analysis does not enable a determination of 
whether the protein spots identified are isoforms, or products of genes with different 
sequences. This was observed for spot 175, 176 and 179, all identified as elongation factor 
1 a (score = 58, 72 and 67 respectively), located at similar apparent molecular weight but 
with differences in pi. At first glance the results from the MASCOT® search engine 
suggested that all three spots were transcriptional products o f the same ORF (ORF 775), 
which had obtained the highest score. However, a closer examination of the results 
suggested the presence o f two elongation 1 a  genes (ORF 775 and ORF 774). An 
aligmnent of the transcriptional product from these two ORFs showed a difference in 
length between the two ORFs and 100% homology in the aligned sequences (Appendix 
III). The shorter ORF (ORF 775) thus obtained the best score with the MASCOT® search 
engine (as the percentage of coverage obtained was higher), however the mass 
spectrometry data obtained cannot differentiate between the two genes. Consequently, spot 
175, 176 and 179 could be either post-translationally modified elongation factor 1 a  or the 
transcripts of different genes.
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Figure 4.4: Alignment of ORFs encoding HSP70. Peptides identified by MALDI-TOF 
analysis of spot 90 are highlighted in blue.
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4.4 Discussion
In this chapter, protein spots were digested with trypsin and 51 were identified to act as 
landmar ks for further proteomic studies. The likelihood o f obtaining identifications by 
peptide mass fingerprinting given the incomplete state of the T. brucei genome-sequencing 
project was determined.
There was a good correlation between spot intensity and spectrum quality, although some 
intense spots gave few peaks by MALDI-TOF. The proteome map revealed that 40.5% of 
proteins visualised by Coomassie staining can be identified using the simple peptide mass 
fingerprinting teehnique with the cuiTent state o f the T. brucei genome database. A protein 
was accepted as identified only if the score was higher than the database score (p) and the 
accuracy under 50 ppm (chapter 3). From the 126 protein spots assessed, 10.3% were 
enzymes (component o f the metabolic pathways), 7% were structural proteins involved in 
the cyto-architecture o f the cell (tubulins, paraflagellar rod proteins, etc...) and 7% were 
elongation factors. Structural proteins are known to be highly expressed in cells, which is 
in accordance with the results obtained from the preliminary proteome map o f T. brucei 
line 927. A significantly high proportion o f identified protein spots (5.55%) were match to 
non-annotated, hypothetical ORFs of T. brucei. The identification of these genes from then 
protein product proves that these are real genes and that they are expressed in T. brucei. 
These ORFs were found to have no homologues in the NCBI database and so can be 
considered to be specific to T. brucei. Because of their specificity to the T. brucei parasite 
these proteins should be further analyse in view o f their potential as drug targets. The 
sample used in this study were excised from Coomassie Brilliant blue stained gel and so 
there has been a unavoidable bias toward the analysis o f the most highly expressed 
proteins.
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With the available T. brucei database, 59% of the peptide mass fingerprints generated were 
not matched to a protein in the two databases searched. Closer examination of the peptide 
mass spectra obtained for these protein spots revealed some poor quality spectra (27 
spectra) attributable to low protein concentration and so these would be unlikely to provide 
identification. In addition, five protein spots were lost during the in-gel trypsin digestion. 
Removal o f the poor quality spectra and lost spots brings the percentage of non-identified 
proteins down to 37.6%. Inspection of the results fi om the MASCOT® search engine 
reveals that a few protem spots with good spectra were not unambiguously identified 
(score < database score). Closer examination o f these mass spectra with the mass spectra 
generated for proteins located at similar molecular mass but with a slightly more acidic or 
basic pi revealed high similarities in the peptide masses. Examination of the results 
obtained with the MASCOT® search engine for these peptide mass fingerprints showed 
that the first scores were just under the database score necessary for unambiguous 
identification. In addition, the protein name and accession number associated with the 
highest score for these spots was the same as that for protein spots with similai* molecular 
mass but slightly different pi. This suggested that these could be accounted for by post- 
translational modification. Most post-translational modifications change the masses o f the 
modified peptides (Table 4.3). Modified peptides would not fit the theoretical values 
calculated fiom the database entries by the MASCOT® search engine and therefore these 
would be eliminated from the identification.
38 good quality peptide mass fingerprints had no match in either the local 71 brucei 
database or the NCBI database suggesting that the sequence of the ORFs encoding these 
protein spots were not available in the database, and that no close homologue of the 
proteins
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PTMtype A Mass 
(Da)
Function and notes
Phosphorylation + 80 Reversible, activation/inactivation of enzyme activity, modulation 
of molecular interactions, signaling
Acétylation + 42 Protein stability, protection of N terminus. Regulation of protein- 
DNA interactions (histones)
Méthylation + 14 Regulation of gene expression
Glycosylation: 
N-I inked 
0-linked
>800 
203, >800
Excreted proteins, cell-cell recognition/signalling 
Reversible, regulatoiy frmctions
Hydroxyproline + 16 Protein stability and protein-ligand interactions
Sulfation + 80 Modulator of protein-protein and receptor-ligand interactions
Pyroglutamic
acid
-17 Protein stability, blocked N terminus
Ubiquitination >1,000 Destruction signal.
Table 4.3: Post-translational modifications and mass shift. Reproduced from 
http : //WWW ■ abrf. or g/index. cfm/dm. ho me
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occur in the sequenced genome o f other organisms. These spots are likely to be identified 
when the whole annotated genome sequence of T. brucei becomes available. The 59% of 
unidentified protein spots can be explained by a combination of some poor quality spectra 
(21.4%), some heavy post-translational modifications (3%) and an incomplete T. brucei 
genome sequence (34.6%).
A possible explanation for the acquisition o f poor mass spectra lies in the limitations o f the 
MALDI-TOF MS. Examination o f peptide mass spectra generated by MALDI-TOF on 100 
proteins from Mycobacteria species showed that peak intensities of arginine containing 
peptides were significantly higher than those o f lysine peptides (Krause et a l,  1999). The 
intensity of some of the lysine peptides can be so low that these peptides cannot be 
separated from background noise in the peptide mass fingerprint. This characteristic of 
peptide mass spectrum generated by MALDI-TOF limits the sequence coverage obtainable 
by PMF analysis, and consequently the score given to a protein spot.
PMF has been used extensively in proteomic studies to identify proteins separated by 
means of 2DE. Peptide mass analysis by MALDI-TOF was shown to combine simplicity 
with high throughput which made it an ideal first step to large scale proteome mapping. 
Wlien complete genomic sequences are available, it has been demonstrated that up to 80% 
of the proteins separated by 2DE and analysed by MALDI-TOF can be positively 
identified (Shevchenko et a l,  1996). However, PMF efficiency for organisms with 
complete genome sequenced varies enormously fr om as little as 33% for Homo sapiens to 
80% for Saccharomyces cerevisae (Table 4.4). These large differences in PMF efficiency 
for organisms where the complete genome has been sequenced can be explained by the 
size and complexity o f their genomes. The human genome (3 Gb) has been completely
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Organism Genome
sequencing
project
Genome
size
Predicted 
number of 
genes
Efficiency 
of PMF
Reference
Saccharomyces
cerevisiae
Complete 12 Mb 6,280 80% Wildgruber 
et al., 2002
Homo sapiens Complete 3 Gb
924 for 
chromosome 
21 and 22
32.6%
Ha et al., 
2002
Helicobacter
pylori
Complete 1.66 Mb 443 50.7% Chao et al., 
2001
T. brucei Not complete 35 Mb 8,000 40.5%
Table 4.4: Proteome mapping projects for Saccharomyces cerevisiae, Homo sapiens, 
Helicobacter pylori and T. brucei. The four proteomic studies were carried out by 2DE of 
proteins and MALDI-TOF analysis o f tryptic digested proteins selected from the two 
dimensional gels.
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sequenced but its use for proteomic studies based on protein identification by PMF is 
limited. This is due to the gene organisation and the mechanisms o f post-transcriptional 
RNA processing. The average human gene contains 10 to 15 exons separated by introns. 
Exons only account for about 2% of the total genome and the remaining 98% constitutes 
introns (24%) and intergenic regions (74%). These features make it difficult to identify 
genes in the human genome by ORF scamiing. An additional factor is the extensive 
occurrence of complex RNA splicing events which is a key feature of human gene 
transcription (Modrek and Lee, 2002; Zhang et al., 2002). Analysis of chromosomes 19 
and 22 showed that there are, on average, 3.2 distinct mRNA transcripts per gene, with 
70% of these involving alternative splicing within the coding region (Lander et al., 2001). 
This means that the peptides predicted directly from the ORF will not correspond to those 
actually translated from the alternative spliced transcripts making the identification 
impossible. Pseudogenes are another major problem for ORF finding in the human 
genome. For example, there are 80 ribosomal protein genes in the human genome but 
>2,000 associated pseudogenes (Zhang et al., 2002). Consequently, the assignment o f 
ORF’s is particularly difficult and far from complete for the human genome. In order to 
have an efficient identification of peptide mass fingerprints, it is necessary to have a 
complete database of the total ORFs and mRNA transcripts. The need for such a “perfect” 
database is because o f the pure statistical basis o f protein identification fr om peptide mass 
data. The proteome in different tissues and cell types would then represent a sub-set of this 
database. However, the importance o f PMF should not be under estimated as, where 
identification is obtained, it provides much needed confirmation that ORFs are expressed.
In comparison, the yeast genome is far simpler than the human genome. S. cerevisiae was 
the first eukaryote genome to be fully sequenced (12 Mb). The work was completed in
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1996 and the detection of ORFs in S. cerevisiae started at the same time. The lower 
complexity o f the yeast genome is mirrored by the efficiency o f protein identification by 
PMF.
The T. brucei genome organization has been determined from the sequencing and 
annotation of cliromosome I and II. This analysis showed a lack of promoters, no introns, 
but large probable polycistronic units. Except for the addition of the spliced leader on 
every transcript, splicing is a rare event in T. brucei. The simple organization o f the T. 
brucei genome means that the annotation of the genome is relatively straightforward and a 
complete database of the total ORFs and mRNA transcripts should be obtainable directly 
from the genome. Consequently, proteins can be identified by direct comparison of PMF 
with theoretical PMF from transcripts predicted from the ORFs, and this is reflected in the 
relatively high rate o f protein identification reported here.
Identification of protein spots on the proteome map showed that post-translationally 
modified proteins were separated by 2DE from the primary translated products (e.g.
HSP70 protein spots). This is because most post-translational modification leads to 
changes in pi. Tliis change in pi gives rise to a specific protein spot pattern on 2D gels. In 
this study 51 proteins spots were identified which corresponded to 30 different proteins. 
Consequently, 40% of the protein spots identified were likely to be iso forms. This might 
seem a high percentage, but comparison with proteome maps fr om various organisms 
available at the Expasy’s web site rhttp://ca.expasv.org/ch2d/2d-index.html) showed this to 
be an average iso form value. Post-translational modification o f a protein can determine its 
activity state, localisation, turnover, and interactions with other proteins. For example, 
kinase cascades are turned on and off by the reversible addition and removal o f phosphate
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groups. As such the determination o f the post-translational modification state of a protein 
is extremely important. Proteomic studies using 2DE and mass spectrometry enable the 
separation and assessment o f the level o f modification of a protein. The particular 
modification and the site of modification can further be analysed by a variety o f techniques 
which have been recently reviewed (Mann and Jensen, 2003; Mann et ah, 2002; Arbersold 
and Goodlett, 2001).
However it is difficult, sometimes impossible with PMF data to differentiate between post- 
translational modifications and transcripts from different but closely related genes in a 
gene family. For example, the number o f a  and p tubulins gene copies on chromosome I 
has been estimated (from mapping data) to be 13-14 in one homologue and at least 9-10 in 
the other, with high homology between them (Hall et a l,  2003). Remarkably, almost 20% 
of the annotated genes on cliromosome I are members of closely related families (Table
4.5).
The production o f a preliminary proteome map of T. brucei demonstrates the feasibility o f 
proteomic studies on this parasite. The lack of a complete and accurately annotated 
genome and protein sequence databases accounted for 34.6% of the non-identified protein 
spots. In 3% of the cases the data collected by MALDI-TOF mass spectrometiy was not 
sufficient for reliable identification o f a protein, especially in cases were the 2DE pattern 
suggested post-translational modification o f the protein. In cases o f ambiguous 
identification by PMF, Tandem mass spectrometry can be used in analysis to generate 
peptide sequence information about a particular protein spot of interest.
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Before embarking on a proteomic study o f Cymelarsan resistance in T. brucei, a biological 
analysis o f the isogenic lines to be used needs to be undertaken to determine potential 
variables which could affect the protein expression in each line. The characterization o f the 
two pairs o f isogenic lines is described in the next chapter.
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Product description Distribution % homology (protein) Number of copies
RHS Clustered 20-99% 5
LRRPl Clustered 93-99% 3
Unknown function Clustered 75-95% 3
Phosphate permease Tandem 97% 2
PGK Tandem 65-89% 3
Unknown function Dispersed 99% 2
ESAG2 Dispersed 68-82% 3
Calpain-like Clustered 6-80% 7
P tubulin Tandem >99% >9
a  tubulin Tandem >99% >9
Histone H3 Tandem >99% 7
Unknown function Tandem 100% 7
Pteridine transporter Tandem >99% 3
Table 4.5: Gene families on chromosome I of T. brucei Partial summary o f the 
characteristic o f gene families found on chromosome I. ND, not determined. Reproduced 
from Hall et al., 2003.
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Chapter V 
Characterisation of isogenic drug sensitive and drug 
resistant iines of trypanosomes
5.1 Introduction
In previous chapters, protocols for the extraction/solubilisation o f proteins from T. brucei and 
their separation by 2DE were developed, a sensitive and specific search engine was selected 
for identification of proteins using mass spectrometry data and a preliminary analysis o f the 
proteome of line 927 demonstrated that 40% of proteins separated by 2DE can be identified 
using the simple technique of PMF. These results have essentially established the main 
methodologies for undertaking proteomic analysis of T. brucei as well as defining the 
limitations. As discussed in the introduction, one application of proteomics is the analysis and 
identification of alterations associated with particular phenotypes and the main aim of the 
project was to apply this technology to analysing the alterations in drug resistant trypanosome 
lines.
Cymelarsan (Melarsamine hydrochloride) is a close analogue of Melarsoprol used iu 
veterinary trypanosomiasis. Cymelarsan is a water-soluble trivalent agent that is very effective 
against T. b. brucei, T evansi and T. equiperdum infections in camels, buffalo, goats and pigs 
(Payne et al, 1994; Nyang’ao et a l, 1995) but is very unstable in solution and forms several 
dissociation products. The primary dissociation product, Melarsen oxide, is thought to be the 
active form of Cymelarsan (Berger and Faiiiamb, 1994) as well as the primary metabolite of
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Melarsoprol in vivo (Keiser et al., 2000). Consequently, Cymelarsan generated resistance can 
be used as a model for Melarsoprol resistance in trypanosomes.
Cymelarsan resistance was generated in vivo in the STIB 386 and STIB 247 lines of 
trypanosomes by gradually increasing sub-curative doses of drug (Scott et al., 1996). 
Comparison of EC50 values obtained from in vitro growth inhibition assays demonstrated that 
procyclic forms of the laboratory-generated Cymelarsan resistant lines were over 500 fold 
more resistant to Cymelarsan than the sensitive parental lines (Table 5.1). Preliminary 
characterisation o f the two pairs of isogenic Imes (386/386Mr, 247/247Mr) showed that the 
drug resistance phenotype was stable after passaging in mice in the absence of drug pressure 
as well as being stable after transmission through tsetse flies (Scott et al, 1996). Cross­
resistance between Cymelarsan and Melarsoprol was observed in bloodstream forms in vivo 
but not in procyclic forms in in vitro inhibition assays for both pairs of isogenic lines (Table 
5.1). This apparent lack o f cross-resistance was observed to be an artifact o f the in vitro assay 
(Scott et al., 1997). In addition, in vitro studies demonstrated that bloodstream forms of the 
Cymelarsan resistant 247 line was partially cross-resistant to two diamidine drugs, 
Pentamidine and Berenil (data not shown, Scott et a l,  1997).
The two paii's o f isogenic lines (386/386Mr and 247/247Mr) have been previously analysed to 
determine whether they possess, transcribe and express the P2 transporter gene {TbATl). 
Southern blot analysis demonstrated that the sensitive 386 and 247 lines both had the genes 
encoding PI and P2 transporters. The Cymelarsan resistant 386 line possessed a TbATl gene 
with the same restriction digestion pattern as the sensitive line, whereas the cluster of genes
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in vitro (ECso) in vivo (MIC in mg/Kg)
Trypanosome line Cymelarsan Melarsoprol Cymelarsan Melarsoprol
386 0.025 0.98 2.0 0.64
386Mr 14 1.3 >40 >40
247 0.06 7.0 0.3 0.32
247Mr 31 16 >40 >40
Table 5.1: Results of in vitro and in vivo cross-resistance assays for the pairs of isogenic 
lines. Resistance o f sensitive (386 and 247) and Cymelarsan induced drug resistant (386Mr 
and 247Mr) lines were tested by growth inhibition assay. Average EC50 values (pM) of 
Cymelarsan and Melarsoprol calculated from growth inhibition assays for the wild type and 
the selected lines. The minimal inhibitory concentration (MIC) values from in vivo assays 
corresponded to the dose required to cure mice infected with the unselected or selected lines. 
Data from Scott et aL, 1996.
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coding for PI transporter was rearranged (Dr R.Burchmore, personal communication). 
Northern analysis showed that bloodstream and procyclic forms of the Cymelarsan resistant 
386 line do not transcribe the TbATl gene, whereas the sensitive 386 line expressed it in both 
life cycle stages. Analysis o f the Cymelarsan resistant 247 line showed that the TbATl gene 
was completely lost (Dr R. Burchmore, personal communication). These unpublished data 
show that the loss of expression of the P2 transporter is associated with the Cymelarsan 
resistance phenotype. The expression of the Cymelarsan resistance in procyclic forms of 
trypanosomes, for wliich no P2 activity can be detected (de Koning et al., 2000), strongly 
suggested that TbATl is not the only gene responsible for conferring arsenical resistance in 
these lines. In addition, the level of Cymelarsan resistanee conferred by knockout of TbATl is 
much lower than the levels detected in these two pairs of isogenic lines (Matovu et al., 2003), 
further supporting the theory o f a multi-factorial mechanism o f drug resistance.
In this chapter the genotypes and phenotypes of the isogenic Cymelarsan sensitive and 
resistant lines were assessed to characterize these lines more completely. An assessment of 
some of the variable, which can affect the proteome of the isogenic lines was undertaken. In 
addition, obvious candidates for the mechanism of Cymelarsan resistance in T  brucei, such as 
export of the drug by a P-glycoprotein and analysis of cross-resistance in regard to P2 
transporter alteration were assessed.
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5.2 Materials and Methods
5.2.1 Commonly used reagents
The trifluoperazine (TFP), prochlorperazine (PCP), verapamil, EDTA, SDS, Tris,
Gentamycin, Berenil and Pentamidine were purchased from SIGMA. Proteinase K, agarose, 
FCS and SDM79 were purchased from Gibco BRL. Reagents purchased from other companies 
are indicated in the text.
5.2.2 In vitro culture of procyclic trypanosomes
Procyclic forms of the pairs of isogenic lines were grown in vitro in complete SDM79 as 
described in chapter 2.
5.2.3 DNA extraction and genotyping of the isogenic lines
The pellet from 1 ml of trypanosome procyclic culture was concentrated in an Eppendorf tube 
by centrifuging for 3 min at 12,000 g, and washed once using 500 pi o f PSG buffer at pH 7.8. 
The trypanosomes were lysed in 100 pi o f lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA pH 
8, 0.5% SDS) with addition of 3.3 pi of 20 mg/ml proteinase K and incubated at 56°C for 4 h. 
The tubes were then incubated for 5 min at 95°C to inactivate the proteinase K and stored at - 
20° C. Genotyping was undertaken by PCR amplification of three highly polymorphic 
minisatellite markers, CRAM, MS42 and 292, using the primers listed in Table 5.2 (MacLeod 
et a l, 1999). PCR was undertaken in 10 pi reaction volumes containing 5 pmoFml of each 
primer, 1 pi of PCR Master mix (ABgene), 1 unit o f Taq polymerase (ABgene), and 200-300 
ng of DNA template. The PCR conditions were as follow: 28 cycles o f dénaturation for 50 sec 
at 95°C, annealing for 50 sec at 64°C and elongation for 3 min at 68°C, on a Robocycler
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Primer Sequence
CRAM G 5’- CTGCTGATGCCGTACATGATGATTTC
CRAMH 5’- AACTCCCTCCCGATCGATCACAAC
MS42F 5’- TTGTGCGGTCGTTAACGCGCGTTCAA
MS42W 5’- GGTGATTCATCGGCTCCCTTACCA
292 G 5’- ACACCCCCTCTCCACTTCAGATAC
292 H 5’- GCTGAACCTGTGGGCCCCTCAATTG
Table 5.2: Sequence of primers for genotyping. Sequences of the primers used to PCR 
amplify the three minisatellites CRAM, MS42 and 292 for genotyping the isogenic lines.
103
Chapter V: Characterisation o f the isogenic drug sensitive and drug resistant lines of trypanosomes
Gradient 96 (Stratagene). Agarose gels for electrophoresis of DNA were prepared as described 
in Sambrook et ah (1989). Powdered agarose (1% w/v, Seakem) was mixed with 0.5x 
electrophoresis buffer (0.045 M Tris-borate, 0.001 M EDTA) and ethidium bromide (1%). The 
DNA samples (10 pi) were mixed with the gel-loading buffer (0.25% (w/v) bromophenol blue, 
30% (v/v) glycerol in water) and loaded into the wells. The samples were run in the gels at 
100 V for 2 h 30 min. The gels were then examined under ultraviolet light and photographed 
with a Gel Imager.
5.2.4 In vitro growth curves of the isogenic lines
Procyclic forms of each isogenic line were grown by inoculating complete SDM79 with 5x10^ 
procyclic trypanosomes, and incubating the cultmes at 25°C. Growth curves were obtained by 
estimating trypanosome concentrations every 24 h over a 7 day period using an Improved 
Neubauer haemocytometer. The experiments were carried out in triplicate. The mean 
trypanosome concentration was plotted against time in hours and from these growth curves, 
the rate of growth and population doubling time (PDT) were calculated. The rate of growth (b) 
over the first three days was calculated by linear regression analysis (y = bx + c). The mean 
PDTs were calculated from the growth rates using the following equation: PDT = ln2/b.
5.2.5 In vitro trypanocidal drug sensitivity testing
5.2.5.1 Growth inhibition assays
Four trypanocidal dmgs were each used in in vitro drug resistance assays on procyclic forms 
of the pairs of isogenic lines. Cymelarsan (Rhône-Mérieux) and Berenil were dissolved in 
filter sterile complete SDM79 medium and Pentamidine was dissolved in 20% DMSO solution 
in complete SDM79 medium. Melarsoprol was available as a 3.6% solution in propylene
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glycol. The drugs were serially diluted in complete SDM79 medium, to obtain concentrations 
ranging from 0.001 pM to 1,000 pM. In microtitre plates, 100 pi o f drug was mixed with 100 
pi of procyclic culture at 2x10^ trypanosomes/ml and incubated at 25°C. The controls 
consisted of 100 pi o f complete SDM79 mixed with 100 pi o f procyclic culture at 2x10^ 
trypanosomes/ml. Growth was assessed by counting the trypanosomes in an Improved 
Neubauer haemocytometer after 24 h incubation. The growth inhibition experiments were 
performed in triplicate, and repeated at least once. The percentage inhibition is expressed 
relative to the cell densities in culture growing in the absence of ding. The growth was plotted 
against increasing drug concentration, and the values between 10% and 90% growth were 
approximated to a straight line by linear regression (R  ^values varying from 0.92 to 0.97). The 
drug concentration which inhibited growth by 50% (EC50 value) was calculated from the 
regression equation.
5.2,5.2 Growth inhibition assays with Cymelarsan and P-glycoprotein inhibitors
Three general P-glycoprotein inhibitors, prochlorperazine (PCP), trifluoperazine (TFP) and 
verapamil were used in combination with Cymelarsan to assess the potential involvement of 
drug efflux as a mechanism of Cymelarsan resistance in procyclic forms of the pafrs of 
isogenic lines. The P-glycoprotein inhibitors were serially diluted in complete SDM79 
medium. The assay was performed in microtiter plates as shown in Table 5.3. The plates were 
incubated for 24 h at 25° C and concentration of tiypanosome was determined using an 
Improved Neubauer haemocytometer. The experiments were performed in triplicate and 
repeated at least once.
5.2.5 3 The Alamar Blue assay
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Controls Drug combination
Cymelarsan: 1 pM 100 pi 100 pi 100 pi
Inhibitor of P-glycoprotein: 1 pM 100 pi 100 pi
Inhibitor of P-glycoprotein: 10 pM 100 pi 100 pi
Trypanosomes (procyclic culture) 100 pi 100 pi 100 pi 100 pi 100 pi
SDM79 100 pi 100 pi 100 pi
Table 5.3: Growth inhibition assays with Cymelarsan and P-glycoprotein inhibitors. The
effect of P-glycoprotein inhibitors on growth inhibition assays of Cymelarsan were tested on 
procyclic forms o f the pairs o f isogenic lines.
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Cymelarsan was serially diluted in complete SDM79 medium, with concentrations ranging 
from 0.001 pM to 1,000 pM. In microtiter plates, 100 pi of Cymelarsan solution was mixed 
with 100 pi o f procyclic culture at 2x10^ trypanosomes/ml and 20 pi of the Alamar Blue dye. 
The control was made by replacing the Cymelarsan solution with complete SDM79. The 
plates were incubated for 24 h at 25° C. Measurements were taken with a LS 55 Luminescence 
Spectrometer (Perkin Elmer instruments) at 530 nm excitation and 590 nm emission 
wavelengths. Thr ee initial concentrations of procyclic cultur es (2x10^, 4x10^ and 6x10*^  
trypanosome/ml) of the Cymelarsan sensitive and resistant lines were tested. Presence and 
viability o f the trypanosomes in each well was confirmed by microscopic examination. Each 
experiment was performed in duplicate and replicated at least once.
5.3 Results
5.3.1 Genotypes of isogenic lines
All procyclic lines were genotyped using three minisatelite markers (CRAM, MS42, 292) as 
described previously by MacLeod et al. (1999). These minisatellite markers were selected as 
they are highly polymorphic and can differentiate between strains of T. brucei with a high 
probability. The genotypes o f 386 and 386Mi’ Imes (Figure 5.1 A) and o f247 and 247Mr lines 
(Figure 5, IB) were each identical for the three minisatellite markers used in this study. These 
data demonstrated that the sensitive and resistant pairs of lines are indeed isogenic as 
originally described (Scott et at., 1995) and no inadvertent substitution of one line for another 
with a different genotype has occurred. This findmg contrasts with the genotyping results of 
RU15 line, a laboratory derived Melarsoprol resistant line made from 427 line, which had a
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A) B)
I I
CRAM
1.5 Kb
MS42 292 CRAM MS42 292
Figure 5.1: Genotypes of the two pairs of isogenic lines. The sizes o f the PCR products 
correspond to the expected sizes for line 386 (2.8 Kb and 2 Kb for CRAM, 2.3 Kb and 1.8 Kb 
for MS42 and 1 Kb and 0.95 Kb for 292) and 247 (2.8 Kb for CRAM, 1.5 Kb for MS42 and 
1.3 Kb for 292) (Dr A. MacLeod, personal communication).
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different genotype from the parent line using these three minisatellite markers (Dr A.
MacLeod, personal communication).
5.3.2 Growth of isogenic lines
The rates of growth of procyclic forms and the population doubling times were calculated to 
investigate whether selection for Cymelarsan resistance had caused a change in growth rate. 
The assessment of in vitro growth of the procyclic forms of 386 and 386Mi* lines showed no 
noticeable difference in growth between the isogenic lines (Figure 5.2A). Both procyclic 
cultures reached a maximum concentration of 1.7x10^ tiypanosomes/ml in the stationary 
phase. Growth rates and mean PDTs were calculated for the isogenic lines from these gi’owth 
curves to assess fuither vai'iability between the lines (Figure 5.2C). The growth rates were 
very similar (0.023 and 0.025 respectively). The in vitro growth curves o f procyclic cultures of 
247 and 247Mr isogenic lines showed no detectable differences in growth between them 
(Figure 5.2B). The maximum trypanosome concentration reached by these iogenic lines was 
1.3x10^ trypanosomes/ml.
Taken together these results suggest that there are no detectable differences in gr owth rates 
between Cymelar san sensitive and resistant lines of 386 and 247. Thus, any proteomic profile 
differences found between the lines are unlikely to be artefacts o f differences in growth that 
might have arisen as a pleiotropic phenotype when the lines were originally selecting for drug 
resistance.
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Growth rate Population doubling time
386 0.023 30.26 h
386Mr 0.025 27.29 h
247 0.021 32.39 h
247Mr 0.020 33.97 h
Figure 5.2: Growth curves of the two pairs of isogenic lines. Procyclic forms of isogenic 
lines o f 386 (A) and 247 (B) were grown in SDM79 in vitro and the average growth rate and 
population doubling time (PDT) were calculated from the gi'owth curves (C). The experiments 
were performed in triplicate.
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5.3.3 Sensitivity and resistance to arsenicals and diamidines
In vitro growth inhibition assays o f Cymelarsan sensitive and resistant lines of 386 and 247 
were used to assess sensitivity/resistance of the pairs of isogenic lines to trypanocidal drugs. 
Two arsenical drugs (Cymelarsan and Melarsoprol) and two diamidine drugs (Pentamidine 
and Berenil) were tested.
The procyclic forms o f386 and 386Mr lines exhibited a dose dependent inhibition of growth 
by Cymelarsan. The 386Mr line was not affected to the same extent by the presence of 
Cymelarsan in the medium compared to the 386 sensitive parental line (Figure 5.3A). At a 
concentration o f 1 pM Cymelarsan, the 386Mr line showed only 25% inhibition in growth 
whereas the 386 line showed 75% inhibition of growth. The 386 line was completely inhibited 
by 10 pM Cymelarsan whereas the 386Mr line was completely inliiblted only by the highest 
concentration of Cymelarsan (1,000 pM). The minimum dose inhibiting 50% of growth 
(EC50) was estimated to be 0.57 pM for 386 and 14.19 pM for 386Mr, showing a 24.9 fold 
increase inEC 5 0 (Table 5.4).
The growth inliibition assays of 386 and 386Mr lines in the presence of Melarsoprol showed 
no detectable differences for most concentrations o f Melai'soprol (Figure 5.3B). The only 
detectable difference was seen at a Melai'soprol concentration of 1 pM, at wliich the 386Mr 
line showed a 25% reduction in growth whereas the 386 line showed a 70% reduction in 
growth. Both isogenic lines of 386 exhibited a 100% inhibition of growth at a concentration of 
10 pM of Melai'soprol. Comparison of the EC50 values of the 386 line and the 386Mr line for 
Melarsoprol showed less than two fold increase in resistance (Table 5.4).
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Figure 5.3: In vitro growth inhibition assays in arsenical and diamidine drugs for the 
isogenic 386 lines. Procyclic forms of 386 and 386Mr lines were grown in SDM79 in the 
presence of the trypanocidal drugs Cymelarsan (A), Melarsoprol (B), Pentamidine (C), Berenil 
for 24 h (D) and Berenil for 48 h (E). The data present the average value from duplicate 
experiments. The lowest concentration corresponds to the control in the absence of drug. The 
error bars represent the mean +/- SEM, n = 6.
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Cymelarsan Melarsoprol Pentamidine Berenil
386 0.57 0.62 10.85 86.4
386Mr 14.19 1.19 17.01 69.24
247 0.17 0.76 140.83 36.93
247Mr 213.79 1.91 82.24 81.22
Table 5.4: Average ECso values (|iiM) from in vitro growth inhibition assays for the two 
pairs of isogenic lines. The assays were performed on procyclic forms of the pairs o f isogenic 
lines for two arsenical drugs (Cymelarsan and Melai’soprol) and two diamidine drugs 
(Pentamidine and Berenil).
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The phenomenon o f cross-resistance between the diamidine, Berenil, and the arsenicals is 
commonly reported as well as cross-resistance with Pentamidine (Fairlamb et al., 1992; 
Frommel and Balber, 1987; Pospichal et al, 1994). Cross-resistance between the arsenicals 
and the diamidinies (Berenil and Pentamidine) was assessed for procyclic forms of the pairs of 
isogenic lines by an in vitro growth inhibition assay.
Resistance of the procyclic forms of the isogenic lines of 386 to Pentamidine was tested using 
the in vitro growth inhibition assay (Figure 5.3C). The 386 and 386Mr lines showed very 
similar growth inhibition curves in the presence o f Pentamidine. 100% growth inhibition was 
detected at a concentration of 1,000 pM Pentamidine for both lines. Comparison of the ECso 
values showed a slight increase (1.56 fold) in resistance to Pentamidine (Table 5.4). Two 
growth inhibition assays for 386 and 386Mr lines were conducted for the diamidine drug 
Berenil (Figure 5.3). Berenil is a tiypanostatic drug and as such might require a longer period 
of exposure to inhibit the growth of the trypanosomes. Consequently, concentrations o f 
trypanosomes were calculated after 24 h (Figur e 5.3D) and 48 h (Figure 5.3E) of incubation in 
the presence of Berenil. For both growth inhibition assays the resistance pattern of 386 and 
386Mr lines were very similar. Berenil had no noticeable effect on the growth of the isogenic 
lines up to a concentration of 10 pM. Both lines exhibited 100% growth inhibition when 
incubated in 1,000 pM Berenil for either 24 h or 48 h. The ECso values for the isogenic lines 
were compared showing that the 386 and 386Mr lines had similar' sensitivity to Berenil (Table 
5.4).
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Growth inhibition assays were conducted in vitro on procyclic forms o f Cymelarsan sensitive 
and resistant 247 lines to assess their sensitivity to two arsenical-based drugs (Cymelarsan and 
Melarsoprol) and two diamidine drugs (Pentamidine and Berenil).
The isogenic lines showed a dose dependent growth inhibition by Cymelarsan and 100% 
inhibition of growth of the 247 sensitive line was observed at a concentration of 1 pM 
Cymelarsan (Figure 5.4A). This concentration of Cymelarsan had no inhibitory effect on the 
growth of the resistant line. 100% inhibition of growth of the 247Mr line was observed at a 
Cymelarsan concentration of 1,000 pM. Comparison of the ECso values for the isogenic lines 
showed a 1,247 fold increase in resistance to Cymelarsan by the resistant line (Table 5.4). 
Growth inliibition assays o f the isogenic lines with Melarsoprol showed a slight difference 
between the lines at concentrations o f 0.1 pM and 1 pM of Melarsoprol (Figure 5.4B). At a 
concentration o f 10 pM o f Melarsoprol both 247 and 247Mr lines exhibited 100% inhibition 
of growth. Comparison o f the ECso values obtained for Melarsoprol with the isogenic lines 
showed a 2.5 fold increase in resistance to Melarsoprol in the 247Mr line (Table 5.4).
Procyclic forms of the 247 and 247Mr lines exliibited similar* growth inhibition patterns in 
increasing concentration of Pentamidine (Figure 5.4C). No effect on the growth of the 
isogenic lines was noticeable up to a concentration of 10 pM Pentamidine. At the highest 
concentration of Pentamidine tested (1,000 pM), 93% of growth was inhibited. The 247 
showed less than a two fold increase in resistance to Pentamidine when compared with the 
247Mr line (Table 5.4). The growth inhibition assays o f 247 and 247Mr lines in the diamidine 
drug Berenil showed no detectable difference in growth (Figure 5.40). At a concentration of
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Figure 5.4: In vitro growth inhibition assay in arsenical and diamidine drugs for the 
isogenic 247 lines. Procyclic forms o f sensitive and Cymelarsan resistant 247 lines were 
grown in SDM79 in the presence of the trypanocidal (hugs Cymelarsan (A), Melarsoprol (B), 
Pentamidine (C), Berenil (D), The lowest concentration corresponds to the control in the 
absence o f drug. The error bars represent the mean -t-/- SEM, n = 6.
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1,000 |iM Berenil both trypanosomes lines exhibited a 100% inhibition of growth. The EC50 
values were calculated for both isogenic lines and a comparison of these showed a 2 . 2  fold 
increased in sensitivity to Berenil by the 247Mr line (Table 5.4).
These results confirmed that the procyclic forms of the Cymelarsan resistant lines were 
resistant to Cymelarsan as compared to the sensitive parents, as originally described (Scott et 
ah, 1996). Taken together these results suggest that in in vitro gr owth inhibition assays the 
procyclic forms of the pairs of isogenics lines had no cross-resistance between Melarsoprol 
and Cymelarsan, and no cross-resistance to the diamidine dmgs in either of the pairs of 
isogenic lines.
5.3.4 The effect of P-glycoprotein inhibitors on Cymelarsan resistance
Recently, two genes encoding P-glycoproteins have been identified in the T. brucei genome 
(Shahi et ah, 2002), Over-expression of one of these genes, the TbMRPA gene, was linked to a 
10 fold increase in Melarsoprol resistance (Shahi et ah, 2002). This report raised the question 
as to whether the resistance of the drug selected lines in this study could arise from a change in 
expression of either of these P-glycoprotein genes. To test tliis hypothesis, an investigation of 
growth hihibition by Cymelarsan in the presence of thiee candidate inhibitors of P- 
glycoprotein was carried out.
Three general P-glycoprotein inhibitors (verapamil, PCP and TFP) were used in combination 
with Cymelarsan in in vitro assays to assess Cymelarsan efidux as a potential mechanism for 
drug resistance in procyclic forms of the two pairs of isogenic lines. Verapamil at 
concentrations of 1 pM or 10 pM had no growth inhibitory effect on any lines (Figure 5.5A
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Figure 5.5; In vitro growth inhibition assays of isogenic 386 lines in the presence of 
Cymelarsan and P-glycoprotein inhibitors. The assays were performed on procyclic forms. 
Three general P-glycoprotein inhibitors (verapamil (A), PC? (B) and TFP(C)) were tested. 
The error bars represent the mean +/- SEM, n = 6.
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Figure 5.6: In vitro growth inhibition assay of isogenic 247 lines in the presence of 
Cymelarsan and P-glycoprotein inhibitors The assays were performed on procyclic forms. 
Three general P-glycoprotein inhibitors (verapamil (A), PCP (B) and TFP(C)) were tested. 
The error bars represent the mean 4-/- SEM, n = 6.
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and 5.6A). The addition of verapamil did not prevent the inhibition o f growth produced by the 
presence of the arsenical in the medium (Figure 5.5 A and 5.6 A). These results were observed 
for all four lines tested. Both PCP and TFP were shown to be toxic to procyclic forms of all 
lines at a concentration of 10 pM, but had no effect on growth at 1 pM. Comparison of the 
growth of trypanosomes exposed to 1 pM of TCP or PCP in the presence of either 0 pM or 1 
pM o f Cymelarsan demonstrated that these P-glycoprotein inhibitors had no noticeable effect 
on the resistance to Cymelarsan (Figures 5.5B, 5.5C, 5.6B and 5.6C).
These results suggest that efflux of Cymelai'san by an over-expressed or altered P-glycoprotein 
in the Cymelarsan resistant 386 and 247 lines was not involved in the mechanism of 
Cymelarsan resistance in procyclic forms.
5.3.5 Drug sensitivity testing using the Alamar Blue assay
The use o f the Alamar Blue dye is based on the ability of cellular enzymes to reduce the non- 
fluorescent blue dye to a pink fluorescent compound, allowing detection o f cell gi'owth by 
spectrofluorometry and specti'ometry. The Alamar Blue assay was recently developed as an in 
vitro assay to test for drug sensitivity o f procyclic trypanosomes in culture (Raz et ah, 1997). 
This assay was shown to be simple, reproducible and economical.
The Alamar Blue assay was used to assess the sensitivity or resistance of the procyclic forms 
of the pairs of isogenic lines in in vitro culture as an alternative to the growth inhibition assay. 
The assay was first performed on procyclic cultures in the absence o f drug and demonstrated 
that the level of reduced Alamar Blue dye produced by Cymelai'san resistant lines was lower 
than the level produced by sensitive lines (Figure 5.7). The assay was then performed in
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Figure 5.7: Alamar Blue assays on the pairs of isogenic lines in the absence of drug. In
vitro reduction of the Alamar blue dye by procyclic forms of isogenic lines o f 386 (A) and 247 
(B) in SDM79. The error bars represent the mean +/- SEM, n = 4.
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increasing concentration of Cymelarsan. The 386 and 247 lines both exhibited a dose- 
dependent killing o f the trypanosomes (Figures 5.8 and 5.9). However, the 386Mr and 247Mr 
lines showed very little dose-dependent killing o f the trypanosomes. Microscopic examination 
of the culture confirmed the presence and viability of the Cymelarsan resistant lines in the 
culture medium for concentration ranging firom 10'  ^to 10^  pM of Cymelarsan.
These results suggest that the mechanism of reduction of the Alamar Blue dye has been 
modified during the selection for Cymelarsan resistance in T. hmcei lines of 386 and 247. This 
unexpected result is investigated lurther in chapter 8.
5.4 Discussion
The main mechanism of arsenical resistance in trypanosomes has long been thought to be due 
to an alteration in uptake of the dmgs mediated by the P2 transporter. However, no activity of 
the P2 transporter has been found in procyclic stages of trypanosomes (de Koiung et al., 
2000). A recent study on field isolates from Uganda has demonstrated the presence of un­
mutated TbATl gene in 50% of the relapsed patients (Mato vu et al., 2001). In addition, the 
knockout of the TbATl gene only conferred a three fold resistance to Melarsoprol (Matovu et 
ah, 2003), which is below the reported resistance observed in in vivo experiment in the two 
pairs of isogenic lines used in this study (MIC > 40 mg/Kg; Table 5.1). Consequently, the 
mechanism of resistance to the arsenicals drugs appears to be multi-factorial and necessitates 
to be investigated.
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The procyclic forms of the laboratory-generated Cymelarsan resistant lines differ fi-om the 
sensitive lines in their ability to survive in high concentration of Cymelarsan. Comparison of 
ECso values calculated from growth inhibition assays evaluated the resistance as 25 fold in the 
386 lines and 1,247 fold in the 247 lines. These values are different from the resistance levels 
described previously for procyclic forms o f these lines wliich were a 500 fold increase in 
resistance for both pairs of isogenic lines (Scott et aï., 1996). The difference in resistance level 
could be explained by the use of a different assay to evaluate the ECso values.
The use of growth inliibition assays with Melai'soprol, Pentamidine and Berenil demonstrated 
the absence o f cross-resistance between Cymelarsan, Melai'soprol and the diamidines drugs. 
All four drugs are known to enter the trypanosomes via a nucleoside transporter, the P2 
transporter, in bloodstream forms (de Koning, 2001). However, the P2 tranporter was shown 
to be a minor entry route for Pentamidine which can also be mediated by HAPTl and LATl 
(de Koning, 2001), potentially explaining the lack of cross-resistance observed between 
Cymelarsan and Pentamidine in this study.
The lack o f cross-resistance with Melarsoprol was expected in the assay of procyclics as 
Melarsoprol itself is not thought to enter the trypanosome via the P2 transporter despite the 
fact that this molecule possesses the recognition site for the P2 transporter (de Koning, 2001). 
Instead, Melarsoprol is thought to enter the trypanosomes via passive diffusion. In order to 
enter via the P2 transporter, Melarsoprol first requires to be metabolised into Melaisen oxide 
and this only happens in vivo (Keiser et al., 2000). This explains why cross-resistance was
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observed in the bloodstream forms of the two pairs of isogenic lines between Cymelarsan and 
Melarsoprol and not in procyclic forms (Scott et ah^ 1996).
Two genes encoding P-glycoprotein were recently discovered in the genome sequencing 
project of T. brucei (Shahi et al., 2002) with good homologies to hoXh. Leishmania and T, cmzi 
P-glycoprotein genes (Figure 5.10), The over-expression of one o f the genes, TbMRPA, in line 
927 was reported to confer a 10 fold increase in Melarsoprol resistance while over-expression 
of the second gene {TbMRPE) was associated with resistance to Suramhi. From these data one 
hypothesis was that over-expression of the TbMRPA gene could account for some or all o f the 
resistance observed in the lines studied here. Inhibition of P-glycoproteins usmg specific 
inhibitors demonstrated that an over-expression or alteration of this gene was not associated 
with Cymelarsan resistance in T. brucei.
The Alamar Blue assay has been recently shown to enable the determination of sensitivity of 
T. b. gambiense and T. b. rhodesiense to Melarsoprol, DFMO, Pentamidine and Suramin (Raz 
et al., 1997). The assay is based on the reduction of the Alamar Blue dye, by intracellular 
enzymes, winch correlates with cell growth and metabolic activity in the presence/absence of 
drug. The use o f the in vitro Alamar Blue assay on each pah of isogenic lines in the absence of 
drug has demonstrated the reduced fluorescence obtained horn the dye by the Cymelarsan 
resistant lines. In addition, the expected dose-dependent response to Cymelarsan, 
corresponding to a loss o f viability, was only observed for the sensitive lines. No change in the 
fluorescence level due to the reduction of Alamar Blue was observed for the resistant lines 
with increasing level of Cymelarsan and loss of viability. The alteration in the fluorescence
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level produced by the Cymelarsan resistant line could be due to a defect in the activity of the 
intracellular enzymes or an alteration in the transport/export of the Alamar Blue dye. The 
analysis o f these two hypothese has been undertaken and the results are presented in chapter 8.
The Cymelarsan resistance observed in the two pairs o f isogenic lines was not associated with 
either a lack of expression of the TbATl gene or over-expression or alteration of a P- 
glycoprotein. Consequently, the resistance mechanism in the procyclic forms of these lines 
does not follow the conventional pattern described so far in the literature. Other genes/proteins 
must be involved in the Cymelarsan resistance which have so fai’ not been identified.
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Figure 5.10: Evolutionary tree showing selected multidrug resistant proteins (MRP) and 
P-glycoproteins (Pgp). Species are Homo sapiens (Hs), Leishmania tarenolae (Lt), 
Leishmania tropica (Ltr), Leishmania donovani (Ld), Leishmania major (Lm), Saccharomyces 
cerevisiae (Sc), Trypanosoma brucei (Tb) and Trypanosoma cruzi (Tc). The two genes 
encoding MRPs from T. brucei are boxed. (Reproduced from Shahi et al, 2002)
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Chapter VI
A proteomic approach to study Cymelarsan resistance InT. brucei line 386
6.1 introduction
Analysis of the isogenic sensitive and resistant lines o f 386 demonstrated that both 
procyclic and bloodstream forms exhibited the Cymelarsan resistance phenotype (Scott et 
al., 1996). The cross-resistance analysis in procyclic forms of the 386 lines ruled out the 
involvement of the P2 transporter in the mechanism of arsenical resistance (chapter 5). In 
addition, the inhibition o f P-glycoproteins had no effect on the resistance phenotype of the 
386Mr line, arguing against the hypothesis that increased efflux o f the drug by an over­
expressed P-glycoprotein could explain the Cymelarsan resistance. With the increase 
number o f reported cases o f Melarsoprol refractory parasites in the field (Stanghellini and 
Josenando, 2001; Legros et al., 1999; Brun et al., 2001; Mato vu et a l,  2001) it is 
imperative to determine the genes/proteins involved in the mechanism of arsenical 
resistance. The well-characterised laboratory derived isogenic lines of 386 were used as a 
model to determine the mechanisms o f drug resistance.
There are a number of approaches to identify the genes that determine resistance to 
arsenical drugs in T. brucei. These include genetic analysis/positional cloning (Tait et al., 
2002), biochemical analysis (Fair lamb, 2002), cloning and functional analysis o f candidate 
genes (Maser et al., 1999) and phenotypic analysis of isogenic parasites lines which are 
resistant or sensitive to the drug. The particular approach taken depends to a large extent 
on the hypotheses as to the mechanism of drug resistance. In the case of laboratory- 
selected lines, it is likely that multiple mechanisms occur to confer the final resistance
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phenotype. In principle, a range of mechanisms could be put forward that include point 
mutations or deletions in genes involved in drug transport, in the drug target or involved in 
drug degradation, as well as alterations in the level of expression o f any of these genes.
The advantages of using either a proteomic or microarray approach in this context are tliat, 
in principle, all the possible mechanisms could be identified, although microaiTay analysis 
will only identify alterations in gene expression at the transcriptional level.
A proteomic approach, assessing the level of protein expression in a pair o f isogenic lines 
was prefeiTed to a micro-array approach. Measured mRNA levels are often implicitly or 
explicitly extrapolated to indicate levels o f activity of the corresponding protein in cell. 
Even a bacterium with a small genome such as Mycoplasma genitalium had 24% more 
proteins expressed than the number predicted on a simple one gene, one protein system 
(Wasinger et ah, 2000). Similarly, a correlation coefficient o f 0.48 was obtained between 
the mRNA and protein abundance deteiinined by 2DE and gel imaging o f human tissues 
(Anderson and Seilhamer, 1997). This correlation coefficient was confirmed using 
techniques such as immunoaffinity-HPLC and Northern analysis (Anderson et ah, 1998). 
These proteomic analyses illustrated the strength of 2DE analysis over micro-array 
technology. The low correlation coefficient obtained is probably due to the fact that the 
rate of degradation of individual inRNAs and protein differ. Proteins are very often the 
target o f drugs and so measuring proteins directly gives a more accurate picture o f the 
biology o f a cell under various conditions. Proteome profiles can be scanned and 
quantitated to search for protein differences such as changes in levels o f pre-existing 
proteins, induction o f new products and alterations in amino acid sequence, 2DE is a 
relatively simple and reproducible technique. Proteome analysis provides data that are of
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critical importance for the description o f the state o f a biological system and that are not 
readily apparent from the sequence and the level o f expression o f mKNA transcripts.
While the number of global proteomic expression profiling studies with pathogens such as 
bacteria and viruses are numerous, the application of these methodologies to protozoan 
parasites has lagged behind. This can be attributed to a number of causes, one o f these is 
that protozoan parasites tend to be difficult to culture and manipulate in vitro, making it 
difficult to obtain enough pure material for proteomic analysis. However, procyclic forms 
o f r. brucei can be cultured relatively easily in vitro and a reproducible solubilisation 
protocol for 2DE analysis o f proteins from trypanosomes has been developed m this study 
(chapter 2). This enables a proteomic expression profiting study to be carried out and a 
comparative analysis made between Cymelarsan sensitive and resistant isogemc Imes.
Differentially expressed protein spots can be analysed by mass spectrometry methods 
enabling protein identification. In the case o f T. brucei, approximately 40% of protein 
spots are predicted to be identifiable using the simple technique o f PMF with the current 
level o f annotation of the T. brucei genome (chapter 4). For protein spots which cannot 
unambiguously be identified by PMF, Tandem MS can be used to generate tiyptic peptide 
sequence information that would either confirm tentative MALDI-TOF identification or 
more readily identify the gene if it is present in the database. In order to analyse the basis 
of Cymelarsan resistance and identify pathways involved in the response to drug treatment, 
the strategy illustrated in Figure 6.1 was used.
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Figure 6.1: Schematic representation of strategies employed to determine protein 
associated with arsenical resistance in isogenic 386 lines. Two mass spectrometry 
approaches were used to increase the likelihood o f identification o f the differentially 
expressed protein. Mass spectrometry data were searched against the NCBIm* and the local 
r. brucei database using the MASCOT® search engine. The corresponding genes were then 
fiirther analysed to assess their presence/absence, transcription and mutations in the lines.
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In this chapter, proteomic techniques were used to compare whole soluble protein 
expression patterns between Cymelarsan sensitive and resistant 386 lines and so detect 
variation in protein expression associated with arsenical resistance. In addition, these 
protein expression patterns were also compared with those of the Cymelar san resistant 386 
line growing in 1 pM Cymelar san to determine whether some protein expressions were 
induced in the presence o f Cymelarsan. Differentially expressed protein spots were 
identified using mass spectrometry techniques and the corresponding genes identified.
These genes were further analysed to define the alterations associated with arsenical
resistance.
6.2 Materials and Methods
6.2.1 Commonly used reagents
The QIAGEN plasmid minikit, QIAquick gel extraction kit, EndoFree plasmid Maxi kit 
and Ni-NTA agarose were all purchased from Qiagen. The competent cells (Top 10, DH5a 
and BL21AIE. coli cells), Rnase Out, Sperscript RT, L-arabinose and the TOPO vectoi 
were pmdiased fr om Invitrogen. The enzymes, EcoRI, Hindlll, BamHI and BsaH were 
purchased from New England BioLab. The antibiotics (Ampicillin and Kanamycin), X-gal, 
Chloroform, Isopropanol, DEPC, formaldehyde and formamide were purchased fr om 
SIGMA. Trizol, pD0NR211 plasmid and pDEST17 vector were purchased fr om GIBCO 
BRL®. Custom PCR MasterMix and the Taq polymerase were purchased fr om ABgene. 
Microspin TM S 200HR, Hybond-N nylon membrane. X-ray films, pre-cast 12% 
polyacrylamide 24 cm gels and the DALTII vertical tank were purchased from Amersham 
Biosciences. Oligonucleotides were synthesised by MWG Biotech.
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6.2.2 In vitro culture of procyclic trypanosomes
The in vitro procyclic cultures o f Cymelarsan sensitive and resistant lines of 386 in 
SDM79 were performed as described in chapter 2. In addition, the Cymelarsan resistant 
386 line was grown in complete SDM79 medium supplemented with 1 pM Cymelarsan 
solution diluted in complete SDM79 medium.
6.2.3 Protein extraction, 2DE and mass spectrometry techniques
6.2.3.1 Protein extraction and 2DE
Proteins extraction from the procyclic cultures was performed as described in chapter 2 
(protocol P2) except that 470 pi of solubilisation buffer was used instead of 350 pi. 24 cm 
strips were used in this study to separate the proteins in the lEF. Rehydration of the strip 
was performed using 470 pi o f protein extract and separation by lEF was performed as 
described in chapter 2, except that the last separation step at 8,000 V was increased to 8 h. 
The second dimension of the 2DE was run with 24 cm, 12% polyacrylamide pre-cast gels 
in a DALT II vertical tank according to the manufacturer’s instructions.
6.2.3.2 MALDI-TOF and Tandem MS
Trypsin digestion of protein spots o f interest and peptide mass fingerprinting by MALDI- 
TOF MS were carried out as described in chapter 3.
For Tandem MS, the protein spots were digested the same way as for peptide mass 
fingerprinting. The samples were purified and concentrated using ZipTips as previously 
described (chapter 3), except that the TFA solution was replaced by formic acid (10%). 1 
pi o f the concentrated sample was loaded into a capillary needle (Protana). The capillary
136
Chapter VI; A  proteomic approach to study Cymelarsan resistance in T. brucei in line 386
needle was linked to the Tandem MS and voltage was applied to enable the spray o f the 
sample (nano-electrospray).
The Tandem mass spectrometer used in this study (Q-STAR) contains two analysers, 
separated by a collision cell. Peptide mass fingerprints were acquired in the first analyser 
(TOF-MS scan), the high intensity peptides were then specifically selected, fr agmented in 
the collision cell and the mass o f the fragment ions were measured in the second analyser, 
producing peptide sequence information.
The Tandem mass spectra were acquired in the following way. The TOF-MS scan was run 
for 10 s and detected doubly, triply and quadruply charged ions whose mass to charge ratio 
(m/z) was between 400 and 1,000. From this, mass spectra were acquired using a data- 
dependent acquisition mode in which each full scan mass spectrum generated by the TOF- 
MS was followed by collision-induced dissociation o f the eight most intense parent ions 
whose signal had reached a threshold o f 20 counts/s. Acquisition was performed with the 
dynamic exclusion o f m/z ratios o f already fi'agmented ions. The fragmentation was 
performed in positive polarity using nitrogen as the collision gas. Mass spectra were 
acquired for 15 s in the range o f 50 to 2,000 m/z. The resulting peptide MS/MS spectra 
were interpreted using the MASCOT® search engine to search the NCBInr and a local T. 
brucei database to identify the genes encoding the particular protein. Partial 
carboxymethylation o f cysteine residues and oxidation o f methionine residues were 
considered in the search.
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6.2.4 Molecular biology methods
6.2.4.1 Sequencing
Once the sequence o f the gene encoding the protein o f interest was identified, primers were 
designed to allow amplification o f the complete coding sequence. Each ORE was cloned 
using primers 274F/274R and 277F/277R (Figure 6.2, Table 6.1). PCR was performed, on 
genomic DNA from 386 and 386Mr lines, in 40 pi reaction volume containing, 4 pi of 
Custom MasterMix buffer, 5 pM o f each primer, 200-300 ng o f DNA template and 4 units 
of Taq polymerase. Amplification was performed on a robocycler (Stratagene) by 
denaturing at 95°C for 50 s, annealing at 63°C for 50 s and extension at 68°C for 2 min for 
30 cycles followed by incubation at 68°C for 15 min. The PCR product was run on a 1% 
agarose gel and extracted from the gel using the QIAquick^’^  gel extraction kit, according 
to the manufacturer’s instructions. Cloning was performed using the TOPO vector and 
competent E. coli TOP 10 cells. Insertion o f the PCR product into the TOPO vector was 
performed by mixing 1 ng o f TOPO vector with the PCR product (1 pi) in water (final 
volume o f 5 pi) and incubating at room temperature for 5 min. 1 pi of this cloning reaction 
was added to a vial o f competent E. coli TOP 10 cells and incubated on ice for 30 min. 
Transformation o f the competent cells was performed using the heat shock method (42°C 
for 30 s followed by 4°C for 2 min). Luria Bertani (LB) medium (250 pi) was then added 
to the vials which were incubated at room temperature for a further 30 min. Selection of 
recombinant E. coli cells was undertaken on LB agar plates containing Ampicillin 
(0.4mg/ml) and X-gal (5 pg/ml, 5-bromo-4-chloro-3-indolyl-P-D-galactoside) at 37°C 
overnight. Single colonies were picked and grown in 10 ml o f LB medium containing 
Ampicillin (0.4 mg/ml) at 37°C overnight. E. coli cells from 3 ml o f culture were 
concentrated in an Eppendorf by centrifuging at 12,000 g for 3 min. The TOPO vector
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Trypll 274F 274G 277F 277G
ORF 274 ORF 277
274R 277R Trypl2
Figure 6.2: Location of primers use for the analysis of ORF 274 and 277. Schematic 
representation o f the two ORFs encoding the CAR protein, with the location o f the primers 
designed for RFLP analysis (Trypl 1/Trypl2), cloning (274F/274R and 277F/277R) and 
Northern analysis (274G/274R and 277G/277R).
Name of 
primer
Sequence Annealing
T°C/Time
Elongation
T°C/Time
Tryp9/ll 5'-GAGGGAGGGGGAATTTCCTC 59°C/50s 68°C/2min30
Tryp9/12 5-GAGCCATGACGAATCI MIG 59°C/50s
68«C/
2min30
274-F 5-CAGCGAATTTATCTACATGC 63°C/50s 68°C/ 2min
274-R 5-TGGCCACGGAAACACTCCTA 63°C/50s 68°C/ 2min
274-G 5-GTGTAAGTGAAACCCCCAAT 63°C/50s 68°C/ 2min
277-F 5-GTGCTACTACATTCGCCTCA 63°C/50s 68°C/ 2mln
277-R 5-CATCACAATGGATGGAGGAT 63‘»C/50s 68°C/ 2mln
277-G 5'-CGATTACCGAGGTGAAAAGT 63°C/50s 68°C/ 2min
NAC Ab-F 5'-GTAACCCGGAAGCTTACGATGGGCGCTAAC 60°C/50s 68°C/2min30
NAC Ab-R 5’-GATCAGTTGGGATCCTAGGTCAGTTCC 60®C/50s 68°C/2min30
AttBl F S'-GGGACAAGTTTGTACAAAAAAGCAGGCTCGATGAGCGCTAACGATGTTCAA 68°C/50s 68®C/2min30
AttB2R 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTATCAG
TTGGGATCCATCGTCAG 68°C/50s
68°C/
2min30
TIMA 5-GCGTAGTGGCCTCCACCTTTG 63®C/50s 68°C/ 2min
TIM-H 5-TGCCGTTGAGTGGGTGAAGATAGC 63°C/50s 68°C/ 2min
BJSIO 5-GGGCAAACAACAGAT
B JS ll 5-CGCAAATGGGCGGTAGGCGTG
Table 6.1: List of primers for the analysis of ORF 274 and 277. Sequence of primers 
used for the analysis o f ORF 274 and ORF 277, and the production o f anti-CAR 
antibodies, with the amplification conditions are given. Dénaturation for all PCR was 
performed at 95°C for 50 s.
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containing the insert was extracted from the E. coli clone using the QIAGEN plasmid 
minikit according to the manufacturer’s instructions. To assess the presence of the insert in 
the TOPO vector, 3 pi o f plasmid was digested with EcoRI (250 U) in 15 pi o f ddH20 
containing 2 pi o f EcoRI buffer at 37°C for 2 h. Digestion products were analysed by 
agarose gel electrophoresis on a 1% agarose gel. Plasmids containing the correct size insert 
were precipitated using 3 M Sodium acetate (1/10**^  volume) and 100% ethanol (2 volumes) 
by incubating at -20°C overnight (Sambrook et al., 1989). The selected clones and the 
primers were then sent for sequencing to the MBSU of the University o f Glasgow.
6.2.4.2 Analysis of transcription
6.2.4.2.1 RNA extraction
Extraction of RNA from procyclic culture was performed under sterile conditions in a 
culture hood, 27 ml o f procyclic cultures at 7x10^ trypanosomes/ml were centrifuged for 8 
min at 12,000 g to collect 1x10® trypanosomes. The pellet was washed once in PSG buffer 
and then re-suspended in 1 ml o f Trizol. Following 5 min incubation at room temperature, 
0.2 ml o f chloroform was added to the solution, the tubes were shaken vigorously and then 
incubated for a further 2 min at room temperature. The phases were separated by 
centrifuging at 4°C for 15 min at 12,000 g and the aqueous phase was transfeiTed into a 
clean Eppendorf to which 0.5 ml o f isopropanol was added, mixed well and incubated at 
room temperature for 10 min. The RNA was pelleted by centrifuging the tubes at 4°C for 
10 min at 12,000 g, and then washed in 75% ethanol prepared in diethyl pyrocarbonate 
(DEPC) treated water. The pellet was air-dried, re-suspended in 100 pi of DEPC treated 
water and treated with DNA-free^^ kit (Ambion) according to the manufactuier’s 
instructions.
6.2.4.2.2 RT PCR
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Total complementary DNA (cDNA) was prepared from RNA dissolved in DEPC treated 
water using an oligo (dT)i5 primer for first strand synthesis. The total cDNA from the RNA 
was produced by incubating the PCR tubes containing the RNA on a robocycler 
(Stratagene) at 70°C for 10 min and then at 4°C for 1 min. To each tube, 4 pi of 5x first 
strand buffer, 0.01 M of DTT, 10 pM o f dNTP mix and 1 pi o f Rnase out was added. After 
the tubes were incubated at 42°C for 5 min, 1 pi o f Superscript RT was added. The 
solution was covered with 6 pi o f mineral oil to prevent evaporation of the solution. Tubes 
were incubated at 46°C for 50 min, followed by 70°C for 15 min and then stored at -20°C. 
This total cDNA was then used as a DNA template in PCR reaction using primers 
274F/274R and 277F/277R to assess the transcription of ORF 274 and 277. The 
amplification was performed as described in section 6.2.4.1 except that the last elongation 
step (68°C for 15 min) was removed.
6.2.4.2.3 Northern blot analysis
The RNA extracted from trypanosomes was run on a 6% formaldehyde gel. Gels were 
made by mixing 2% melted agarose with 12% formaldehyde in 20x Northern gel buffer 
(0.036M Na2HP0 4 , 0.004M NaH2P 0 4 )- 3 pi of the RNA samples were mixed with 3.5 pi 
of formaldehyde, 10 pi o f formamide, 1 pi o f 20xNorthern gel buffer and double distilled 
water to a final volume o f 20 pi. The samples were incubated at 55°C for 15min and 
chilled on ice. 2 pi o f RNAse-free loading buffer (50% glycerol, 1 mM EDTA pH8, 0.25% 
Bromophenol blue, 0.25% Xylene cyanol FF) was added to the samples, and the samples 
were loaded onto the gel. The gel was run at 60 V for 6 h and then incubated in 20x SSC 
(0.3 M Tri-sodium citrate, 3 M sodium clrloride, pH 7.0) at room temperature for 30 min. 
The RNA was transferred onto a Hybond-N nylon membrane at room temperatuie 
overnight (Sambrook et al., 1989). Cross-linking of the RNA onto the membrane was 
performed in a Spectrolinker XL-100 UV crosslinker (Spectronics Corporation). The
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membrane was incubated in the pre-hybridisation solution (7.5 ml formamide, 3.75 ml 20x 
SSC, 3 ml 5Ox Dendhart, 0.1 ml NaIÎ2P0 4  pH 6.5, 0.3 ml HS DNA, 0.15 ml 10% SDS and 
0.15 ml 0.5 M EDTA) at 42°C for a minimum o f 4 h. The probes were generated by PCR 
amplification of genomic DNA from the Cymelarsan sensitive 386 line, using primers 
274G/274R, 277G/277R and TIM-A/TJM-F (Figure 6.2, Table 6.1). The PCR products 
were run on a 1% agarose gel and the fragment corresponding to the correct size product 
were recovered from the gel using the QIAquick^*^ gel extraction kit according to the 
manufacturer’s instructions. The PCR products were labelled with a ^^P (NEN Life 
Science) using the Stratagene Prime-IT II random primer labelling kit according to the 
manufacturer’s instructions. The labelled probe was purified using a Microspin TM S 
200HR column according to the manufactiner’s instructions. The probe was denatured for 
5 min at 95°C, before being added to the hybridisation solution. Hybridisation was allowed 
to take place overnight at 42°C. The probe was then removed and the membrane washed in 
0.1% SDS and O.lxSSC at 57°C for 3 cycles of 30 min. The membrane was exposed to a 
X-ray film for 7 days at -80°C and the autoradiographs were developed using a Compact 
X4 film processor (X-graph Imaging Systems) according to the manufactuier’s 
instructions.
6.2.4.3 Production of antibody
Antibodies to the expressed product o f ORF 274 were produced in mice using a DNA 
vaccination strategy (Figure 6.3). Mice were first injected with the pcDNA3.1(+) plasmid 
containing ORF 274 and then with a recombinant protein produced from ORF 274 to boost 
the antibody response.
6.2.4.3.1 Cloning in pcDNA3.1(+)
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The pcDNAS.l plasmid was donated by Dr Gill Douce (University o f Glasgow). The 
forward primer was designed from the sequence o f ORF 274 and modified to contain the 
Kozak translation initiation sequence, an ATG codon and a Hindlll restriction site. The 
reverse primer was designed from the sequence o f ORF 274 and modified to contain a stop 
codon and a BamHI restriction site, to facilitate cloning in the right open reading frame and 
forward orientation (Figure 6.4). PCR was performed on genomic DNA from line 927 
using these primers in a 40 pi reaction as previously described. The PCR products and 
pcDNA 3.1 (+) plasmid were digested using Hindlll and BamHI restriction enzymes by 
incubating at 56°C for 1 h. Transformation of Top 10 F. coli competent cells with the 
plasmid and PCR product was carried out as previously described. Single colonies of the 
transformed E. coli cells were picked, grown up in LB medium and the plasmid extracted 
as previously described. The plasmid from these clones was sequenced by the MBSU of 
the University o f Glasgow, using the BJS 10 and BJS 11 primers (Table 6.1), to determine 
whether the insert was in frame. One clone, with the insert in frame and in the right 
orientation, was selected and grown in 100 ml o f LB medium containing Ampicillin (0.4 
mg/ml). Plasmid DNA was extracted from a 100 ml culture using the EndoFree® plasmid 
Maxi kit, according to the manufacturer instructions. The purified plasmid was given to Dr 
Gill Douce (University o f Glasgow) for coating onto gold particles and injection into mice 
by gene-gun technology.
6.2.4,3.2 Expression of recombinant protein in E, coli (Gateway system)
The Gateway Cloning Technology is a universal cloning system that takes advantage o f the 
site-specific recombination properties o f bacteriophage lambda (Tandy, 1989) to provide a 
rapid and highly effective way to move a gene of interest into multiple vector systems.
The Gateway Cloning Technology was used for cloning PCR products flanked by an attB
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TREU 927 line
Cloning in 
pcDNA3.1(+) vectori
Sequencing of 2 clones
i
Growth in 100 ml culture
i
Plasmid extraction with 
EndoFree maxi kit
i
Coat gold particles with 
plasmid
Day 1 Day 16
Cloning in pD0NR211 :
Entry Clt^e
Recombination event between 
Entry Clone (pD0NR21 l)and 
Expression vector (pDESTl?)i
Expression of His tag CAR 
protein in E. coli BL21A1
i
Ni-column purification of 
recombinant CAR protein
Day 21 Day 35
Genegun Genegun Protein boost First bleed
Figure 6.3: The genegun technology. Schematic representation o f the strategy used to 
produce antibody against Tryp9.0.000322-274 (CAR gene) fiom the reference line 927. 
The mice was injected on day 1 and day 16 with gold particles coated with the plasmid 
pcDNA3.1(+) containing the Kozak initiation sequence and ORF 274 in frame with the T7 
promoter and on day 28 with a purified N terminal His tagged CAR protein.
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NAC Ab-F: 5’-GTA ACC CGG AAG CTT ACG ATG CGC GCTAACi 1 I
Hindlll Kozak consensus
restriction sequence
site
NAC Ab-R: 5’- GAT CAG TTG GGA TCC TAG GTC AGT TCCi
BamHI restriction 
site
Figure 6.4: Prim ers for cloning in plasmid pcDNA3.1(+). Sequences o f the forward and 
reverse primers designed to clone ORF 274 in plasmid pcDNA3.1(+) for the production o f 
antibodies in mice. The forward primer contains the start codon (underlined), a Hindlll 
restriction site (blue) and the Kozak translation initiation sequence (bold). The reverse 
primer contains the stop codon (underlined) and a BamHI restriction site (blue).
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recombination sites to generate Entry Clones. Primers were designed to contain the attB 
recombination sites in frame with the start codon (forward primer) and the stop codon 
(reverse primer). Amplification using these primers was performed on 200-300 ng of DNA 
from line 927 in a 40 pi reaction, using the conditions described in Table 6.1. The PCR 
products were run out on a 1% agarose gel and the band coiTesponding to the predicted 
size of ORF 274 was extracted from the gel using the QIAquick™ gel extraction kit and 
pui'ified using 30% PEG 8000/ 30 mM MgCE. The Entry Clone was generated using the 
purified PCR product and the pDONR211 plasmid with insertion into the plasmid being 
undertaken according to the manufacturer instructions. This plasmid was used to transform 
DH5a competent cells and recombmant cells were selected on LB agar plates containing 
Kanamycin (50 pg/ml). Single colonies were picked and grown in LB medium containing 
Kanamycin (50 pg/ml), and the plasmid was extracted from 3 ml o f culture using the 
QIAGEN plasmid minikit.
The Entry Vector was generated by a recombination event between the pDONR211 
plasmid, containing ORF 274 from trypanosome line 927, and the pDEST 17 vector 
containing a T7 promoter and 6 histidines at the N terminus. The recombinant pDEST17 
vector was introduced into BL21AI competent cells. Recombinant cells were selected on 
LB agar plates containing Ampicillin (100 pg/ml) by growth at 37°C overnight. Single 
colonies were then grown in LB medium at 31°C. The recombinant protein was expressed 
by growing the transformed BL21AI cells on LB medium containing Ampicillin (100 
pg/ml) at 37°C for 3 h on a shaker. Expression o f the recombinant protein was induced by 
addition o f L-arabinose in the culture medium and incubation at 37°C for 4 h. The cells 
were pelleted (4°C for 15 min at 12,000 g) and stored at -20°C. Recombinant protein, from 
the induced BL21AI cells, was extracted by sonicating the cells in Binding buffer (10 mM
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Tris-HCl pH 7.8, 5 mM Imidazole, 0.5 M NaCl, 10% glycerol) on ice 20 times for 30 s. 
The recombinant protein was purified from the extract using affinity chromatography on 
Ni-NTA agarose according to the manufacturer’s instruction. The purity of the eluted 
protein was assessed by running the fractions on a 12% SDS-PAGE gel. The gel was 
stained with Coomassie Brilliant blue.
Antiserum to the recombinant protein was obtained from female mice immunised by a 
genegun injection of plasmid pcDNA 3.1 (+) containing ORF 274 (day 1 and 16) followed 
by intraperitoneal innoculation o f a booster o f 0.2 mg/ml recombinant protein with 0.1 ml 
o f complete Freund’s adjuvant. All injections and bleeding of the mice were performed by 
Dr Gill Douce. A first bleed was obtained after 35 days, and the production of antibody 
tested by Western dot blot analysis against the recombinant CAR protein (data not shown). 
The final bleed was made on day 45.
6.2.4 3 Western blot analysis
Western blot analysis o f proteins separated onto SDS-PAGE gels were carried out as 
described in chapter 2.
6.3 Results
6.3.1 Comparative proteomic analysis of Cymelarsan sensitive and 
resistant T. brucei using broad pH ranges
In order to compare the protein expression profiles of Cymelar san sensitive and resistant 
lines o f 386, soluble proteins extracted from procyclic cultures were separated by 2DE. 
Proteins extracted ft om 1x10^ procyclic form parasites were separated in the first
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dimension according to their isoelectric point, on IPG strips (pH 4-7), and then by 
molecular weight on a 12% polyacrylamide gel. After staining the gels with Sypro ruby, 
they were compared by subtractive analysis, using the ImageMaster 2DElite software. The 
comparison showed that, out o f 485 proteins separated on the 2D gels, there was only one 
protein spot (spot 2) differentially expressed between the lines (Figure 6.5). The protein 
spot present in the soluble protein extract o f 386, at about pi = 4.5, was absent ftom the 
extract of the 386Mr line. This protein spot was located adjacent to a protein spot, present 
in both lines, with approximately the same molecular weight but a more acidic pi (spot 1).
In order to ensure that the difference observed between 386 and 386Mr lines was not due 
to minor differences in sample preparation, fiirther protein extractions were made fi’om 
procyclic form parasites. These were separated by 2DE, as before, and stained with either 
Sypro ruby or Coomassie Brilliant blue. Nine independent soluble trypanosome protein 
extracts were run on 2D gels, all o f which consistently revealed the absence of the protein 
spot around pH 4.5 in the 386Mr line (Figure 6.6A and 6.6B). This con&med that the 
differentially expressed protein spot was not due to sample preparation. In addition, the 
missing protein spot could not be detected in the 386Mr protein extracts using either the 
insensitive Coomassie Brilliant blue staining or the sensitive Sypro ruby staining.
This suggests that the observed difference was not an artifact due to variation in sample 
loading.
2D gels were run using soluble protein extracts from procyclic forms o f 386Mr line 
growing in 1 pM of Cymelarsan in SDM79 (Figure 6.6C). These gels also revealed the 
absence of the protein spot around pH 4.5 in the 386Mr line growing in the presence of the
148
Chapter VI: A proteomic approach to study Cymelarsan resistance in T. hnicei in line 386
A)
B)
pH 4 pH 7
- I *
* ' A  ' v i !" V A.i
i
Figure 6.5: 2D gels of procyclic forms of isogenic 386 lines, pH 4-7. Broad pH range 
isoelectric focusing (pH 4-7) 2D gels for 386 (A) and 386Mr (B) lines. Soluble proteins 
extracted from 1x10* procyclic trypanosomes were loaded onto the gel. The gels were 
stained with Sypro ruby. Image analysis using the 2DElite software revealed over 485 
distinct protein spots. One protein spot indicated by an arrow was differentially expressed 
between the lines.
149
Chapter VI; A proteomic approach to study Cymelarsan resistance in T. brucei in line 386
A)
B)
i t
C)
Figure 6.6: Close-up of the differentially expressed protein spot. Close-up of a section 
of the gels between pH 4.4 and 4.6 from 2D gels on broad pH range lEF (pH 4-7) for 386 
(A), 386Mr (B) and 386Mr growing in the presence of I pM Cymelarsan (C). Soluble 
proteins, from 1x10* parasites grown in SDM79, were separated on pH 4-7 2D gels and 
stained with Coomassie Brilliant blue. An arrow indicates the differentially expressed 
protein spot (spot 2).
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drug. No other difference in the 2D protein pattern was observed in over 485 protein spots 
separated by 2DE and visualised by Sypro ruby staining.
6.3.2 Comparative proteomic analysis of Cymelarsan sensitive and 
resistant T. brucei using narrow pH ranges
With complex samples, such as the whole cell extract employed m tliis study, 2DE analysis 
on wide-range pH gradient reveals only a small percentage o f the whole proteome because 
o f insufficient spatial resolution. The use o f narrow range focusing gels can provide 
increased resolution of proteins with similar electrophoretic mobilities. Zoom-in gels in the 
pH range between 4 and 7 (IPG 4-5,4.5-5.5, and 5.5-6.7) were used in the first dimension 
separation to increase the resolving power of 2DE on whole cell extracts from procyclic 
forms o f the two isogenic lines.
63.2.1 Analysis of Cymelarsan resistance on pH 4-5
To determine whether other proteins were differentially expressed between the pan of 
isogenic lines, whole soluble protein extract from procyclic forms were separated on a 
narrow pH range gel o f pH 4 to 5. The gels were stained with Coomassie Brilliant blue, 
compared and one differentially expressed protein spot detected between the lines. One 
protein spot (at approximately pi ~ 4.5) on the 2D pattern o f proteins from the 386Mr line 
was missing when compared with the 2D gel separation from the 386 line. On the gel from 
the 386 line this protein spot was located adjacent to a second protein spot, present in both 
lines, which had approximately the same molecular weight but a more acidic pi (data not 
shown).
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63.2.2 Analysis of Cymelarsan resistance on pH 4.5-5.5
Proteins extracted from 1x10* procyclic stage trypanosomes were separated on narrow 
isoelectric focusing, pH 4.5 to 5.5 strips, prior to separation according to their molecular 
weight on 12% polyacrylamide gels. Analysis o f the Coomassie Brilliant blue stained gels 
using the ImageMaster 2DElite software revealed almost 200 spots on each gel (157 spots 
on the 386 gel, 198 spots on the 386Mi*) (Figure 6.7A and 6.7B). The protein patterns were 
very similar for the two lines. The variation in the number o f protein spots detected was 
due to very faint spots which were not detected in the extract from 386. As this was only 
observed for the faint spots it is likely that these differences were due to a difference in 
quantity of protein loaded rather than real variation between the samples associated with 
Cymelarsan resistance. This was confirmed by the fact that the differences in protein 
detected on these gels were not reproducible, based on the analysis o f thiee independent 
extractions.
6.3.2.3 Analysis of Cymelarsan resistance on pH S.5-6.7
Soluble proteins from 1x10* of procyclic forms o f the 386 and 386Mr lines were extracted 
and separated on 2D gels as described above but using a narrow pH range o f pH 5.5-6.7 for 
lEF. Analysis o f the Coomassie Brilliant blue stained gels using the ImageMaster 2DElite 
software revealed the presence of 124 protein spots on the gel from the 386 line and 104 
protein spots on the gel from the 386Mr line. Most o f the protein spots missing on the gel 
from sensitive parasites corresponded to very faint spots detected in the 386Mi' line. These 
were likely to be missing fr om the resistant protein separation due to the difficulties in 
loading exactly the same amount o f protein fr'om both lines. Subtractive analysis of the 2D 
gels revealed that a highly abundant protein spot present m the extract o f the 386 line was 
missing from the extract of the 386Mr line (Figure 6.8 A and 6.8B). This protein spot (spot
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Figure 6.7: 2D gels of procyclic forms of isogenic 386 lines, pH 4.5-S.5. Narrow pH 
isoelectric focusing (pH 4.5 to 5.5) 2D gels o f 386 (A) and 386Mr (B) lines. Soluble 
proteins from 1x10* procyclic parasites grown in SDM79 were separated by 2DE. 
Subtractive analysis o f Coomassie Brilliant blue stained 2D gels revealed no difference in 
protein expression pattern between the two isogenic lines.
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Figure 6.8: 2D gels of procyclic forms of isogenic 386 lines, pH 5.5-6.7. Narrow pH 
isoelectric focusing (pH 5.5 to 6.7) 2D gels of 386 (A) and 386Mr (B) lines. Soluble 
proteins from 1x10* procyclic parasites were separated onto the 2D gel prior to Coomassie 
Brilliant blue staining. Subtractive analysis o f the 2D gels revealed one protein spot 
differentially expressed (spot B) between the isogenic lines of 386.
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B) had a pi o f around 5.8 and in the sensitive line was adjacent to another protein spot 
(spot A), present in both lines, with a similar molecular weight but a more acidic pL Due to 
technical difficulties with the 2DE system, this experiment was not repeated.
Taken together, the results from the 2D analysis demonstrated that two protein spots were 
differentially expressed between the procyclic stages of the pair o f isogenic lines of 386 
from over 1,000 protein spots analysed both on broad and narrow pH ranges. The two 
differentially expressed protein spots were visible on Coomassie Brilliant blue stained gels, 
suggesting that they were highly abundant in the cell. The absence o f protein spot 2 (pi 
4.5), in the protein extract o f the 386Mi' line, was confirmed in nine independent protein 
extractions separated on pH 4-7 gels and also on the narrow pH 4-5 range gel. The absence 
o f spot B (pi = 5.8) in the protein extract of the 386Mr line was only shown in one 
experiment. Both spot 2 and spot B are adjacent to spots with similar molecular weight but 
a more acidic pi, suggesting that spot B could be an isoform of spot A and spot 2 could be 
an iso form o f spot 1.
6.3.3 Identification of differentially expressed proteins
The mass spectrometry techniques, MALDI-TOF and Tandem MS, were used to determine 
the identity of the differentially expressed protein spots observed by 2DE between the 
procyclic forms o f Cymelarsan sensitive and resistant 386 lines.
The differentially expressed protein spots detected on pH 4-7, pH4-5 and pH 5.5-6.7 gels, 
as well as nearby protein spots, were excised from the gels, digested with trypsm and 
analysed by mass spectrometry. Mass spectra were acquiied initially by MALDI-TOF MS 
to provide a peptide mass fingerprint. In addition. Tandem MS was also carried out to 
confirm the identification obtained by PMF and to identify spots for which no
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identification was obtained by PMF analysis. One of the mass spectra obtained from 
Tandem MS analysis of spot 1 fr om the 386 line and corresponding to peptide sequence 
FPGNTTFLIFGEAQLGDTTMQTQEAAAR is given as an example in Figure 6.9.
PMF and peptide sequence tag were performed on five protein spots from the 386 line and 
four proteins fr om the 386Mr line, excised from pH 4-7 gels (Figure 6.10A and 6.1 OB). 
Analysis o f the peptide mass fingerprints was carried out using the MASCOT® search 
engine on the NCBIm- and the local T. brucei databases. Protein spot 4 and 5 from both 
386 and 386Mr lines were identified as p tubulin (gi number: 9366734) (Figure 6 .IOC). No 
identity could be assigned to either protein spot 1 or 2 by searching either the NCBInr or 
the local T. brucei databases with their peptide mass fingerprints (Figure 6. IOC), Analysis 
by Tandem MS confirmed the identity of spot 4 and 5 for both 386 and 386Mr lines as P 
tubulins, with scores of 204 and 469 for the 386 line and 142 and 437 for the 386Mi* line 
(Figure 6.IOC). Tandem MS analysis on spot 3 enabled its identification as another p 
tubulin (gi number: 9366734) with a score o f 74 and 143 for the 386 and 386Mi' line 
respectively (see Appendix IV). Using the sequence information generated by Tandem MS 
no identification for protein spots 1 and 2 could be made searching the NCBInr database. 
The MASCOT® search engine was then used to search the local T. brucei database. The 
two protein spots (spot 1 and 2) from the 386 line and the corresponding protein spot (spot 
1) from the 386Mr line, all matched a putative open reading fr ame, accession number 
Tryp9.0.000322-274 (GeneDB), located on Chromosome IX with scores of 123, 178 and 
217 respectively (Table 6.2). The differentially expressed protein spot, and the adjacent 
spot, detected on pH4-5 gels were analysed by Tandem MS and found to both match onto 
Tiyp9.0.000322-274 (data not shown).
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Figure 6.9: Example of a Tandem mass spectrum. Tandem mass spectrum of the tryptic, 
micropurified peptides derived from in gel digestion of protein spot 1 from 386Mr 2D gel. 
The parent peptide (1528.4 Da) was selected out o f the mixture in the first analyser and 
was then dissociated by collision with nitrogen. The resulting fragments were separated in 
the second analyser producing the Tandem mass spectrum. The spectrum gives the mass to 
charge ratio (m/z) o f the tryptic peptide against their intensity. Ions generally have a charge 
state corresponding to the number o f positively charged amino acid plus the charge 
formally localized at the N terminus of the peptide. Thus tryptic peptides are often doubly 
charged, or triply if they contain a histidyl residue.
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Sample MALDI-TOF Tandem MS
gi number Name Score Peptide Coverage ID Score
386/1 Tryp9.0.000322-
274*
Hypothetical
protein
123
386/2 Tryp9.0.000322-
274*
Hypothetical
protein
178
386/3 9366734 P tubulin 74
386/4 9366734 P
tubulin
68 5 16% p tubulin 204
386/5 9366734 P
tubulin
162 11 38% P tubulin 469
386Mr/l Tryp9.0.000322-
274*
Hypothetical
protein
217
386Mr/2 Absent
386Mr/3 9366734 P tubulin 143
386Mr/4 9366734 P
tubulin
73 5 16% p tubulin 142
386Mr/5 9366734 P
tubulin
101 9 18% p tubulin 437
Figure 6.10: Mass spectrometry analysis of spot 2. Location of the differentially 
expressed protein spot (spot 2) on 2D gels from 386 (A) and 386Mr (B) lines. The protein 
spots were digested and the resulting tryptic peptides were analysed by MALDI-TOF MS 
and Tandem MS. The summary o f results (C) showed the identity o f the proteins as 
identified using the MASCOT search engine to search the NCBInr database (Taxonomy: 
all species) and a local T. brucei database (*GeneDB accession number).
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Sample Score
Peptide
score Sequence of matching peptides Name
386 spot 1 123 55 AALSFWNQPEVYR Tryp9.0.000322~274
54 QTPDDVEIVEGEFDDK
13 MGLKPEPNISK
3B6Mr spot 1 222 14 MGLKPEPNiSK Tryp9.0.000322-274
61 AVSGALVEEVGTAGEETSELAGETPAAAAPSESK
67 QTPDDVEIVEGEFDDK
55 AALSFWNQPEVYR
5 EIAWMAQGK
386 spot 2 178 60 AALSFWNQPEVYR Tryp9.0.0a0322-274
45 MGLKPEPNISK
35 QTPDDVEIVEGEFDDKEIAWMAQGK
37 NNKGDIVNAIMELTMDPN
Table 6.2: Detailed results from the MASCOT® search engine for spot 1 and 2. The
table gives the sequence o f peptides from the local T. brucei database corresponding to the 
mass spectra obtained from the protein spots. The score indicates the probability that the 
protein in the database corresponds to the protein from the 2D gel. A score over 23 
corresponds to the probability o f the protein from the database to be a random match o f 
less than 5% (p<0.05).
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Mass spectrometry analysis was performed on the differentially expressed protein spot and 
surrounding protein spots from the narrow (pH 5.5-6.7) range strips (Figure 6.11). Four 
protein spots from the 386 line and three protein spots from the 386Mr line (Figure 6.11A 
and 6.1 IB) were excised from the 2D gels and digested with trypsin. Tandem MS analysis 
was performed on the tryptic peptides. The mass spectra obtained were seaiched against 
the NCBInr and the local T, brucei databases using the MASCOT® search engine. The 
protein spots surrounding the differentially expressed protein, were identified with high 
confidence as an enolase (spot C) and a pyridoxine kinase (spot D) (Figure 6.11C,
Appendix 4). The differentially expressed protein spot (spot B) matched onto an arginine 
kinase (score = 510). Spot A from the 386Mr, adjacent to spot B on the 386 2D gel, was 
also identified as an ai’ginine kinase (score = 487). Tliree gene copies of aiginine kinase are 
present in the T. brucei genome (ORF 342, 343 and 345) with high homology to each 
other. One peptide, sequenced fr om both spot A and B by Tandem MS, showed that spot A 
and B are not isoforms as they matched onto different ORFs (Table 6.3). Spot A matched 
onto ORF 345 while spot B match onto either ORF 342 or 343. These results suggest that 
unlike the CAR protein, spot A and B are not transcripts of the same ORF that have been 
modified post-translationally. No identification was made for spot A o f the 386 line due to 
the loss o f the sample during Tandem MS analysis.
The analysis of the protein spots separated by 2DE using mass spectrometry enabled the 
identification of the differentially expressed protein spots. Spot 2 from gel pH 4-7 and 
from gel pH 4-5 were matched onto a non-annotated ORF, which was then designated as 
the Cymelarsan Resistance Associated protein (CAR protein) and spot B on gel pH 5,5- 6.7 
was identified as an arginine kinase. Spot 1, adjacent to the CAR protein on 2D gels o f the 
386 line and present in both lines, was matched onto the same ORF as the CAR protein.
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A) B)
A B
D
#
C)
Sample gi number ID Score
386/A
386/B ORF 342* / ORF 343 Arginine kinase 510
386/C 8132069 Enolase 333
386/D 24559793 Pyridoxine kinase 218
386Mr/A ORF 345* Arginine kinase 487
386Mr/B Absent
386Mr/C 8132069 Enolase 573
386Mr/D 24559793 Pyridoxine kinase 276
Figure 6.11: Mass spectrometry analysis of spot B. Close-up view of narrow pH range 
isoelectric focusing (pH 5.5-6.7) 2D gels o f 386 (A) and 386Mr (B) lines showing the 
differentially expressed protein spot. Proteins were digested using trypsin and analysed by 
Tandem MS. A summary of the results obtained from searching the NCBInr and local T. 
brucei database (*GeneDB accession number) using the MASCOT® search engine is given 
(C). A score over 53 in this case corresponds to the probability o f the protein from the 
database to be a random match o f less than 5% (p<0.05).
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Sample Score Peptide score Sequence of matching peptides Name
386Mr/A 487 40 WLTSDVFK ORF 345
42 LGLSEYEAVK
60 ACEYWPTGR
59 EMQDGILELIK
31 SLAGYPFNPCLTK
43 TFLVWVNEEDHLR
75 DFGDLNTLVDVDPEGK
55 ETQQQLIDDHFLFK
49 LGFLTFCPSNLGTTIR
30 GTAGEHSDSPDGIYDISNK
6 QPPKDFGDLNTLVDVDPEGK
386/B 510 50 ÙLTSDVFÏ ORF 342/ ORF 343
58 LGLSEYEAVK
60 ACEYWPTGR
62 EMQDGILELIK
30 SLAGYPFNPCLTK
65 TFLVWVNEEDHLR
65 DFGDLNTLVDVDPEGK
63 ETQQQLIDDHFLFK
57 LGFLTFCPSNLGTTIR
Table 6.3: Detailed results from the MASCOT® search engine for spot A and B. The
table gives the sequence o f peptides from the local T. brucei database corresponding to the 
mass spectra obtained from the protein spots. The score indicates the probability that the 
protein in the database corresponds to the protein from the 2D gel. A score over 53 in this 
case corresponds to the probability o f the protein from the database to be a random match 
of less than 5% (p<0.05). One identified peptide, highlighted in blue, enabled to 
differentiate ORF 345 from ORF 342 and ORF 343.
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suggesting that spot 1 was an iso form o f the CAR protein. Spot A and B were both 
identified as arginine kinase. However, the Tandem MS analysis demonstrated that spot A 
matched onto ORF 345 while spot B matched onto either ORF 342 or ORF 343. These 
results would suggest that the transcript o f either ORF 342 or ORF 343 (or both) is present 
in the 386 line but not in the 386Mr line at pH 5.8 on the 2D gel.
6.3.4 Molecular analysis of the CAR locus
6.3.4.1 Presence of the CAR gene in the isogenic 386 lines
The CAR protein was found to be differentially expressed between 386 and 386Mi* lines. It 
was located at around pH 4.5 on 2D gels and was matched onto a putative ORF 
(Tryp9,0.000322-274) from the reference line 927. BLAST searches in GeneDB using the 
sequence from this protein revealed that there was another copy of the gene situated 
upstream fr om Tryp9.0.000322-274, called Tiyp9.0.000322-277. These ORFs will 
thereafter be referred to as ORF 274 and ORF 277. Both copies have identical nucleotide 
(564 bp) sequences in the reference line 927. No signal peptides or transmembrane 
domains were found in the predicted protein sequence. Searches with the programs 
InterPro and Pfam (available at http ; //ca. expasv. org/tools/) showed the presence of a 
Nascent polypeptide Associated Complex domain (NAC domain) at the N terminus 
(amino acid residues 29-88) and an UBiquitin-Associated domain (UBA domain) at the C 
terminus (amino acid residues 146-186) (Figure 6.12). The DNA and corresponding amino 
acid sequence of ORF 274 fr om the reference line 927 aie given in Figui'e 6.13.
In order to confirm the presence of the two ORFs in 927 and investigate whether both 
homologues occur in the 386 and 386Mr lines, primers were designed to the 5’UTR of
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A)
E score Organism gi number Name
2e-04 T. cruzi 21435928 NAC alpha mRNA
0.004 Mus musculus 20345404 mRNA
B)
E score Organism gi number Name
Ie-52 T. cruzi 21435929 NAC alpha
5e-40 Leishmania major 12311802 possible nascent polypeptide 
associated complex subunit, copy 2
le-32 Leishmania major 12311803 possible nascent polypeptide 
associated complex subunit, copy 1
3e-32 Leishmania infantum 8671200 nascent polypeptide associated 
complex homologue, alpha chain
C ) Systematic Name: TRYP9.0.000322-274
Product: POSSIBLE NASCENT POLYPEPTIDE ASSOCIATED COMPLEX SUBUNIT, COPY 
1. (1 Other), predicted by automatic BLAST annotation 
Location Cliromosome: 9 Contig Location: 18909.. 19472 Length: 564 bp
Predicted Peptide Properties
Mass: 20.1 kDa Amino acids: 188 Isoelectric point: pH 4.2 Charge: -11.5
Signal Peptide: Not found
Domain Information
Database Acc. No./ID
InterPro
Pfam
InterPro
IPR002715
PF0I849
IPR000449
PF00627
Transmembrane Domains: 0 found
Description
Nascent polypeptide-associated complex NAC 
NAC domain
Ubiquitin-associated domain 
UBA/TS-N domain
Figure 6.12: Summary of BLAST searches in NCBI and GeneDB with ORF 274.
Summary o f BLASTn searches (A) and BLASTp searches (B) in NCBInr database using 
ORF 274 from the reference line 927. Information provided by GeneDB about ORF 274 
(C).
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ATGAGC GCTAAC GAT GTT CAA AACCCT CCA GTGGAA GACGAC GAG 
M S A N D V Q N P  P V E D D E
GTC CCA ACC CTCGAA GCT GCT GAC ACT CAA CAG GCT TCC AAGCCA  
V P T L E A A D T Q Q A S K P
TCC A AG CGC TACGCA AAGGCT ATG GCC AAG ATG GGTTTG AAA CCT 
S K R Y A K A M A K M G. .. L_ K ,7 1
GAG CCA AAC ATC TCT AAGGTA CAC ATT CGC AAA CGT GCG GCG CTC
B P N 1 S-------» ----X--Ü---- !-------- E----- K-R a  A U
NAC Domain
TCT TTT GTG GTG AAC CAA CCC GAG GTGTAC CGC TTT CCA GGA ACC 
S ' F "V" "V" N " " 'q  " P ' Ï F P G T
AAC ACA TTC CTA ATC TTT GGT GAA GCT CA G CTT GGC GACACA ACG 
N T F L I  F G E A O L G D T  T
ATG CAA ACG CAG GAA GCC GCA GCT CGC GCG GTG TCT GGC GCC CTT 
M Q T  Q E A A A R  V S G A ~ 1 |
GTG GAG GAG GTG GGA ACT GCA GGA GAG GAA ACC TCT GAG CTT 
V  E Ë V G T A G E  E T S E ft
GCT GGT GAA ACT CCT GCA GCA GCT GCC CCA TCT GAG AG CAAA CAG 
pt G Ë f  A A 'A'.....A' 'P ' y È 5 1^  I
ACT CCC GAC GAT GTC GAG ATT GTG GAA GGC GAA TTC GAC GAT
ir p D D V »  I V .  E G K * .  s ~ r j
AAG GAG ATT GCT GTG GTT ATG GCA CAA GGC AAA ACG GAC CGC ATT_ | __ I .  I . . A ...V ..V.. ...A , 0  .5  3 _I ___ D R___ I
UBA dom ain
GGA GCA ATC CGC GCC CTT CGG AAC AAC AAG GGA GAT ATC GTC A AT 
G A I R A L R N N K G D I V  N
GCT ATC ATG GAA CTG ACG ATG GAT CCC AAC 
A 1 M E L  T M D P N
Figure 6.13: Schematic representation of the DNA and amino acid sequences of ORF 
274 from T. brucei line 927. Two domains were predicted by PedictProtein 
(http: //cubic, bioc. columbia.edu/predictprotein/) in the ORF. A nascent polypeptide 
associated domain (NAC domain, underlined) and an ubiquitin-associated domain (UBA 
domain, underlined). Peptides, from trypsin digestion of spot 1 from 386Mr line, 
sequenced by Tandem MS matching onto the theoretical peptides from the translated ORF 
274 are highlighted in blue.
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ORF 274 and 3 ’UTR of ORF 277. PCR amplification of 927 genomic DNA was predicted 
to give a 2 Kb product that should contain two EcoRI sites and one BamHI site. PCR 
amplification of 927 genomic DNA confirmed the size prediction and digestion with 
EcoRI and BamHI confirmed the presence of the restriction sites. The same experiment 
carried out on genomic DNA from 386 and 386Mr lines confirmed the presence of the two 
ORFs in these lines (Figure 6.15). This experiment demonstrated the potential presence of 
two ORFs, identical to each other in the genome reference line 927, potentially each 
encoding the CAR protein in 386 and 386Mi’ lines.
A mutation in the ORF of one o f the Imes could account for the disappearance of a CAR 
protein iso form on 2D gels of the 386Mr lines. This possibility was assessed by cloning 
and sequencing the genes. An alignment o f the ORFs and their 3’ and 5’UTR regions was 
performed to identify regions of low homology which could be used to design ORF 
specific primers. As there is no robust bioinformatic method o f identifying the precise 
boundaries o f 3’ and 5’UTRs, 287 bp upstream and 233 bp downstream of ORF 274 was 
compared with 171 bp upsteam and 260 bp downstream of ORF 277. The ahgnment o f the 
ORFs confirmed the 100% homology in the translated region of the genes. The 5’UTR was 
shown to be highly conserved over 116 bp upstream of the start codon whereas only 19 bp 
aligned in the 3’UTR regions. These regions were followed by highly divergent sequences, 
which were used to design the ORF-specific primers (Figure 6.16). Analysis o f the 
sequence of the expected PCR product for ORF 274 and ORF 277 using these primers 
enabled the detection of a BsaJI restriction site present at different positions in the 3’UTR 
of the ORFs, 27 bp downstream the codon stop o f ORF 274 and 137 bp downstream of the 
codon stop o f ORF 277 (Figure 6.16). The digestion of the PCR products, amplified using 
the ORF specific primers, with the restriction enzyme BsaJI, generatmg fragments o f the
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927 386 386Mr
^ ____  2 Kb<-------  1.65 Kb
Figure 6.14: PCR amplification of the tandem repeat of ORF 274 and 277. PCR
performed on line 927, 386 and 386Mr using primers Tryp9/11 and Tryp9/12, amplified a 
DNA fragment containing both open reading frames. The 2 Kb PCR product (expected size 
from reference line 927 database) was recovered for all three lines.
927 386 386Mr 927 386 386Mr
2 Kb 
1.65 Kb
1 Kb 
850 bp 
650 bp
500 bp 
400 bp
EcoRI BamHI
Figure 6.15: RFLP analysis on the tandem repeat of ORF 274 and 277. Digestion of 
the 2 Kb PCR product using the restriction enzymes EcoRI and BamHI. The restriction 
fragments corresponded to the predicted sizes o f EcoRI digestion (968 bp, 641 bp and 391 
bp) and BamHI digestion (968b bp, 764 bp and 269 bp).
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ORF274 1 GAGGGAGGGGGAATTTCCTCTGCTTATATATTTACATTTGAATCAGCGAA 5 0
ORF277 1 CAAAAATTATAA 12
5 1  TTTATCTACATGCATACACATCTTCCTTTACATTATTTATCCACTGCGTG 1 0 0
 I  I .............. I I - . 1 . .  . 1 . I . I I . . I I . I . 1 . 11 I I I I I
1 3  AAATGTTTGTGCTACTACATTCGCCTCATTCCTTCGTTTTTCTCTGCGTG 62
1 0  it c t g c t t t t a g a t t t c t c c c t c c c t g t t t t B M c g c a t t t c a a c t t t t c t  1 5 0
I I I I I I I I  I M I I I I  I I  I I  I I  I I  I I  I I I I I  I  I I  I I  M I I I  I I I  I I  I ! I I I  
63  TCTGCTTTTAGATTTCTCCCTCCCTGTTTtH B c GCATTTCAACTTTTCT 1 1 2
1 5 1  TTTCCCTTCTTACATTTCTTTCGCTACATCCAATCTGAACAGTAACCCGG 2 0 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1 1 3  TTTCCCTTCTTACATTTCTTTCGCTACATCCAATCTGAACAGTAACCCGG 1 6 2
2 0 1  ACCATCACGATGAGCGCTAACGATGTTCAAAACCCTCCAGTGGAAGACGA 2 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1 6 3  ACCATCACGATGAGCGCTAACGATGTTCAAAACCCTCCAGTGGAAGACGA 2 1 2
2 5 1  CGAGGTCCCAACCCTCGAAGCTGCTGACACTCAACAGGCTTCCAAGCCAT 3 0 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 1 3  CGAGGTCCCAACCCTCGAAGCTGCTGACACTCAACAGGCTTCCAAGCCAT 2 62
3 0 1  CCAAGCGCTACGCAAAGGCTATGGCCAAGATGGGTTTGAAACCTGAGCCA 3 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 6 3  CCAAGCGCTACGCAAAGGCTATGGCCAAGATGGGTTTGAAACCTGAGCCA 3 1 2
3 5 1  AACATCTCTAAGGTACACATTCGCAAACGTGCGGCGCTCTCTTTTGTGGT 4 00
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
3 1 3  AACATCTCTAAGGTACACATTCGCAAACGTGCGGCGCTCTCTTTTGTGGT 3 6 2
4 01  GAACCAACCCGAGGTGTACCGCTTTCCAGGAACCAACACATTCCTAATCT 4 50
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
3 6 3  GAACCAACCCGAGGTGTACCGCTTTCCAGGAACCAACACATTCCTAATCT 41 2
4 51  TTGGTGAAGCTCAGCTTGGCGACACAACGATGCAAACGCAGGAAGCCGCA 5 0 0
I I I I I I I I I I I  I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
4 1 3  TTGGTGAAGCTCAGCTTGGCGACACAACGATGCAAACGCAGGAAGCCGCA 4 62
5 0 1  GCTCGCGCGGTGTCTGGCGCCCTTGTGGAGGAGGTGGGAACTGCAGGAGA 5 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
4 6 3  GCTCGCGCGGTGTCTGGCGCCCTTGTGGAGGAGGTGGGAACTGCAGGAGA 5 1 2
5 5 1  GGAAACCTCTGAGCTTGCTGGTGAAACTCCTGCAGCAGCTGCCCCATCTG 6 0 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
5 1 3  GGAAACCTCTGAGCTTGCTGGTGAAACTCCTGCAGCAGCTGCCCCATCTG 5 6 2
6 0 1  AGAGCAAACAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGAC 6 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
5 6 3  AGAGCAAACAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGAC 6 1 2
6 5 1  GATAAGGAGATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCATTGG 7 00
I I I I I I I I I M M I I  I I  I I  I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
6 1 3  GATAAGGAGATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCATTGG 66 2
7 01  AGCAATCCGCGCCCTTCGGAACAACAAGGGAGATATCGTCAATGCTATCA 7 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
6 6 3  AGCAATCCGCGCCCTTCGGAACAACAAGGGAGATATCGTCAATGCTATCA 7 1 2
7 5 1  TGGAACTGACGATGGATCCCAACggTCGAGAGTGCTTTTCGTGAGCAAC 8 0 0
I I I I I I I I I I I I I I I I I I I I I I I 11 I I  I I I I I I I I I I I I I I I I I I I I • I .
7 1 3  TGG7\ACTGACGATGGATCCCAAcB B t CGAGAGTGCTTTTCGTGAGGGAT 7 62
8 0 1  AGTGTAAGTGAAACCCCCAATAAGGACATAAGGGGGATGGAGGGAAATGA 8 5 0
• • • • • I - 1 11111 I —  I • • I  I . . .  I ....................7 6 3  TAÉDGa M t GAAAAGTTTTTTCTTAATTTCCTTTTTAAAAATAATGGCCT 8 1 2
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8 5 1  A A A C TG TA A G A AA A A A A TA TGA G A TTTG A A G TG G A C TC TC A G A AG TG ATT 9 0 0
. I I . . .  I I I  I . . . I . I . . I I . I . . I  I ...............................
8 1 3  GAAAGTTAAACGTGAGTCACGTAATGTTGACCCACCGTCTCAGTCGTGCA 8 62
9 0 1  TGTGGGGTTCTGiCTA(lÉAGTGTTTCCGTGGCCACCTGCTTGTAAGTTAC 9 5 0
8 6 3  CAGTGAATCCTCCATCCATTGTGATGTTAACATAACTTTTTCCTCACATC 9 1 2
9 5 1  GAAGGAAAGAATGTGCGAGAACAATATACAGTGATAACAGAAAAGAGTAA 1 0 0 0
........................ I  1 . . I . I --------I . . .  I  I . I .
9 1 3  TTTCCTTTTTTTCCTTTGTCTGTACTTTCTTATACTTCTTGTTTCTGCAG 9 6 2
1 0 0 1  GTGATA 1 0 0 6
. . I . I .
9 6 3  TGGTTTGATCGGCCAAAAGATTCGTCATGGCTC 9 9 5
Figure 6.16: Alignment of ORF 274 with ORF 277 from line 927. The start and stop 
codon for each ORF are highlighted in blue. The divergent sequences in the 3’ and 5’UTR 
regions were used to design ORF specific primers (underlined sequences). The BsaJI 
restriction sites are highlighted in red.
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850 bp 
650 bp 
500 bp
Figure 6.17: Specificity of the primers designed for ORF 274 and 277. PCR using the 
ORF specific primers on genomic DNA from 927, 386 and 386Mr amplified a fragment o f  
the expected size (ORF 274: 891 bp and ORF 277: 868 bp). The PCR product from each 
ORF was digested using the BsaJI restriction enzyme. The digestion products 
corresponded to the expected sizes (ORF 274: 370 bp and 500 bp and ORF 277: 123 bp, 
350 bp and 395 bp).
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expected sizes for each ORF (Figure 6.17). Both ORFs from 386 and 386Mr lines were 
cloned, using the ORF specific primers, and sequenced to determine whether any 
nucleotide difference could be detected. Differences between sequences o f different clones 
o f ORF 274 were observed which appear consistent with allelic variation (nucleotides 
highlighted in green. Figure 6.18). Other differences however appear randomly in the 
sequences and were probably due to PCR errors by the Taq polymerase or sequencing 
errors. Taken together the sequencing o f the ORFs would suggest that both ORF 274 and 
277 from the 386 line are identical to theh homologues in 386Mr line (Figure 6.18 and 
6,19) and that ORF 274 is identical to ORF 277. No mutations were found in the translated 
gene products o f ORF 274 and 277 that could account for the absence o f the CAR protein 
spot (spot 2) in the 386Mi' extract detected by 2DE.
6.B.4.2 Transcription of ORF 274 and 277 in the isogenic lines
The sequencing of the two ORFs from both the 386 and 386Mr lines demonstrated that 
both ORFs were identical. These results suggest that the lack o f expression at the protein 
level o f one isoform of the CAR protein is not due to an alteration in coding region of 
either o f the genes. An alternative explanation for the differences at the protein level could 
be that there are differences in the level o f transcripts fr om the two ORFs between the 386 
and 386Mr lines. To analyse this possibility, Northern blot and RT-PCR analyses were 
performed.
Primers were designed in the 3’UTR regions o f each ORF to produce 150 bp long probes 
which should specifically hybridise to the transcripts fr om one or the other ORF (Figure 
6.1). In the Northern analysis, the membrane was first probed with a PCR product 
amplified from the coding region for TIM as a positive control. The TIM probe showed the
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3 8 6 , c l o n e l (1 )
3 8 6 , c l o n e 2 ( 1 )
3 8 6 , c l o n e l ? (1 )
3 8 6 , c l o n e l 9 (1 )
3 8 6 M r , c l o n e 5 (1 )
3 8 6 M r , c l o n e 3 (1 )
3 8 6 , c l o n e l ( 3 7 )
3 8 6 , c l o n e 2 ( 5 0 )
3 8 6 , c l o n e l ? ( 4 2 )
3 8 6 , c l o n e l 9 ( 3 8 )
3 8 6 M r , c l o n e 5 ( 5 1 )
3 8 6 M r , c l o n e 3 ( 4 9 )
3 8 6 , c l o n e l ( 8 7 )
3 8 6 , c l o n e 2 ( 1 0 0 )
3 8 6 , c l o n e l ? ( 9 2 )
3 8 6 , c l o n e l 9 ( 8 8 )
3 8 6 M r , c l o n e 5 ( 1 0 1 )
3 8 6 M r , c l o n e 3 ( 9 9 )
3 8 6 , c l o n e l ( 1 3 7 )
3 8 6 , c l o n e 2 ( 1 5 0 )
3 8 6 , c l o n e l ? ( 1 4 2 )
3 8 6 , c l o n e l 9 ( 1 3 8 )
3 8 6 M r , c l o n e s ( 1 5 1 )
3 8 6 M r , c l o n e 3 ( 1 4 9 )
3 8 6 , c l o n e l ( 1 8 7 )
3 8 6 , c l o n e 2 ( 2 0 0 )
3 8 6 , c l o n e l ? ( 1 9 2 )
3 8 6 , c l o n e 19 ( 1 8 8 )
3 8 6 M r , c l o n e s ( 2 0 1 )
3 8 6 M r , c l o n e 3 ( 1 9 9 )
3 8 6 , c l o n e l ( 2 3 7 )
3 8 6 , c l o n e 2 ( 2 5 0 )
3 8 6 , c l o n e l ? ( 2 4 2 )
3 8 6 , c l o n e l 9 ( 2 3 8 )
3 8 6 M r , c l o n e s ( 2 5 1 )
3 8 6 M r , c l o n e s ( 2 4 9 )
3 8 6 , c l o n e l ( 2 8 7 )
3 8 6 , c l o n e 2 ( 3 0 0 )
3 8 6 , c l o n e l ? ( 2 9 2 )
3 8 6 , c l o n e 19 ( 2 8 8 )
3 8 6 M r , c l o n e s ( 3 0 1 )
3 8 6 M r , c l o n e 3 ( 2 9 9 )
3 8 6 , c l o n e l ( 3 3 7 )
3 8 6 , c l o n e 2 ( 3 5 0 )
3 8 6 , c l o n e l ? ( 3 4 2 )
3 8 6 , c l o n e l 9 ( 3 3 8 )
3 8 6 M r , c l o n e s ( 3 5 1 )
3 8 6 M r , c l o n e s ( 3 4 9 )
3 8 6 , c l o n e l ( 3 8 7 )
3 8 6 , c l o n e 2 ( 4 0 0 )
3 8 6 , c l o n e l ? ( 3 9 2 )
3 8 6 , c l o n e l 9 ( 3 8 8 )
3 8 6 M r , c l o n e s ( 4 0 1 )
3 8 6 M r , c l o n e s ( 3 9 9 )
3 8 6 , c l o n e l ( 4 3 7 )
3 8 6 , c l o n e 2 ( 4 5 0 )
3 8 6 , c l o n e l ? ( 4 4 2 )
3 8 6 , c l o n e l 9 ( 4 3 8 )
3 8 6 M r , c l o n e s ( 4 5 1 )
3 8 6 M r , c l o n e s ( 4 4 9 )
1 5 0
-CT#rGCGTGTCTGTTT#TAGATTTCTCCTTCCCTGT 
rGCGTGTCTGTTTgTAGATTTCTCCTTCCCTGT 
iTigCigrG CG TG TCTG TTTgTAG A TTTCTCCTTCCCTG T 
CC'l*rGCGTGTCTGTTT§TAGATTTCTCCTTCCCTGT 
cnrUCTTCd^BBCTTpGCGTGTCTGTTTgrAGATTTCTCCTTCCCTGT 
"TC C TT C G T m C T T T G C G T G T C T G T T T C T A G A T T T C T C C T T C C C T G T
5 1 __________________________________  1 0 0
TTTyjCGCATTTCAACTTTBCTTTTjCClTCTTiCATTTCTTTCGCTAA 
TTT#,TQCGCJlTTTCAACTTT#CTTTTgCCmrCT'I*CATTTCTTTCGCTAA 
TTTATGCGCATTTCAjÆTT10CTTTT#CCmrCTT#CATTTCTTTCGCTAA 
TTTATGCGCATTTCAACTrrCCTTTTfccfccTTiCATTTCTTTCGCTAA 
TTT^TQCGCATTTCAACTTTfcTTTofcciTCTîlcATTTCTTTCGCTAA 
TTTATCCGCATTTCAACTTTflCTTTTflCcjTCTqlcATTTCTTTCGCTAA 
1 0 1  1 5 0
ATCCAATCflGAACAGTAACCCGGACCATCAC||ATGAGCGCTA2U:GAT6TT
a t c c a a t c I G a a c a G t a a c c c G G a c c a t c a c | a t g a g c 6 c t a a c g a t g t t
ATCCAATŒGAACAGTAACCCGGACCATCACiATGAGCGCTAACGATGTT
ATCCAATŒSAACAGTAACCCGGACCATCAC§ATGAGCGCTAACGATGTT
a t c c a a t c J g a a c a g t a a c c c g g a c c a t c a c t a t g a g c g c t a a c g a t g t t
ATCCAATCCGAACAGTAACCCGGACCATCACjpVTGAGCGCTAACGATGTT 
1 5 1  2 0 0
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCGAAGCCGCT^ 
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCGAAGCCGCTa 
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCGWIGCCGCTG§ 
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCG»AGCCGCTGG 
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCGAAGCCGCT^ 
CAAAACCCTCCAGTGGAAGACGACGAGGTCCCAACCCTCGAAGCCGCTC^ 
2 0 1  2 5 0
CACTCAACAGGCTTCCAAGCCATCCAAGCGCTACGCAAAGGCTATGGCCA
c a c t c a a c a g g c t t c c a a g c c a t c c a a g c g c t a c g c a a a g g c t a t g g c c a
CACTCAACAGGCTTCCAAGCCATCCAAGCGCTACGCAAAGGCTATGGCCA 
CACTCAACAGGCTTCCAAGCCATCCAAGCGCTACGCAAAGGCTATGGCCA 
CACTCAACAGGCTTCCAAGCCATCCAAGCGCTACGCAAAGGCTATGGCCA 
CACTCAACAGGCTTCCAAGCCATCCAAGCGCTACGCAAAGGCTATGGCCA 
2 5 1  3 0 0
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
AGATGGGTTTGAAACCTGAGCCAAACATCTCTAAGGTACACATTCGCAAA 
3 0 1  3 5 0
C6TGCGGCGCTCTCTTTTGTGGTGAACCAACCCGAGGT6TACCGCTTTCC
c g t g c g g c g c t c t c t t t t g t g g t g a a c c a a c c c g a g g t g t a c c g c t t t c c
CGTGCGGCGCTCTCTTTTGTGGTGAACCAACCCGAGGTOTACCGCTTTCC
c g t g c g g c g c t c t c t t t t g t g g t g a a c c a a c c c g a g g t g t a c c g c t t t c c
CGTGCGGCGCTCTCTTTTGTGGTGAACCAACCCGAGGTGTACCGCTTTCC
c g t g c g g c g c t c t c t t t t g t g g t g a a c c a a c c c g a g g t g t a c c g c t t t c c  
3 5 1  4 0 0
|GGAACCAACACATTCCTAATCTTTGGTGAAGCTCAGCTTGGCGACACAA 
jcGAACCAACACATTCCTAATCTTTGGTGAAGCTCAGCTTGGCGACACAA
■ g g a a c c a a c a c a t t c c t a a t c t t t g g t g a a g c t c a g c t t g g c g a c a c a a  
I g g a a c c a a c a c a t t c c t a a t c t t t g g t g a a g c t c a g c t t g g c g a c a c a a  
g g g a a c c a a c a c a t t c c t a a t c t t t g g t g a a g c t c a g c t t g g c g a c a c a a  
J g g a a c c a a c a c a t t c c t a a t c t t t g g t g a a g c t c a g c t t g g c g a c a c a a  
4 0 1  4 5 0
§ g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g | g t c t g g c g c c c t t g t g
■ g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g c g t c t g g c g c c c t t g t g
| g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g | g t c t g g c g c c c t t g t g
t g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g § g t c t g g c g c c c t t g t g
■ g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g I g t g t g g c g c c c t t g t g
| g a t g c a a a c g c a g g a a g c c g c a g c t c g c g c g g | g t c t g g c g c c c t t g t g
4 5 1  5 0 0
g a g g a g g t g g g a a c t g c a g g a g a g g a a a c c t c t I a g c t t g c t g g t g a a a c
g a g g a g g t g g g a a c t g c a g g a g a g g a a a c c t c t I a g c t t g c t g g t g a a a c
GAGGAGGTGGGAACTGCAGGAGAGGAAACCTCTgAGCTTGCTGGTGAAAC
g a g g a g g t g g g a a c t g c a g g a g a g g a a a c c t c t c a g c t t g c t g g t g a a a c
GAGGAGGTGGGAACTGCAGGAGAGGAAACCTCTCAGCTTGCTGGTGAAAC
g a g g a g g t g g g a a c t g c a g g a g a g g a a a c c t c t g a g c t t g c t g g t g a a a c
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5 0 1  5 5 0
TCCTGCAGCAGCTGCCCCATCTGlGAGCAAACAGACTCCCGACGfifcTCG 
TCCTGCAGCAGCTGCCCCATCTG|GAGCAAACAGACTCCCGAa3alGTCG
t c c t G c a G c a G c t G c c c c a t c t G G G a G c a a a c a G a c t c c c G a c G a I s t c G
TCCTGCAGCAGCTGCCCCATCTGflGAGCAAACAGACTCCCGACGAlGTCG
TCCTGCAGCAGCTGCCCCATCTŒGAGCAAACAGACTCCCGACGACGTCG
TCCTGCAGCAGCTGCCCCATCTGiGAGCAAACAGACTCCCGACGfl®STCG
5 5 1  6 0 0
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTATjGCA
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTATfGCA
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTATAGCA
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTAT§GCA
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTAT|GCA
AGATTGTGGAAGGCGAATTCGACGATAAGGAGATTGCTGTGGTTATiGCA
6 0 1  6 5 0
CAAGGCAAAACGGACCGCATTGGAGCAATCCGCGCC|CTTGGAACAACA
CAAGGCAAAACGGACCGCATTGGAGCAATCCGCGCCTjrgGGAACAACA
c a a G G c a a a a c G G a c c G c a t t G G a G c a a t c c G c G c c H t | g g a a c a a c a
c a a g g c a a a a c g g a c c g c a t t g g a g c a a t c c g c g c c | | M g g a a c a a c a
c a a g g c a a a a c g g a c c g c a t t g g a g c a a t c c g c g c c | t | g g a a c a a c a
CAAGGCAAAACGGACCGCATTGGAGCAATCCGCGCCgrgGGAACAACA
6 5 1  7 0 0
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
AGGGAGATATCGTCAATGCTATCATGGAACTGACGATGGATCCCAACTGA
7 0 1  7 5 0
TC#tGAGTGCTTTTC(##G($^C0GTGTAAGTGAAACgCCCAATAAGGA
t c a a g a g t g c t t t t c c ^ g I gcI a c g g t g t a a g t g a a a c I c c c a a t a a g g a
TCflltGAGtGCTTTTCGfGaGCj|AC|GTGTAAGTGAAAclcCCAATAAGGA 
TCmGAGTGCTTTTCGfGJ|GCGAC^TGTAAGTGAAAc|cCCaATAAGGA 
Tcftu3AfiTGCTTTTCGS*GAGCjACiGTGTAAGTGAAACTCCC3tATAAGGA 
TC#lGAGTGCTTTTCG^AGC0A(#3TGTAAGTGAAACg|CCCAATAAGGA 
7 5 1  8 0 0
CA#&AGGGGGATGGAGGGagrGAAAACTGTA#G#AAAAAATA] 
CABVAGGGGGATGGAGGGAHrGAAAACTGTjaGllütAAAATAl 
CAÊAAGGGGGATGGAGGGAg'GAAAACTGTAgaAAAAAATATgAGA'I 
CAgAAGGGGGATGGAGGGa^gTGAAAACTGTAmmAAAAAATATgAGAI 
O^UVGGGGGATGGAeSGA^rGAAAACTGTagGpJVAAAATATgAGAT
8 0 1 _____________  8 5 0ggpggPgg|ggGtoGTC------------------------------------mMkTGGACTCT#lG0----------------------------------------
#NM Nm BS3M -#|GTGATTTGTGGGGTTCTTGCCTAGG AGTGTTT
-------------------------------------------*ÇBP?f5GAl:fCÎSI-GAAGTATTC-------------------------------
Figure 6.18: Alignment of ORF 274 sequences from isogenic 386 lines. Start codon 
(ATG) and stop codon (TOA) are indicated in pink. The sequences from line 386 (clone 1, 
2, 17 and 19) are aligned against sequences from line 386Mr (clone 3 and 5). Allelic 
differences are highlighted in green.
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51  _  1 0 0
t a ^ t t t c t c c t t c c c t g t t o ^ [ B c g c a t t t c a a c t t t t c t t t t c c (:B t
T A yT T rC T C C T T C C C T Q T T T iy jC O C aiT yPC A A C T T T T C T T T T C C C T T
T jy T T T C T C C T T C C C T 6 T T r J |f e aCA,TTTCAACTTTTCTTTTGCCpT
TAgATTTGTGGTTGGCTGTTT% H BGCATTTGAACTTTTGTTTTCCCgT 
TA§ATTTGTGCTTGCCTGTTT'l|iBCGGATTTGAAGTTTTGTTTTCCC§T 
TAAATTTGTGGTTGCCTQTTTT§TgGGCATTTGAACTTTTGTTTTCC(^tr 
1 0 1  1 5 0
CTTgCATTTCTTTCGCTAAATGGAATGTGAAGAGTAAGGGGGAGGATGAC 
GTTAGATTTGTTTGGGTAAATGGAATGTGAAGAGTAAGGGGGAGGATGAC
c t t J g a t t t g t t t g g g t a a a t g g a a t g t g a a g a g t a a g g g g g a g g a t g a c
GTT#GATTTGTTTGGGTAAATGGAATGTGAAGAGTAAGCGGGAGCATGAC
g t t I g a t t t g t t t g g g t a a a t g c a a t g t g a a g a g t a a g g g g g a g g a t g a c  
g t t S g a t t t g t t t c g g t a a a t c g a a t g t g a a g a g t a a g g c g g a g g a t g a g  
1 5 1  2 0 0
g a t g a g g g c t a a c g a t g t t g a a a a g g g t g g a g t g g a a g a c q a c g a g g t c g
g a t g a g g g c t a a g g a t g t t g a a a a g g g t g g a g t g g a a g a c g a c g a g g t c c
GATGAGGGGTAAGGATGTTGAAAAGGGTGGAGTGGAAGACCaU2GAGGTGG
g a t g a g g g c t a a g g a t g t t g a a a a g g g t g g a g t g g a a g a g g a g g a g g t g c
GATGAGGGGTAAGGATGTTGAAAAGCGTGGAGTGGAAGAGGACGAGGTGG
g a t g a g c g c t a a g g a t g t t g a a a a g g g t c g a g t g g a a g a g g a g g a g g t g g  
2 0 1  2 5 0
CAGCCCTCGAAGCCGCflGAGAGTGAAGAGGGTTGGAAGCCATCCAAGCGC 
;CCTCGAAGCCGCaGAGAGTGAAGAGGGTTGGAAGCCATCCAAGCGG 
:CCTCGM6CCGciGAGAGTGAAGAGGGTTGGAAGCCATCCAAGGGG 
jc c t c g a a g c c g c I g a g a g t g a a g a g g g t t g g a a g c c a t c g a a g g g c
:CCTCGAAGCCGCjGAGAGTGAAGAGGGTTGGAAGGGATCGAAGGGC
:c t c g a a g c c g c c g a g a c t g a a g a g g g t t g g a a g g g a t g g a a g g g c
2 5 1  3 0 0
t a c g g a a a g g g t a t g g c c a a g a t g g g t t t g a a a c c t g a g c c a a a c a t c t g
TAGGGAAAGGGTATGGGGAAGATGGGTTT(yVAACGTGAGGGAAACATGTG 
TAGGGAAAGGGTATGGGGAAGATGGGTTTGAAAGGTGAGGGAAAGATGTG 
TAGGGAAAGGGTATGGGGAAGATGGGTTTGAAAGGTGAGGGAAAGATGTG 
TAGGGAAAGGCTATGGCGAAGATGGGTTTGAAACCTGAGGGAAACATCTG 
TAGGGAAAGGGTATGGCGAAGATGGGTTTGAAACGTGAGGGAAACATGTG 
3 0 1  3 5 0
TAAGGTACJVCATTC(3CAA|CGTGCGGCGCGGTGTTTTGTGGTGAACCAAG 
TAAGGTACAGATTGGGAA-CGTGC(3GCGd|CTGTTTTGTGGTGAAGGAAG 
TAAGGTAGAGATTGGGAA1GGTGCG(3CGŒCTGTTTTGTGGTGAAGGAAC 
TAAGGTACAGATTGGCAfl§CGTGCGGCGCKTCTTTTGTGGT(yVACGAAC 
TAAGGTAGAGATTG(%AA0GGTGCGGCGCm:TGTTTTGTGGTGAAGCAAC 
TAAGGTAGAGATTCGGAA0GGTGCGGCGCg|cTGTTTTGTGGTGAAGCAAG 
3 5 1  4 0 0
GC(3AGGTGTACCGCTTTCCAGGAACCAACAGATTGCTAATGTTTGGTGAA 
CGGAGGTGTAGCGCTTTCCAGGAACCAAGACATTCCTAATCTTTGGTGAA 
GGGAGGTGTAGGGCTTTGGA(3GRACCAAGAGATTGGTAATCTTTC3GTGAA 
CCGAGGTGTAGGGCTTTCCAGGAAGCAACAGATTCCTAATCTTTGGTGAA 
GCGAGGTGTAGGGGTTTCGAGGAAGGAAGAGATTGCTAATGTTTGGTGAA 
CGGAGGTGTAGCGCTTTCGAGGAAGGAAGAGATTGCTAATGTTTGGTGAA 
4 0 1  4 5 0
GGTGAGCgTGGCGA0AGAAGGATGGAgAGGGAGG§AGCGGGAGGTGGGGC 
GGTGAGGGTGGCGACAGAAGGATGCAgAGGGAGGgAGGGGGAGCTGGCGC 
GGTGAGG§TGGGGAttlGAAGGAT(3GA|ACGCAGGPAGCCGGAGGTGGGGC 
GGTGAGC#TGGGGA#AGAAGGATGGAGAGGGAGG0AGGGGGAGGTGGGGG 
g g t g a g c J t g g g g a |a g a a g g a t g g a § a g g g a g g g a g g g g g a g g t g g g g c  
GGTGAG(#rGGGGAgAGAAGGATGGA#AGGGAGG#AGGGGGAGGTGGGGG 
4 5 1  5 0 0
g g t g t c t g g c g c c c t t g t g g a g g a g g t g g g a a g t g g a g g a g a g g a a a g g t
GGTGTGTGGGGCCCTTGTGGAGGAGGTGGGAAGTGGAGGAGAGGAAAGGT 
GGTGTGTGGCGGGCTTGTGGAGGAGGTGGGAAGTCKAGGAGAGGAAAGGT 
GGTGTGTGGGGGGGTTGTGGAGGAGGTGGGAAGTGGAGGAGAGGAAAGGT 
GGTGTGTGGGGGGGTTGTGGAGGAGGTGGGAACTGGAGGAGAGGAAAGGT 
GGTGTGTGGGGGGCTTGTGGAGGAGGTGGGAAGTGGAGGAGAGGAAAGGT 
5 0 1  5 5 0
CT#AGCTTGCTGGTGAAACTCGTGGAGGAGGTGGGGgATGTGAGAGCAAA
g t c a g g t t g g t g g t g a a a g t g g t g g a g g a g g t g g g g J a t g t g a g a g g a a a
GTgAGGTTGCTGGTGAAAGTGGTGGAGGAGGTGCGGgATGTGAGAGGAAA
c t J a g g t t g g t g g t c s a a a g t g g t g g a g g a g g t g g g g t a t g t g a g a g g a a a
GTgAGGTTGGTGGTGAAAGTGGTGGAGGAGGTGGGGgATGTGAGAGGAAA
CT@^GGTTGGTGGTGAAAGTGCTGGAGGAGCTGCGG0ATCTGAGAGGAAA
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CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
CAGACTCCCGACGATGTCGAGATTGTGGAAGGCGAATTCGACGATAAGGA 
6 0 1  6 5 0
GATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCATCGGiAGCAAfcC 
GATTGCTGTGGTTATGGC%CAAGGCAAAACGGACCGCAI#GGAGCA9mcC
g a t t g c t g t g g t t a t g g c a c a a g g c a a a a c g g a c c g c a iI g g a g c a i& c
GATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCAnGGAGCAAlCC 
GATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCATBGGAGCAACCC 
GATTGCTGTGGTTATGGCACAAGGCAAAACGGACCGCATjGGAGCAfliCC 
6 5 1  100
GCGCCCTTCGGAACAACAA6GGAGATATCGTCAATGCTATCAT|GAACTG 
GCGCCCTTCG6AACAACAAGGGAGATATCGTCAATGCTATCAT|GAACTG
G c G c c c t t c G G a a c a a c a a G G G a G a t a t c G t c a a t G c t a t c a t a G a a c t G
GCGCCCTTCGGAACAACAAGGGAGATATCGTCAATGCTATCA'I*GAACTG 
GCGCCCTTCGGAACAACAAGGGAGATATCGTCAATGCTATCAigGAACTG 
GCGCCCTTCGGAACAACAAGGGAGATATCGTCAATGCTATCATfGAACTG 
? 0 1  ? 5 0
ACGATGGATCCCAAL##1'CGAGAGTGCTTT'I#GTGAGCGATTACCAAGG 
ACGATGGATCCCAAŒWCGAGAGTGCTTTI#GTGAGCGATTACCgAGG 
ACGATGGATCCCAAcfGmCGA6AGTGCTTTliGTGAGCGATTACC|AGG 
ACGATGGATCCCAACiTGATCGAGAGTGCTTTT@GTGAGCGATTACC0AGG
a c g a t g g a t c c c a a c |P Ia t c g a g a g t g c t t t t § g t g a g c g a t t a c c | a g 6
ACGATGGATCCCAAC^IiTCGAGAGTGCTTTTYGTGAGCGATTACCiAGG 
? 5 1  8 0 0
TGA§AfcTTTTTTCTTAATTT-CCTTTTTAAAAATAATGGCCTGAAAGTT 
TGA0A#GTTTTTTCTTAATTT-CCTTTTTAAAAATAATGGCCTGAAAGTT 
TGAlAqGTTTTTTCTTAATTTACCTTTTTAAAAATAATGGCCTGAAAGTT
t G a J v t g t t t t t t c t t a a t t t - c c t t t t t a a a a a t a a t g g c c t g a a a g t t
TGAgMjGTTTTTTCTTAATTT-CCTTTTTAAAAATAATGGCCTGAAAGTT
t g a g a J g t t t t t t c t t a a t t t - c c t t t t t a a a a a t a a t g g c c t g a a a g t t  
8 0 1  8 5 0
A A - C A T - l A G T - g g g r G T T ^ ^  B T G T tg g A -T C -T G C -C A G T G A
ACCGTCqgAGTCGTGCACAGTGA-^W^ GTggjTAATGTGqg---------------------------------
r— A G lfH P  A TGTTdcgGCg---------------------------------------r—AGT------------ -------------------------------------------------------------------------AGTgFP#-
Figure 6.19: Alignment of ORF 277 sequences from isogenic 386 lines. Start codon 
(ATG) and stop codon (TGA) are indicated in pink. The sequences from line 386 (clone 3, 
4, 14 and 15) are aligned against sequences from line 386Mr (clone 7 and 9 ).
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presence of intact RNA molecules on the membrane (Figure 6.20A). PCR products 
amplified fr om genomic DNA of line 386, for the coding region o f ORF 274 were then 
used to probe the membrane. This probe gave a faint signal after 8 days exposure (Figure 
6.20B). The membrane was then washed and hybridised in succession with probes 
designed in the 3’UTR of ORF 274 and the 3’UTR of ORF 277. No signal was obtained 
using these two probes after 8 days exposui'e. The lack of detection of a signal with the 
3’UTR/ORF specific probes could be due to a relatively low level o f transcripts from these 
genes making Northern blot analysis too insensitive. On this basis, RT-PCR analysis was 
conducted. Total cDNA was synthesized from RNA extracted from 386 and 386Mi* lines as 
described in Materials and Methods. No product was recovered fr om the PCR 
amplification performed on the mRNA extract fr om 386 and 386M showing the absence o f 
contamination in the mRNA extract. PCR amplification from these cDNA preparations 
was undertaken using primers for the TIM gene (positive control) and the ORF specific 
primers (274F/274R and 277F/277R). A PCR product corresponding to the predicted size 
for the ORF was identified for each ORF of 386 and 386Mr lines (Figure 6.21). Thus both 
ORFs are transcribed m both 386 and 386Mi’ lines. These results suggest that the absence 
of the CAR protein observed on 2D gels o f the 386Mr line was not due to a mutation or a 
defect in transcription o f one o f the two ORFs.
6.3.4 3 Translation of CAR protein and detection of its isoforms 
In order to confirm the identity o f the CAR protein spot differentially expressed between 
the isogenic lines, antibodies were raised in mice against the gene products o f ORF 274. 
These were used to identify the protein by Western blotting. The DNA vaccination 
technique was used in combination with a prime boost strategy to produce antibodies 
against ORF 274 in mice, as described in Materials and Methods.
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A) B)
Figure 6.20: Northern blot analysis for transcription of ORF 274 and 277. RNA was
extracted from procyclic forms o f 386 and 386Mr lines. The blot was probed using the 
TIM product as a loading control (A) and subsequently probed in succession with a PCR 
product from the coding region o f ORF 274 (B), a PCR product from the 3’UTR o f ORF 
274 and a PCR product from the 3 ’UTR of ORF 277. No product could be detected using 
the probes designed in the 3’UTR of the genes.
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Figure 6.21: RT-PCR analysis of ORF 274 and 277. Total cDNA was produced from 
mRNA extracted from 386 and 386Mr lines. PCR reaction on total cDNA, using the ORF 
specific primers (274F/274R and 277F/277R), demonstrated the transcription of both 
ORFs in each line. The TIM primers were used in the PCR reaction as a loading control. 
No product could be recovered from performing the PCR reaction on the mRNA extract.
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The recombinant gene product o f ORF 274, to be used for boosting the antibody 
production, was purified from the bacterial extract using a Ni-NTA agarose column. The 
elution fractions from the column were run on a 12% SDS-PAGE gel and the gel stained 
with Coomassie Brilliant blue to assess the production and purity o f the recombinant 
protein (Figure 6.22A). A main band was detected in elution fractions 1 and 2 with a 
molecular weight o f about 34 kDa. This is higher than the predicted gene product size of 
ORF 274 (20.1 kDa). In order to confirm that this band was the gene product o f ORF 274, 
the band was excised from the gel, trypsin digested and analysed by Tandem MS. The 
resulting tryptic peptides were analysed by Tandem MS and the mass spectra generated 
were used to search the local T. brucei database with the MASCOT® search engine. The 
Tandem mass spectra matched onto ORF 274 (score of 213) (Figure 6.22B).
Western blot analysis o f whole protein extract from 386 and 386Mr lines separated on 
SDS-PAGE gel demonstrated the presence o f the gene product o f ORF 274 in both lines 
(Figure 6.23 A) and the specificity o f the antibody produced by the DNA vaccination 
technique (Figure 6.23B). Detection o f isoforms o f the gene product o f ORF 274 was 
performed by running whole protein extract on 7 cm 2D gels and transferring the separated 
proteins onto a membrane. The Western blot analysis revealed the presence o f three 
iso forms of the gene product o f ORF 274 at location of 34 kDa and pH 4.5 in the 386 line 
and only two iso forms at this location in the 386Mr line (Figur e 6.24). This experiment 
confirmed that the CAR protein and spot 1 were the gene products of ORF 274, as 
previously determined by mass spectrometry analysis. The analysis o f isoforms by Western 
blot on 2D gel revealed the presence of another isoform of the CAR protein located 
adjacent to the two previously identified isoforms in the 386 line. In addition, two more 
protein spots were detected in both 386 and 386Mi* lines using these antibodies, but these
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B)
Sample name Score Peptide sequence Peptide
score
Recombinant gene product of ORF 
274
213 AALSFVVNQPEVYR 55
GDIVNAIMELTDPN 9
QTPDDVEIVEGEFDDK 66
FPGTNTFLIFGEAQLGDTTM 36
AVSGALVEEVGTAGEETSEL 48
Figure 6.22: SDS-PAGE gel of purified recombinant gene product of ORF 274. The
protein was purified from the E. coll ceil extract using a nickel NT A agarose column. The 
fractions from the column were run on a SDS-PAGE gel (A). The band containing the 
purified protein was excised and digested with trypsin. Summary o f the results obtained 
from the MASCOT® search engine using the Tandem mass spectra generated from tryptic 
peptides of the purified His-tagged gene product o f ORF 274 expressed in E. coli. The 
MASCOT® search engine was used to search the local T. brucei database (B). A score over 
23 indicates that the probability of the protein from the database to be a random match is 
less than 5% (p<0.05).
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Figure 6.23: Western blot analysis of expression of the gene product of ORF 274 in 
isogenic 386 lines. Proteins from 386 (lane 2 and 3) and 386Mr (lane 4 and 5) lines were 
run on SDS-PAGE gels and transferred on a membrane. The gene product o f ORF 274 was 
detected using antiserum from mice (1/167). The antibodies were detected with HRP 
conjugated anti mouse IgG (1/1,000) and the ECL detection kit. The positive control (lane 
1) consisted of the recombinant gene product of ORF 274. Serum from non-immunised 
mice was used as a negative control (B).
&
Figure 6.24: Western blot analysis of expression of isoforms of gene product of ORF 
274 in isogenic 386 lines. Whole protein extract from 386 (A) and 386Mr (B) lines were 
separated by 2DE on pH 4-7 gels. The proteins were electro-blotted on a membrane and 
presence of isoforms was assessed by Western blotting using serum from immunised mice 
(1/10,000). Close up view of the isoforms o f the gene product o f ORF 274 detected in the 
386 (C) and the 386Mr (D) lines.
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were much less intense and were not located at 34 kDa, pH 4,5 (data not shown). These 
could be degradation products of spot 1 and 2.
6.3.5 Features of predicted ammo acid sequence of arginine kinase
The differentially expressed protein spot located at pH 5.8 (spot B) had been identified as 
arginine kinase from either ORF 342 or 343. The difference in molecular weight and pi of 
the predicted transcript product from each ORF are shown in Table 6.4. The amino acid 
sequence of ORF 342 was analysed using the PredictProtein software available at the 
Expasy web site. The amino acid sequence contained all the characteristic consensus 
blocks o f the guanidino kinase family, and a putative actin binding domain (CPSNLGT) 
(Figure 6.25). The genes are present as tandem repeat on chromosome IX of the reference 
line 927.
6.4 Discussion
Whole cell preparations o f T. brucei proteins could be sepaiated by 2DE into over 1,000 
distinct protein spots on various pH ranges gels. Comparison o f the 2DE pattern of proteins 
extracted from 386 and 386Mr confirmed the prediction that the vast majority o f proteins 
were identical. The analysis focussed on identifying consistent differences in protein 
patterns between the isogenic lines in order to identify an alteration associated with 
Cymelarsan resistance.
The data presented provide evidence for a correlation between the absences o f protein spot 
2 (34 kDa, pi 4.5) and spot B (40 kDa, pi 5.8) on the 2D gels and the Cymelarsan 
resistance phenotype in T. brucei line 386. Protein spot 2 was identified as the gene 
product o f a non-annotated ORF, and was named Cymelarsan Associated Resistance
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 1 alg get ace cgc gac get gee gag Ug gaa aag get ill gcg aaa ctg cag get gca-----------------------------------------------------
I M A T R D  V A A E L E  K A F A K L Q A APD204945
61 aaggactgccagtcgctgttgaagaaatat ctgacaag gat gtc ttc aag aag eta aag 
21 K D C Q S L L K K  Y L T  S D  V F K K  L K
121 ^caagaagacgaagttggg get accttactt ^  g c  att caa tct ^  gacagaac 
41 D K K T  K L G A T L L D V l  Q S G  V Q N
PD001475
181 etc ^  too gg  g t gg  ttatat gcaeea gae gea gaa gpc tac aet g g ttt  gcegac 
61 L D  S G V G L Y A P  D A E A Y T V F A D
241 ete tte ^  ece g e  att gag tac eag aac ggc tte aag g a  aeg gae aaa eaa eea
81 L F D  P V  l E D Y Q N G F K V  T D K Q  P
301 eea aag ^  tte gg  ^ tta a a t  acgetggt gae g t  gat e e g ^ a  gg aaatat g e  
101 _P K D F G D L N T  L V D V P P  E G  K Y V
361 attteeæ eeg  g e e g t g e  ggcegeag etegcc gg  tae eea tte aac eeatgcta  
121 1 S T  R V R C G  R S L A G Y P F N P C LPD001404
421 acg aag gag eag tac g a g ^ a tg ^ g t e a  e g  g g  egg gaa eaa etg age aca atg aca 
141 T K E Q Y E E M E  S R V  R E Q  L S T M T
481 ^  gat etg eaa gg  act tat tst ecgett tet ggp atg aeg aaa ^  aea eaa eag eag 
161 D P L Q G T Y Y P L S G M T  K E 1 Q Q Q
541 ctaatt gat gac cac tte etc tte aag gag gge gat e g  tte etg eaa get gee ggc gea 
1 8 1 L 1 D D H F L F K E  G D R F L Q  A A G  A
601 tgc ^gtat tggcegaet gg  e g  gg  ate tac eat aac aat gac aagæa tte ete g g  
2 0 1 C E Y W P T G R G  l Y H N N
661 t^ g g a a t  ^  g a g ^  eae etgeg  ateatt tee aag eag aag ggp gggaac ttgaag 
221 ■ ■ ■ ■ i  E D H L R I I S K Q K G G N L K
721 ^ g  g c  tte ggc e g  ett g g  aag gpa g g  aac ate att ^ a  aag aag g g  gagttttet 
241 E V F G R L V K A V N l  l E K  K V E F S
PD001404
781 eg git gac ega ett gg  tte etg acg tte tgc eee teg aae ete ggc aeg acg ate egc 
261 R D P R  L G F L T  F C P S N L G  T T 1 R
841 gaatt ggeac ate aaattaeegaaaett gg  get ^  egc get aaa ett gag ^ g  g t  
281 A I V H I K L P K L G A P R A K L E  E V
901 get gca aaatat aae etg eag ga  e g  gggaea get ggg igeactet gae age cet ^
301 A A K Y N L Q  V R G  T A G E H S P S  P PPD001395
961 gga att ta ^  ate age aae aag egc ege ete gge eta teg ^ g  tat ^ g  gee ga  aag 
321 G l Y P l S  N K R R L G L S  E Y E A V K
1021 gaa atg eaa gae gg  att ett gag etc ate aaa etg gag aag teg aag tag 
341 E M Q P  G I L E  L I K  L E K  S K 
Figure 6.25: Schematic representation of the DNA and amino acid sequences of 
arginine kinase (ORF 345) from F. brucei A signature sequence pattern of 
ATP:guanidine kinase (yellow) containing a reactive cysteine residue at position 271 was 
discovered and a putative actin binding domain (blue). Characteristic consensus sequences 
according to ProDom database are underlined.
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Name Location Size Molecular weight pi
Chr9contigl60.tmp0342 Chromosome IX 1215 bp 44.7 kDa 4.9
Clir9contigl 60.tmp0343 Cliromosome IX 1113 bp 41.4 kDa 5.9
Chr9contig 160.tmp0345 Clu'omosome IX 1071 bp 40.1 kDa 6.4
Table 6.4: Information about the three genes encoding arginine kinase in T. brucei.
The information was reproduced from GeneDB.
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(CAR) protein and protein spot B was identified as an arginine kinase. The correlation 
between the absence o f the CAR protein (spot 2) and Cymelarsan resistance was 
demonstrated on both broad and narrow pH range gels stained with the sensitive Sypro 
ruby dye and insensitive Coomassie brilliant blue stain.
Tandem MS analysis identified the CAR protein as matching ORF 274 on cliromosome IX 
o f T. brucei. The predicted pi calculated from the sequence of ORF 274 corresponded to 
the location o f the CAR protein on the 2D gel. However, the predicted molecular weight 
(20.1 kDa) was lower than the observed molecular weight (34 kDa) o f the CAR protem.
This was also observed on SDS-PAGE gels for the recombinant gene product o f ORF 274 
produced for the antibody production. A Small Ubiquitin-related Modifier (SUMO) 
protem attachment site was identified in the predicted sequence o f the protein.
Modification o f the CAR protem by a SUMO protein would add 11 kDa to the molecular 
weight o f the protem. The SUMO proteins are covalently conjugated onto lysme residues 
within target sequences. Most sumoylated proteins are nuclear, and three main functional 
roles of SUMO have been proposed: 1) protein targeting sumoylation has been shown to be 
important for nuclear import, 2) enhancement o f protein stability, potential competition 
with (and inhibition of) ubiquitination and 3) transcriptional control (i.e. negative 
regulation of transcription from the androgen receptor) (Hay, 2001). The molecular weight 
of the recombinant gene product o f ORF 274 produced in E. coli. for the generation of 
antibodies in mice was measured by mass spectrometry as 22 kDa, corresponding to 2 kDa 
higher than the expected molecular weight. The high molecular weight observed on SDS- 
PAGE and 2D gels is therefore not due to the attaehment o f a SUMO protem. An 
alternative explanation for the discrepancy in molecular weight is that the CAR protem is 
made o f 16% of acidic residues (aspartate and glutamic acid). The high proportion of
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negatively charged amino acids could account for the discrepancy between expected 
molecular weight and the apparent molecular weight of the CAR protein on 2D and SDS- 
PAGE gel The location o f arginine kinase on 2D gel corresponded to the predicted 
molecular weight and pi determined from the gene sequence of ORF 343 in GeneDB.
A BLAST analysis o f GeneDB identified the presence o f another copy o f ORF 274 (Figure 
6.26) and two more copies o f the arginine kinase gene (Figure 6.27). The genes, encoding 
the CAR protein and spot 1, were present as tandem repeats on chromosome IX of 
reference line 927. As the sequences o f the two ORFs are identical one would predict that 
the duplication had occuiTed recently. Duplication is important for genes whose functions 
are essential for the survival of the species (Gu et al., 2003).
Two protein spots, which differed in isoelectric point on 2D gels of 386, were matched 
onto either ORF 274 or 277. As both ORFs have identical predicted amino acid sequences 
and no other homologues were found in the T. brucei genome, it is likely that the iso form 
is due to a post-translational modification. In principle, comparison o f the mass spectrum 
of the modified protein with the unmodified protein should allow the identification o f the 
modified peptide. However, the low sequence coverage obtained in Tandem MS for these 
protein spots meant that the identification of the modified peptide was not possible. In 
order to analyse reliably the differences, a higher quantity o f protein would be required. 
This could now be achieved by immunoprécipitation using the antiserum to the expressed 
product of ORF 274.
185
Chapter VI: A proteomic approach to study Cymelarsan resistance in T. brucei in line 386
10,000 
1
15,000 20,000 30,000
2 — 3 — 4 — 5
30,000 35,000
6 7 8
Figure 6.26: Representation of ORF 274 and 277 on chromosome IX of T. brucei.
Complementary string o f Chromosome IX (10 Kb to 35 Kb) with boxes indicating putative 
ORFs with homology to proteins in NCBI (yellow) or without homology to proteins in 
NCBI (white). Ubiquitin conjugating E2 enzyme (1), 60S ribosomai protein LIO (2), ORF 
274 (3), ORF 277 (4), chaperone (5), cell cycle check point protein (6), metaloprotease like 
protein (7) and tyrosine phosphatase (8).
730,000HM
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Figure 6.27: Representation of arginine kinase genes on chromosome IX of F. bruceL
String o f Chromosome IX (725 Kb to 760 Kb) with boxes indicating putative ORFs 
without homology to proteins in NCBI (white), putative ORFs with homology to protein in 
NCBI (yellow) and experimentally characterised ORFs (red). This region of the 
chromosome contains genes encoding glutamate dehydrogenase (1), NAD/FAD dependent 
dehydrogenase (2), 40s ribosomai protein S3 (3), calmodulin (4), phosphatase protein (4), 
conserved hypothetical protein (5), arginine kinase ORF 342 (6), arginine kinase ORF 343 
(7), arginine Mnase ORF 345 (8), ABC transporter (9), myo-inositol-1 phosphatase (10) 
and a transmembrane protein (11).
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Sequence pattern searches on the predicted amino acid sequences o f ORF 274 and 
argirdne kinase revealed a number of possible modification sites, including potential 
phosphorylation and glycosylation sites (Figure 6.28). NetPhos predicted five threonines 
and two serines as putative phosphorylation sites on the gene product of ORF 274, and 14 
putative phosphorylation sites on arginine kinase (ORF 342). The protein spots from the 
2D gel were identified by mass spectrometry. Because post-translational modification 
causes a peptide mass shift, any peptide found to match onto the protein can be considered 
free fi'om modification. This reduced the potential modification sites present on the gene 
product o f ORF 274 and arginine kinase to 5 and 10 phosphorylation sites respectively 
(Figuie 6.28). Protein phosphorylation can be involved in the activation/inactivation of 
enzyme activity, modulation o f molecular interactions and signalling. For example, 
activation of a kinase by protein phosphorylation is a hallmark of intracellular signalling 
cascades (Hunter, 1995). Potential post-translational regulation of the gene product of 
ORF 274 and 277 could allow lai'ge amounts o f the protein and enzyme to be present in the 
cell in an inactive form.
InterPro and Pfam searches revealed the presence o f a nascent polypeptide associated 
complex (a NAC domain) at the N terminal and an ubiquitin associated domain (DBA 
domain) at the C terminal o f the gene product of ORF 274. In humans, NAC is a 
hetero dimeric complex of two subunits: a  NAC of 33 kDa and p NAC of 21 kDa. 
Similarly, a  (Egd2p) and p (Egdlp) subunits have been found in yeast (Shi et ah, 1995). 
The mammalian NAC complex acts in the regulation of co-translational transport of 
proteins into the endoplasmic reticulum, and was also shown to be involved in 
transcriptional regulation. In yeast however, the NAC complex has a different function as 
it binds ribosomes, protecting newly synthesized polypeptide chains from degradation and
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MSANDVONPPVEDDEVPTLEAADTOOASKPSKRYAKAMAKMGLKPEPgiS
KVHIRKRAALSFVVNOPEVYRFPGTNTFLIFGEAOLGDTTMOTOEAAARA
VSGALVEEVGTAGEETSELAGETPAAAAPSESKOTPDDVEIVEGEFDDKE
IA V V M A O |K M kTGATRAERNNKGDIVNAIMELTMDPN
B)
MATRDVAAELEKAFAKJLOAAKDCQSLLKKYLTSDVFKKLKKKTKLGATLLDVIO
SGVQNLDSGVGLYAPDAEAYTVFADLFDPVIEDYQNGFKVTDKOPPKDFGDLNTL
VDVDPEGKYVISTRVRCGRSLAGYPFNPCLTKEOYEEMESRVREOLSTMTDDLOG
t y y p l s g m t k e iq q q u d d h f l J E E I d r f l q a a g a c e y w p t g r g iy h n n d k if l v
WVNEEDHLRIISKQKGGNLKEVFGRLVKAVNIIEKKVEFSRDDRLGFLTFCPSNLG
TTIRAIVHTKEPKI.GADR K ia E V A A K YNLQVRGTAGEHSDSPDGIYDISNKRRLG
LSEYEAVKEMODGILEÜEflftcSK
Figure 6.28: Predicted post-translational modification sites on gene product of ORF
274 (A) and arginine kinase (B). Potential threonine and serine phosphorylation sites 
(yellow), as predicted by NetPhos (http://www cbs.dtu.dk/services/NetPhos). N- 
glycosylation site (blue) as predicted by NetNGlyc
(http://www.cbs dtu.dk/services/NetNGlvc). and SUMO protein attachment site (red) as 
predicted by Abgent ( http : //www. abgent. co m/cgi -bin/t ools.pl) are shown on the amino acid 
sequence. No myristoylation (http://mendel imp.univie.ac.at/mvristate/SUPLpredictor.htm) 
or sulfination sites (http://us.expasy.org/cgi-bin/sulfinator.pl) were found. The sequences 
underlined correspond to the matching peptide fragmented by Tandem MS from spot 2 and 
spot B.
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preventing any inappropriate translocation into the reticulum (Wang et al., 1995). The role 
o f such domains in T. brucei remains to be elucidated.
The UBA domain was first identified in 1996 in proteins that function in ubiquitin 
mediated proteolysis (Hofmann and Bucher, 1996). Since then this domain has been found 
in proteins that lack any obvious link to proteolysis. The structure and function o f the UBA 
domain has been mainly studied in humans and yeast. The UBA domain is composed o f 35 
amino acid residues which form a sequence motif containing three alpha helices (Figure 
6.29). Sti'uctui'e analysis o f various UBA containing proteins suggest that conserved 
residues contribute to the common structure of the UBA domain, while divergent residues 
on the surface o f the helices would permit the selective interaction with different protein 
targets. Target proteins include ubiquitin, multi-ubiquitin chains, ubiquitinated proteins and 
other effectors, predicting a role for this motif in protein-protein interaction and subcellular 
targeting (Wilkinson et ah, 2001; Mueller and Feigon, 2002; Hofinann and Bucher, 1996). 
The association o f the NAC and UBA domains m a protem is not uncommon, as shown in 
yeast with Egdp2 (Shi et ah, 1995; Wang et ah, 1995). The association o f the two domains 
in one protein could indicate that the function of this protein is in the degradation or 
refolding o f newly synthesised proteins with folding defects.
Arginine kinase belongs to a family o f conserved proteins with phosphotransferase 
activity, the guanidine kinases. Arginine kinase catalyse the synthesis o f N-phosphorylated 
guanidine compounds by the reversible transfer o f a phosphoryl group from ATP to an 
enzyme-specific guanidine acceptor. Phosphoarginine, the reaction product, plays a crucial 
role as an energy reserve because the high-energy phosphate can be transferred when a
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Figure 6.29: UBA domain structure. Ribbon representation o f the structure o f a human 
DNA repair protein UBA domain as determined by NMR spectroscopy. The representation 
sows the characteristic compact three-helix bundle encoded by the conserved residues of 
all UBA domains (reproduced from Dieckmann et al., 1998).
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renewal o f ATP is needed. ATP consumption and high energy phosphate regeneration are 
required to support processes such as stage differentiation, cell division and motility. 
Phosphoarginine is presumed to support rapid bursts o f cellular activity hi the short term 
until metabolic pathways such as glycogenolysis, glycolysis and oxidative phosphorylation 
are switched on (Hird and McLean, 1986). Arginine kinase has been identified in T. brucei 
(Pereira et ah, 2002) and T. cruzi (Pereira et ah, 2000; Pereira et ah, 1999). These gene 
sequences contain all the characteristic consensus blocks of the guanidino kinase family 
and a putative actin-binding domain (Pereha et aL, 2000).
The results presented in this chapter suggest that the absence of the CAR protein, an 
iso form of spot 1, is associated with Cymelarsan resistance in T. brucei. The question 
arises as to whether the change in CAR expression is a general feature o f Cymelarsan 
resistance in T. brucei or is a particular attribute o f the 386Mr line only. A proteomic 
analysis o f a second pair o f isogenic lines o f Cymelarsan resistant and sensitive T. brucei 
lines has been undertaken and the results are presented in the next chapter.
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Chapter VII
Association of the CAR protein and Cymelarsan resistance
in line 247 and 927
7A Introduction
The proteomic study performed on the pair of isogenic lines of 386 demonstrated a positive 
correlation between the absence of the CAR protein (located at pH 4.5, 34 kDa) with 
resistance to Cymelarsan in T. brucei (chapter 6). The CAR protein and its isoforms are 
encoded by two ORFs present as a tandem repeat on chi omosome IX. Analysis of these ORFs 
in the 386 and 386Mi' lines demonstrated the absence of sequence differences between the 
ORFs that could account for the presence o f the CAR protein isoform of spot 1, in the 
sensitive 386 line. In addition, both ORFs were transcribed in both isogenic 386 lines. 
Consequently, it was suggested that the presence of three protein spots encoded by ORF 274 
and 277 (one of which being the CAR protein spot) in the sensitive line was due to a post- 
translational modification, and that the protein spots encoded by ORF 274 and 277 in the 
resistant line is not modified.
The question arises as to whether the change in CAR protein expression is a general feature of 
Cymelarsan resistance or is a particular attribute of the 386M' line only. To address this 
question a 2DE analysis was undertaken with of a second pah of isogenic lines of Cymelarsan 
sensitive and resistant lines o f247. The Cymelarsan resistant line o f247 was generated from 
the sensitive 247 line in-vivo by increasing sub-curative doses of Cymelarsan (Scott ei aL,
1996). This line was produced following the same protocol as the 368 isogenic lines.
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Resistance to Cymelarsan in the procyclic form of the laboratory induced resistant line of 247 
was shown to be 1,257 fold greater than hi the parental line (chapter 5).
Proteins from Cymelarsan sensitive and resistant 247 lines were separated by 2DE and 
analysed by Tandem MS. Subtractive analysis o f the region o f the gel at pH 4.5 and 34 kDa 
was undertaken. Western blot analysis using antibodies raised against the transcriptional 
product of ORF 274 was performed on 2D gels to analyse the CAR protein spot and its 
isoforms in 247 and 247Mr lines. In addition, a 2DE analysis of the genome reference line 927 
was undertaken. In each case, the analysis was focussed on expression of transcriptional 
products of ORF 274 and 277 rather than undertaking a general proteome scan.
7.2 Materials and Methods
7.2.1 in vitro culture of procyclic trypanosomas
Procyclic forms of the thi ee lines were gi'own in-vitro in complete SDM79 as described m 
chapter 2.
7.2.2 Protein extraction, 2DE and mass spectrometry
Whole soluble protein extract was obtained from 1x10^ procyclic forms of trypanosomes using 
protocol F2 as described in chapter 2. Fresh protein extracts were made for each gel as 
proteins from the 247 lines seemed to degrade when stored at -20°C (data not shown).
The whole soluble protein extract was separated by 2DE on pH 4-7 gels as described in 
chapter 6. The gels were stained with either Sypro orange or colloidal Coomassie blue stain.
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For Sypro orange staining, the gels were fixed overnight in a solution of 7.5% acetic acid and 
10% methanol. The gels were incubated in 0,005% SDS for 1 h and then transferred in the 
Sypro orange dye diluted (1/5,000) in 7.5% acetic acid in which they were left overnight. Gels 
were rinsed briefly in a solution of 7.5% acetic acid and 30% methanol, and images were 
acquired immediately with the Typhoon scanner as previously described (chapter 2) using the 
green laser.
For colloidal Coomassie blue staining, the gel was fixed for 3 h in a solution of acetic acid 
(10%) and ethanol (40%). The gel was washed twice in water for 10 min before bemg 
transferred into the colloidal Coomassie blue stain (1 part methanoFl part colloidal stock (50 g 
ammonium sulphate, 6 ml ortho-phosphoric acid, 500 ml ddHzO, 10 ml o f a 5% Coomassie 
blue G 250 solution)). The gel was left to stain for three days. The gel images were acquired as 
described in chapter 2.
Protein spots of interest were excised from the gel and digested with trypsin using the in-gel 
protein digestion protocol described in chapter 3. Tandem MS analysis of the proteins was 
performed as described in chapter 4.
7.2.3 SDS-PAGE gels and Western blot analysis
SDS PAGE gels and Western blot analysis were performed as described m chapter 6.
7.3 Results
7.3.1 Proteomic analysis of the isogenic 247 lines
Proteins from the isogenic lines o f247 were extracted and separated by 2DE on pH 4-7 gels to 
detect the CAR protein spot and its isoforms in 247 and 247Mr lines. Tandem mass
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spectrometry was performed to identify the protein spots located at and around the expected 
location of the CAR protein on the 2D gels. The gels were stamed with Sypro orange.
Analysis of the gels using the ImageMaster 2DElite showed 363 proteins spots on the gel from 
the 247 line and 388 protein spots on the gel from the 247Mr line. The general 2D pattern of 
proteins from the 247 and 247Mi‘ lines was very similai', as expected from isogenic lines 
(Figure 7.1). In addition, comparison of the gels from the two pairs of isogenic lines (386 and 
247) revealed a high similarity in 2D pattern on pH 4-7 gels. Comparison of the 2D pattern in 
the area of the gel at approximately 34 kDa and pH 4.5 between 247 and 247Mr lines showed 
no differentially expressed protein spots. Protein spots located in this area were excised from 
the gels, digested with tiypsin and analysed by Tandem MS. Protein spots 1, 3 and 4 fr om the 
sensitive line 2D gel and 1, 2, 3, and 4 from the resistant line 2D gel were identified with high 
confidence as (3 tubulins (Figure 7.2). p tubulins had previously been found to surround the 
CAR protein spots on 2D gels from the isogenic lines of 386 (chapter 6). The identification o f 
these spots demonstrated that the location on the gels fr om the 247 lines corresponded to the 
location o f the CAR protein spots on gels from the 386 lines. No protein spots were detected at 
the expected location of the CAR protein spots on the gels from 247 and 247Mi’ (Figure 7.1).
7.3.2 Presence of ORF 274 and 277 in isogenic 247 lines
Since the CAR protein spot and its isoforms could not be visualised on 2D gels o f247 and 
247Mr lines at the expected location, the question arises as to whether the ORFs encoding the 
CAR protem exist in the 247 genome. To address this question, a PCR was performed on 
genomic DNA of lines 247 and 247Mr using ORF specific primers (274F/274R, 277F/277R). 
PCR products of the expected size were observed for both ORF 274 and 277 in 247 and 
247Mr lines (Figure 7.3). In addition, a smaller PCR product was also amplified using these
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B)
Figure 7.1: 2D gels of procyclic forms of isogenic 247 lines, pH 4-7. Broad pH range 
isoelectric focussing (pH4-7) 2D gels o f procyclic forms of 247 (A) and 247Mr (B) lines. The 
gels were stained with Sypro orange.
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A)
Name Score Peptide identified gi/number
247
1 Tubulin beta chain 223 4 9366734
2 No ID
3 Tubulin beta chain 133 3 9366734
4 Tubulin beta chain 116 2 9366734
5 Chaperonin HSP60 404 7 18277736
247Mr
1 Tubulin beta chain 270 6 9366734
2 Tubulin beta chain 143 3 9366734
3 Tubulin beta chain 123 2 9366734
4 Tubulin beta chain 99 2 9366734
5 Chaperonin HSP60 65 2 18277736
Figure 7.2: Tandem mass spectrometry analysis of protein spots located in the expected 
region of the CAR protein. Location o f the protein spots from 247 (A) and 247Mr (B) lines. 
The table (C) gives a summary o f the results obtained searching the NCBInr database using 
the MASCOT search engine with the mass spectra acquired. The empty circles indicate the 
expected position of the CAR protein spot and its iso form.
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k — 850 bp
k — 650 bp
k — 500 bp
Figure 7.3: PCR amplification of ORF 274 and 277 from isogenic 247 lines. The PCR was
performed using the ORF specific primers. The main product corresponded to the expected 
size for each ORF (ORF 274 = 891 bp, ORF 277 = 868 bp).
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primers. This smaller product was not recovered from PCR amplification of genomic DNA 
from the 927, 386 and 386Mr lines.
These results would suggest that the pafr o f isogenic 247 lines both contain ORF 274 and 277 
in their genome.
7.3.3 Presence of expressed product of ORF 274 and 277 in isogenic 247 
lines
The CAR protein spot and its isoform could not be detected on 2D gels o f247 and 247Mr 
lines at its expected location. However, ORF 274 and 277, encoding the CAR protein, were 
shown to be present in each line. In view of these results a Western blot analysis of whole cell 
extract separated by SDS-PAGE gel was performed. This analysis revealed the presence of 
ORF 274 protein in both lines (Figure 7.4). The protein detected had a similai' molecular' 
weight to the recombinant His tagged transcriptional product of ORF 274 (34 kDa). Higher 
molecular weight bands were also detected in the lane containing purified recombinant His 
tagged protein. These probably correspond to dimers and trimers of the transcriptional product 
of ORF 274, however no molecular weight marker was run on the gel so the size cannot be 
determined.
To assess the number o f CAR protein isoforms and thefr pis in 247 and 247 Mi' lines, 2D gels 
o f these lines were i*un and Western blotted. Only one transcriptional product of ORF 274 
could be detected at 34 kDa, pH 4.5 for both 247 and 247Mr lines (Figuie 7.5). Other products 
were detected at lower molecular' weight and basic pH in both 247 and 247Mi' lines. These 
fainter spots might conespond to degradation products or could indicate a cross-specificity
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A) B)
1 2 3
F  I
1 2  3
Figure 7.4: Western blot analysis of expression of the gene product of ORF 274 in the 
isogenic 247 lines Protein extracts from 247 (lane 2) and 247Mr (lane 3) were separated by 
SDS-PAGE gels and electro-transferred onto a nitrocellulose membrane. The membrane was 
blotted with mouse anti-CAR antibody and detected with HRP-conjugated anti-mouse IgG 
(1/1000) and the ECL detection kit. The positive control was the His-tagged recombinant CAR 
protein (lane 1).
Serum from non-immunised mice was used as negative control (B).
A) B)
« 4 m i pH 4 pH 7
Figure 7.5: Western blot analysis of expression of isoforms of the gene product of ORF 
274 in isogenic 247 lines. Cymelarsan sensitive (A) and resistant (B) 247 lines.
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of the antiserum to another protein not detected on one dimensional SDS-PAGE gels.
7.3.4 Proteomic analysis of line 927
Protein extracted from procyclic forms of line 927 were separated by 2DE on pH 4-7 gel and 
stained with colloidal Coomassie blue. I am grateful to Anne Fladas for running and staining 
the gel. Examination of the 2D gel revealed a similar general 2D pattern of protein spots at 
location of 34 kDa and pH 4.5 as lines o f386 and 247. A protein spot located on the 2D gel at 
the expected position of a CAR protein isoform was detected. This spot (spot 6) was excised 
from the gel, digested with trypsin and analysed by Tandem MS. The MASCOT® search 
engine was used to search the NCBInr and the local T. brucei database. The protein spot 
matched onto ORF 274 encoding the CAR protein with a score of 95, indicating an correct 
identification vdthin 95% confidence limits (Figure 7.6).
These results would suggest that only one isoform of the CAR protein was present in line 927 
at a location of 34 kDa and pH 4.5.
7.4 Discussion
The presence of the CAR protein spot and its isoform in T. brucei isogenic Cymelarsan 
sensitive and resistant 247 lines and the genome reference 927 line was assessed by 2DE 
analysis and Western blot analysis as the absence o f the CAR protein was associated with 
resistance to Cymelarsan in the 386 lines.
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No protein spot could be detected by Sypro orange staining at the expected location on the 
CAR protein spot and its isoforms in 247 and 247Mr. However, a single protein product of 
ORF 274 was detected by Western blot analysis of 2D gels at the expected location for both 
Cymelarsan sensitive and resistant 247 lines. This suggests that the quantity of protein of ORF 
274/277 expressed in the 247 lines is lower than the sensitivity o f the Sypro orange stain, or 
alternatively that it doesn’t stain with Sypro orange. In addition, these results suggest that in 
the isogenic 247 lines the transcriptional product of ORF 274 and 277 was perhaps expressed 
at a lower level than in 386 lines where the CAR protein is readily detectable by Coomassie 
Brilliant blue.
Only one transcriptional product of ORF 274 and 277 was detected at pH 4.5, 34 kDa in both 
247 and 247Mr lines, suggesting that the CAR protein is not associated with Cymelarsan 
resistance in this pan o f T. brucei isogenic lines.
A possible clue to the mechanism o f Cymelarsan resistance in T. brucei is the diminished 
metabolism of the Alamar Blue dye in the 386Mr and 247Mr (chapter 5). This new phenotype 
associated with cymelarsan resistance in the two pans of isogenic lines will be Anther 
investigated in the next chapter.
2 0 2
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Line Name Score Peptide identified Contig name
927 CAR protein 95 3 ORF 274
Ç I
Contig name Score p score Peptide sequence
Tryp9.0.00322-274 95 56 AALSFVVNQPEVYR
OTPDDVEIVEGEFDDK
GDIVNAIMELTMDPN
Figure 7.6; Mass spectrometry analysis of protein spot located at the expected region of 
the CAR protein in line 927. Analysis o f colloidal Coomassie blue stained 2D gels of protein 
extracted from 927 revealed the presence of a spot at the region of the CAR protein (A). 
Results from the MASCOT® search engine searching the local T. brucei database are 
presented in table B and C.
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Chapter VIII 
The Alamar Blue phenotype
8.1 Introduction
The use o f the Alamar Blue dye in in vitro assays for testing sensitivity o f cells to drugs is 
based on the ability o f intracellular enzymes to reduce the non-fluorescent blue dye to a pink 
fluorescent compound (Figure 8.1). The reduction o f the dye correlates with growth and 
metabolic activity of the cells in the presence/absence o f drug, and can be measured by 
spectrofluorometiy and spectrometry. The Alamar Blue assay was recently developed as an in- 
vitro assay to test drug sensitivity/resistance of procyclic trypanosomes in culture (Raz et al.,
1997). The assay was shown to be simple, fast, reproducible and economical.
The assay perfoimed in the absence of drug on procyclic stages of each pair o f isogenic lines, 
demonstrated a marked difference in the level of reduction of the Alamar Blue dye between 
the Cymelarsan sensitive and resistant lines as shown in chapter 5. In the presence of 
increasing concentrations of Cymelarsan, the sensitive Imes (247 and 386) showed a dose 
dependent response with a decrease in fluorescence from Alamar Blue as the trypanosomes 
viability is lost. In contrast, the two resistant lines (386Mr and 247Mr) showed no change in 
the level o f Alamar Blue fluorescence with increasing levels of Cymelarsan (0.001 pM to
1,000 pM).
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A)
B)
C)
CH:H2N
Figure 8.1: Structure of the Alamar Blue dye and the Isometamidium. The reduced form 
of the Alamar Blue dye (B) is fluorescent and can be detected by spectrofluorometry or 
spectrometry. The structural similarities between the oxidized Alamar Blue stmctuie (A) and 
Isometamidium (C) are highlighted in blue. The structure of Isometamidium correspond to the 
active form (red isoform) of the drug found in Samorin®.
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The fluorescence from the Alamar Blue dye produced by the Cymelarsan resistant lines was 
almost constant whether the trypanosomes were alive or dead. However, the fluorescence from 
the Alamar Blue dye was higher in the presence of Cymelarsan resistant lines than without 
trypanosomes in the medium, demonstrating some reduction of the Alamar Blue dye by the 
trypanosomes (chapter 5). The decrease ability to reduce Alamar Blue shown by the 
Cymelarsan resistant lines demonstrated an unexpected association of the Alamar Blue 
phenotype with Cymelarsan resistance.
This new phenotype associated with Cymelarsan resistance might potentially be linked to the 
mechanism of Cymelarsan resistance in T. brucei. In this chapter, an attempt is made to 
identify the mechanism that impaired the reduction of the Alamar Blue dye in the Cymelarsan 
resistant lines. The Alamar Blue dye can only be reduced by intracellular enzymes (O’Brien et 
al., 2000), therefore two possible mechanisms of decrease in reduction of Alamar Blue were 
tested; the presence and activity o f reductive enzymes in the lines and the transport/export of 
the Alamar Blue dye into/from the trypanosomes.
To test for the presence and activity of reductive enzymes, the following question was 
addressed:
1- is there any difference in cell lysate reductive activity of Alamai* Blue between the 
sensitive and resistant lines?
To test whether and how the Alamar Blue dye was taken up by trypanosomes, the following 
questions were addressed:
1- Wliat are the effect of P-glycoprotein inhibitors on the reduction of the Alamai' Blue 
dye?
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2- Wliat is the activity o f the transporter for Isometamidium, wliich possess a common 
structure with the Alamar Blue dye?
3- What aie the actions of chloroquine and other lysosomotropic agents on the reduction 
of the Alamar Blue dye?
4- What is the localisation o f the reduced Alamar Blue due inside trypanosomes?
8.2 Materials and Methods
8.2.1 Commonly used reagents
Ammonium chloride, Bafilomycin A l, Concanamycin A, chloroquhie, verapamil, PCP, TFP 
were purchased from SIGMA. LS 55 Luminescence Spectrometer was from Perkin Elmer 
instruments. The fluorescent microscope and camera were pui'chased fr om Zeiss. Samorin® 
was purchased from May and Baker (UK). Alamar Blue was purchased from Trek Diagnostic 
System, Inc. and Cymelarsan was a kind gift fr om Rhone Merieux. Chloroquine was a gift 
from Dr Lisa Ranford-Cartwright (University of Glasgow).
8.2.2 In vitro culture of procyclic trypanosomes and cell lysate 
preparation
Procyclic stages of each paii’ of isogenic lines were grown in vitro in complete SDM79 as 
described in chapter 2.
Cell lysates were prepared in PBS in the presence of protease inhibitor cocktail and nucleases 
as described m chapter 2. The protein concentration from the cell lysate was deteimined using 
a Coomassie Plus Protein Assay (Pierce) according to the manufacturer’s instmctions, using 
bovine serum albumin as the protein standard.
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8.2.3 In vitro drug sensitivity testing
8.2.3.1 The Alamar Blue assay
The Alamar Blue assay was performed on procyclic cultures o f the two pairs of isogenic lines 
(386/386Mr and 247/247Mr) as described in chapter 5.
Doubling serial dilutions of test compounds (P-glycoprotein inhibitors, chloroquine, 
Bafilomycin A l, Concanamycin A and ammonium chloride) in complete SDM79 were set out 
in a 96 well plate in duplicate, in a volume o f 100 pi (Table 8.1). 100 pi o f trypanosome 
culture (2x10^ trypano some/ml) were added to each well, with 20 pi of the Alamar Blue dye. 
Measurements with a LS 55 Luminescence Spectrometer were taken, after 24 h incubation at 
25°C, as described in chapter 5. Each experiment was performed in duplicate and replicated at 
least once. The presence and viability of the trypanosomes in each well was confiimed by 
microscopy.
The Alamar Blue assay was also performed directly on cell lysates Ifom each pair o f the 
isogenic lines. In the first experiment, the cell lysate (100 pi) and Alamar Blue dye (10 pi) 
were mixed to assess the level o f reduction of the dye by the intracellular enzymes from 
Cymelarsan sensitive and resistant lines o f386 and 247. The measurements were taken after 
incubation for 24 h at 25°C. In the second experiment, the assay was performed in the 
presence of doubling serial dilutions o f  chloroquine in PBS to assess the action of chloroquine 
on the intracellular enzymes. 100 pi o f chloroquine (0.005 to 50 pM) was mixed with cell 
lysate (100 pi) and Alamar Blue dye (20 pi), incubated for 24 h a t 25 °C and the reduction of
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Final concentration
Inhibitor Compound Minimum Maximum
Inhibitor of P-glycoprotein Verapamil 0.01 mM 1 mM
PGP 0.01 mM 1 mM
TFP 0.01 mM 1 mM
Inhibitor of proton pump Chloroquine 5 pM 50 pM
Bafilomycin Al 0.001 pM 32 pM
Concanamycin A 0.01 pM 29 pM
Ammonium chloride 0.01 mM IM
Table 8.1: Concentrations of test compounds used in the Alamar Blue assay.
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the Alamar Blue dye was recorded using a LS 55 Luminescence Spectrometer as described in 
chapter 5. The experiment was performed m duplicate and repeated at least once.
8.2.3.2 Growth inhibition assay
To assess for the relationship between the decrease in fluorescence of the Alamar Blue dye 
and resistance to the trypanocidal drug Isometamidium, an in vitro growth inhibition assay 
was performed as previously described in chapter 5. The drug was serially diluted in complete 
SDM79 with final concentrations ranging from 0.001 pM to 1,000 pM. The percentage 
inhibition is expressed relative to the cell densities in cultures giowhig in the absence o f 
Isometamidium. The experiment was carried out in triplicate and was repeated at least three 
times on each pafr o f the isogenic lines.
8.2.4 Fluorescence microscopy
The localisation of the reduced Alamar Blue dye and Isometamidium in procyclic stages of 
each pair of the isogenic trypanosomes were investigated by fluorescence microscopy using 
the intrinsic fluorescence o f these compounds.
The localisation of the Alamai' Blue dye in procyclic trypanosomes was observed by adding 20 
pi of the Alamar Blue dye to 200 pi o f procyclic cultures. After incubating for 1 min at room 
temperature, 5 pi o f live trypanosomes were placed on a slide and covered with a coverslip. 
Cells were immediately exammed on a Zeiss UV microscope (Axiovert 200M) fitted with a 
DAPI filter, and images taken with a camera (AxioCam) using Axiovision software, version
3.0 (Zeiss). Trypanosomes were also observed under phase contrast to assess the 
morphological integrity o f the cells.
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To assess for the effect of chloroquine on the localisation of the Alamar Blue dye inside the 
trypanosomes, chloroquine was mixed with the Alamar Blue dye m SDM79 at a concentration 
of 50 pM, and added to procyclic trypanosomes of each pair o f isogenic lines. The mixture 
was immediately placed on a sUde, covered with a coverslip and viewed using a DAPI filter 
and phase contrast microscopy as previously described.
Procyclic stages of the isogenic lines (10 pi at 6x1 O*’ trypanosome/ml) were mixed with 10 
pM Isometamidium (10 pi) in SDM79. The presence of the Isometamidium drug inside each 
pair of isogenic lines was assessed by fluorescence microscopy as previously described. The 
viability and morphological integrity o f the cells were assessed by phase contrast microscopy.
8.3 Results
8.3.1 Enzymatic reduction of the Alamar Blue dye
To test whether the difference in the level o f reduced Alamar Blue dye produced by 
Cymelarsan sensitive and resistant lines was due to a defect in the ability o f the parasite’s 
intracellular enzyme to metabolise the Alamar Blue dye, Alamar Blue assays were performed 
on cell lysate from each pair o f isogenic lines. The fluorescence, recorded at 590 nm, showed 
no detectable difference in the level o f reduction of the Alamar Blue dye between cell lysates 
from Cymelarsan sensitive and resistant lines for both pairs of isogenic lines, as compared to 
the difference in fluorescence observed for live trypanosomes (Table 8.2).
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Line Average protein 
concentration 
(mg/ml)
Average 
optical 
density (at 
530 nm)
Ratio: optical 
density/concentration
Control 0 25.42 -
Cell lysate 386 2.98 276.06 92.63
386Mr 2.58 217.08 84.14
247 n 3.40 395.58 116.34
247Mr 3.40 326.35 95.98
Procyclic
trypanosome
386 - 251.16
386Mr - 177.08 “
247 - 219.53 -
247Mr - 123.97 -
Table 8.2: In vitro Alamar Blue assays on cell lysates from the two pairs of isogenic lines.
The cell lysates were prepared in PBS and the control consisted of PBS only. The optical 
density obtamed for procyclic trypanosomes (4x10® trypanosome/ml) was added in the table 
for comparison of Alamar blue reduction from live trypanosome and cell lysates.
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These results would suggest that both Cymelarsan sensitive and resistant lines possess the 
enzymes able to reduce the Alamar Blue dye, and that the enzymes are active in both 
Cymelarsan sensitive and resistant lines.
8.3.2 Assessment of the efflux of the Alamar Blue dye by P-glycoprotein
Efflux of drugs through a membrane protein, P-glycoprotein, has been reported as a 
mechanism of dmg resistance in T. cruzi (Neal et a l, 1989) and T. congolense (Sutherland and 
Holmes, 1993). An increased efflux o f the Alamar Blue dye could explain the decreased 
fluorescence produced by the Cymelarsan resistant lines. To assess this hypothesis the Alamar 
Blue assay was performed in the presence o f three general inhibitors o f P-glycoproteins 
(verapamil, PCP and TFP) on each pair of isogenic lines. These three compounds have been 
reported to revert drug resistance by inhibition of P - glycoproteins at concentrations of 5 pM 
for TFP and PCP and 15 pM verapamil in Leishmania (Basselm et a l,  2002) and 8 pM for 
verapamil in T. cruzi (Neal et al., 1989). For both pairs of isogenic lines, verapamil, PCP and 
TFP were lethal to trypanosomes at concentrations of 1 mM, 0.1 mM and 0.1 mM respectively 
as assessed by microscopic exammation o f the cultures. At non-lethal concentrations, the 
presence of the P-glycoprotein inliibitors had no effect on the level o f reduced Alamar Blue 
dye produced by the 386Mr and 247Mr after 24 h exposure (Figure 8.2 and 8.3). Similarly, the 
level of reduced Alamar Blue dye produced by the 386 and 247 lines was not altered by the 
presence of P-glycoprotein inhibitors at sub-lethal doses. These results suggest that the low 
level of fluorescence obtained from the reduction of the Alamar Blue dye observed in 
Cymelarsan resistant lines is not associated with an increased efflux o f the dye by an over­
expressed P-glycoprotein.
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Figure 8.2: Alamar Blue assays in the presence of P-glycoprotein inhibitors for the 
isogenic lines of 386. Procyclic forms were incubated in the presence o f the Alamar Blue dye 
and three common P-glycoprotein inhibitors, verapamil (A), proclilorperazine (PCP, B) and 
trifluoperazine (TFP, C) in SDM 79. The status of the procyclic culture is indicated for each 
concentration o f inhibitors as alive (+) or dead (-) as assessed by microscopy. The lowest 
concentration corresponds to the control in the absence of drug. The error bars represent the 
mean +/- SEM, n = 4.
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Figure 8.3: Alamar Blue assays in the presence of P-glycoprotein inhibitors for the 
isogenic lines of 247. Procyclic forms were incubated in the presence o f the Alamar Blue and 
three common P-glycoprotein inhibitors, verapamil (A), prochlorperazine (PCP, B) and 
trifluoperazine (TFP, C) in SDM79. The status of the procyclic culture is indicated for each 
concentration of inhibitors as alive (+) or dead (-) as assessed by microscopy. The lowest 
concentration corresponds to the control in the absence o f drug. The error bars represent the 
mean +/- SEM, n = 4.
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8.3.3 Mode of transport of the Alamar Blue dye
8.3.3.1 A possible transporter for the Alamar Blue dye
Isometamidium is a trypanocidal drug structurally similar to the Alamar Blue dye (Figure 8.1). 
It possesses the same three phenyl ring structure, a positively charged quaternary ammonium 
in the same position on the ring, and a NH2 group (corresponding to a OH group in the Alamar 
Blue dye) able to form a hydrogen bond (Figure 8.1). These structural similarities could imply 
an uptake of the Alamar Blue dye mediated via the same transporter tliat is used by 
Isometamidium (de Koning, personal communication). To test whether there was a defect in 
the Isometamidium transporter in the two Cymelarsan resistant lines that could be linked to the 
decrease level of reduced Alamar Blue dye produced, a growth inhibition assay was performed 
on isogenic lines o f386 and 247 in the presence of Isometamidium. Isometamidium is a 
naturally fluorescent ding wlrich stains the nucleus and the kinetoplast o f trypanosomes. This 
characteristic was also used to assess the uptake of Isometamidium into the trypanosomes.
In vitro growth inhibition assays o f procyclic stages of each pah of isogenic lines were 
performed in the presence o f serially diluted Isometamidium in SDM79. Both Cymelarsan 
sensitive and resistant lines exhibited a dose-dependent response to the drug. No detectable 
diflerences in dose-dependent inhibition were observed between sensitive and resistant lines 
for both pairs of isogenic lines (Figure 8.4A and 8.5 A). Fluorescence microscopy of the 
procyclic forms of the isogenic lines incubated in 10 pM of Isometamidium using the DAPI 
filter showed the staining of the kinetoplast by the drug (Figure 8.4C and 8.5C). The stained
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Figure 8.4: Isometamidium in the isogenic 386 lines. In vitro growth inhibition assay o f  
procylic forms of the isogenic 386 lines (A) for Isometamidium in SDM79. Phase contrast (B) 
and DAPI (C) images of isogenic 386 lines showing the staining o f the kinetoplast by the 
drug. The lowest concentration on the graph corresponds to the control in the absence of drug. 
The error bars represent the mean +/- SEM, n = 9.
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Figure 8.5: Isometamidium in the isogenic 247 lines. In vitro growth inhibition assay o f  
procyclic forms o f isogenic 247 lines in the presence of Isometamidium in SDM79. Phase 
contrast (B) and under DAPI filter (C) images of the lines showing the staining of the 
kinetoplast by Isometamidium. The lowest concentration on the graph corresponds to the 
control in the absence of drug. The error bars represent the mean +/- SEM, n = 9.
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kinetoplast was detectable in both Cymelarsan sensitive and resistant lines, demonstrating the 
occurrence of Isometamidium uptake. The pairs of isogenic lines were also observed under 
phase contrast (Figure 8.4B and 8.5B) to assess the morphological integrity of the 
trypanosomes. These results suggest that a defect m the transporter mediating the uptake of 
Isometamidium is not associated to neither the Alamar Blue phenotype nor Cymelarsan 
resistance.
5.3.3.2 Localisation of the reduced Alamar Blue dye in trypanosomes
When reduction of Alamar Blue takes place the dye transforms from a cliarged, non- 
fluorescent, blue compound to a non-charged, fluorescent, pink compound. To assess the 
localisation and potential concentration of the reduced Alamar Blue dye inside tiypanosomes, 
procyclic forms of each pair of isogenic lines were incubated m the presence of the Alamar 
Blue dye and examined by fluorescence microscopy using a DAPI filter. Fluorescence 
microscopy showed the presence and accumulation of the reduced Alamar Blue dye m 
vesicular-like organelles (Figure 8.6). These organelles were distributed throughout the cell in 
both sensitive and resistant lines o f386 and 247. The fluorescent organelles can be observed 
almost immediately after mixing the dye with the trypanosomes. The morphological integrity 
of the trypanosomes was intact as assessed by phase contrast microscopy (Figuie 8.6).
5.3.3.2 Endocytosis
The weak base chloroquine is a lysosomotropic agent known to reduce the acidity of 
endosomes and lysosomes (Ki’ogstad et al., 1985). Chloroquine has been used, in many 
organisms, to assess the uptake and degradation of material through the endocytic pathway 
and is thought to act by blocking the formation of the secondary lysosome. Studies on the
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Figure 8.6: Localisation of the Alamar Blue dye in the pairs of isogenic lines. Phase 
contrast and fluorescence microscopy of trypanosomes after incubation in Alamar Blue 
showed the presence and concentration of the reduced Alamar Blue dye in vesicle like pockets 
inside the trypanosomes.
220
Chapter VIII; The Alamar Blue phenotype
internalisation of HDL and anti-CRAM IgG by endocytosis, for example, revealed that 
exposure of procyclic trypanosomes to 50 pM of chloroquine completely abolished the 
lysosomal degradation of these molecules (Lee et al., 1999; Liu et al., 2000).
Chloroquine was used to determine whether the Alamar Blue dye was transported into 
trypanosomes via the endocytic pathway. The Alamar Blue assay was performed on procyclic 
stages o f each pair of isogenic lines in concentrations o f chloroquine up to 50 pM. A dose 
dependent decrease in the fluorescence from the Alamar Blue dye was observed for the 
sensitive lines and at a concentration of 50 pM of chloroquine, the fluorescence had dropped 
to a level similar to that produced by the Cymelarsan resistant lines (Figure 8.7A and 8.8A). 
The presence of cliloroquine in the medium had no detectable effect on the fluorescence fr om 
the Alamar Blue dye produced by the Cymelarsan resistant Imes.
Fluorescence microscopy performed on the procyclic forms of each pair of isogenic lines 
incubated m the presence of chloroquine and Alamar Blue showed the reduced dye in vesicle­
like organelles in both sensitive and resistant lines (Figure 8.7C/E and 8.8C/E). These 
structures were distributed throughout the cell, as previously seen in the absence of 
chloroquine (Figure 8.6). The organelles appeared larger and more numerous in the 
trypanosomes incubated in the presence of chloroquine. The trypanosomes were intact as 
assessed by phase contrast microscopy (Figure 8.7B/D and 8.8B/D).
Chloroquine is believed to act on the endocytic pathway at the level of secondary lysosome 
formation by reducing the acidity of endosomes and lysosomes tliroughthe inhibition of the
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Figure 8.7: Alamar Blue assays of the isogenic 386 lines incubated in the presence of 
chloroquine (A). The status o f the procyclic culture is indicated, for each concentration of 
drug, as alive (+) or dead (-) as assessed by microscopy. Phase contrast (B and D) and 
fluorescent (C and E) images of the procyclic lines in the presence o f Alamar Blue and 50 pM 
of chloroquine. The error bars represent the mean +/- SEM, n = 4.
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Figure 8.8: Alamar Blue assays of the isogenic 247 lines incubated in the presence of 
chloroquine (A). The status o f the procyclic culture is indicated, for each concentration of 
drug, as alive (+) or dead (-) as assessed by microscopy. Phase contrast (B and D) and 
fluorescent (C and E) images of the procyclic lines in the presence of Alamar Blue and 50 pM 
of chloroquine. The error bars represent the mean +/- SEM, n = 4.
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proton pumps present on these organelles. Tliis in turn is thought to inhibit the formation of 
the secondary lysosomes. To assess whether the difference in the level of reduced Alamar 
Blue dye produced by Cymelarsan sensitive and resistant lines was due to a reduced 
acidification of endosomes and lysosomes, three known inhibitors o f proton pumps were 
tested for their ability to decrease the level o f reduced dye produced by the sensitive lines. 
Bafilomycin Al and Concanamycin A are macrolide antibiotics know to specifically inhibit 
two types of proton pumps: V-ATPase at nM concentration and P-ATPases at mM 
concentration (Drose and Altendorf 1997). The tliird inhibitor, ammonium chloride, is a weak 
base that has been shown to increase Plasmodium falciparum vesicles pH at concentration of 
50 mM, in a similar way as cliloroquine (Krogstad ei al., 1985).
Bafilomycin Al (up to 3.2 pM), Concanamycin A (up to 29 pM) and ammonium chloride (up 
to 1 M) were used in the Alamar Blue assay on procyclic forms of each pair of isogenic lines 
to determine whether the reduced acidification of endosomes and lysosomes in trypanosomes 
was finked to the level o f reduction of the Alamai* Blue dye. Microscopic examination of the 
cultures after 24 h demonstrated that concentrations of 3.2 pM of Bafilomycin Al and 1 M 
ammonium chloride were lethal to procyclic trypanosomes (Figure 8.9A/C and 8. lOA/C). Sub- 
lethal concentrations of Bafilomycin Al and ammonium chloride had no detectable effect on 
the level of reduced Alamai* Blue dye produced by Cymelarsan sensitive and resistant fines. 
Similarly, Concanamycin A up to 29 pM had no effect on the level o f reduced Alamai* Blue 
dye produced by sensitive and resistant lines (Figure 8.9B and 8.1 OB).
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Figure 8.9: Alamar Blue assays of the isogenie 386 lines in the presence of lysosomotropic 
agents. Three lysosomotropic agents were tested (Bafilomycin Al (A), Concanamycin A (B) 
and ammonium chloride (C)) m vitro in SDM79. The status of the cultui e is indicated as alive 
(+) or dead (-) as assessed by microscopy for each concentration of inhibitors. The lowest 
concentration corresponds to the control in the absence of drug. The eiTor bars represent the 
mean +/- SEM, n = 4.
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Figure 8.10; Alamar Blue assays of the isogenic 247 lines in the presence of 
lysosomotropic agents. Three lysosomotropic agents were tested (Bafilomycin Al (A), 
Concanamycin A (B) and ammonium chloride (C)) in vitro in SDM79. The status of the 
procyclic culture is indicated as alive (+) or dead (-) as assessed by microscopy for each 
concentration o f inhibitors. The lowest concentration corresponds to the control in the absence 
o f drug. The error bars represent the mean +/- SEM, n = 4.
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Taken together the results suggest that the reduction of the Alamar Blue dye is sensitive to the 
presence of chloroquine in the medium. However, the action of chloroquine on the production 
of the reduced Alamar Blue dye is not associated to its ability to decrease the acidity level of 
endosomes and lysosomes. The question arises as to the mode of action of chloroquine on the 
reduction of the Alamar Blue dye. One possibility is that chloroquine might inhibit the 
intracellular enzymes responsible for the reduction of the Alamar Blue dye. To test this 
hypothesis, an in vitro Alamai' Blue assay was performed on cell lysates fi'om sensitive and 
resistant lines o f 386 and 247 in the presence o f chloroquine (Figuie 8.11). At a concentration 
of 50 p,M of chloroquine the fluorescence has dropped slightly in both sensitive and resistant 
lines. However, the drop in fluorescence observed on cell lysates was lower that that observed 
for live trypanosomes. These results would suggest that the intracellulai’ enzymes responsible 
for the reduction of the Alamar Blue dye are not inliibited by chloroquine.
Suramin has been reported to bind to serum proteins because it is negatively charged and enter 
the trypanosome via a LDL receptor mediated endocytosis (Vansterkenburg et al., 1993). The 
Alamar Blue dye is also negatively charged and could potentially use an equivalent route of 
entry into trypanosomes. An in vitro Alamar Blue assay on procyclic trypanosomes incubated 
in the presence and the absence of serum however showed no detectable differences in level of 
fluorescence (Figure 8.12). These results suggest that the entry o f the Alamar Blue dye into 
trypanosomes does not requiie binding to serum components.
8.3.3.4 The effect of Cymelarsan on the localisation of the reduced Alamar Blue dye in 
trypanosomes
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Figure 8.11: Alamar Blue assays on cell lysates in the presence of chloroquine.
Chloroquine was added to cell lysates from each pair of isogenic lines to assess its effect on 
the intracellular enzymes responsible for the reduction of the Alamar Blue dye. The error bars 
represent the mean +/- SEM, n = 2.
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Figure 8.12: Uptake of the Alamar Blue dye in the absence of serum Procyclic 
trypanosomes were incubated in Alamar Blue in the presence and absence of serum to test 
whether uptake occurred via binding to serum components. The error bars represent the mean 
+/- SEM, n = 2.
229
Chapter VIII: The Alamar Blue phenotype
To assess whether Cymelarsan had an effect of the reduction and localisation of the Alamar 
Blue dye in the trypanosome cells, each pair of isogenic lines was incubated in the presence of 
Alamar Blue and observed by fluorescence microscopy using a DAPI filter prior to the 
addition o f Cymelarsan. After addition of Cymelarsan the fluorescence from the vesicle-like 
structure disappears rapidly while the trypanosomes were still morphologically intact (Table 
8.3). This phenomenon was observed for both sensitive and resistant lines, and suggests that 
the Cymelarsan might affect the membrane of the vesicle-like structures in a way that enables 
the fluorescent Alamar Blue dye to leak out.
8.4 Discussion
The Alamar Blue assay was developed by Raz et al. (1997) to assess the sensitivity o f Afiican 
trypanosomes to various drugs in vitro. The trypanocidal activity o f drugs such as 
Melarsoprol, DFMO, Pentamidine and Sm*amin against T. b. gamhiense (STIB 930) and T. b. 
rhodesiense (STIB 900) was shown to be readily assayed (Raz et al., 1997). In the results 
presented here, assaying Cymelarsan sensitive and resistant lines showed an association of 
Cymelarsan resistance with a decreased production of reduced Alamar Blue dye. Two 
mechanisms by which the Cymelarsan resistant lines could produce less reduced Alamar Blue 
were assessed: a) the ability of cellular enzymes to reduce the Alamar Blue dye and b) the 
mode of transport/efflux of the Alamar Blue dye.
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Line Drug Fluorescence
microscopy
Phase contrast 
microscopy
386 Alamar Blue - Vesicles like structure Intact
Alamar Blue Cymelarsan None Intact
386Mr Alamar Blue - Vesicles like structure Intact
Alamar Blue Cymelarsan None Intact
247 Alamar Blue - Vesicles like structure Intact
Alamar Blue Cymelarsan None Intact
247Mr Alamar Blue - Vesicles like structure Intact
Alamar Blue Cymelarsan None Intact
Table 8.3: Fluorescence microscopy of each pair isogenic lines in the presence of Alamar 
Blue and Cymelarsan. The effect o f Cymelarsan of the distribution of the reduced Alamar 
Blue dye inside the trypanosomes was assessed by fluorescence microscopy. The experiment 
was performed only once for each pair of isogenic lines.
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The Alamar Blue assay is based on the ability of intra-cellular enzymes to reduce the non- 
fluorescent blue dye to a pink fluorescent compound. Cell lysate from sensitive and 
Cymelarsan resistant lines reduced the Alamar Blue dye in vitro. Many enzymes have been 
reported to be able to reduce the Alamar Blue dye in vitro. The list includes mitochondrial 
enzymes such as flavin mononucleotide dehydrogenase, flavin adenine dinucleotide 
dehydrogenase, nicotinamide adenine dinucleotide dehydrogenase, nicotinamide adenine 
phosphate dehydrogenase, dihydrolipoamine dehydrogenase, NAD(P)H;qumone 
oxidoreductase and cytochromes (Gonzalez and Tarloff, 2001). It would seem unlikely that all 
these enzymes could be altered in the Cymelarsan resistant line, and this is confirmed by the 
experiment carried out on the cell lysates.
The Alamar Blue assay is based on the fact that the dye can only be reduced by intra-cellular 
enzymes and therefore requires the uptake o f the dye in order for it to be reduced to the 
fluorescent product, and then excreted into the medium (O’Brien et al., 2000). The route of 
entry of Alamar Blue into the trypanosome is unknown. Uptake by the parasite can be the 
result of passive diffusion, receptor-mediated uptake, transporter-mediated uptake or 
endocytosis. The chemical structuie o f the oxidised Alamar Blue dye (Figm’e 8.1) would 
indicate that the molecule is unable to diffuse inside the cell due to its charged state so it is 
likely that a mode of transport is required. There are two possible modes of transport by which 
a compound can enter a trypanosome: through a transporter or via the endocytic pathway.
Comparison of the stmctwe of the oxidised Alamar Blue dye with vaiious tiypanocial drugs 
revealed a structural similarity with Isometamidium. This structural similarity suggested that
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the Isometamidium transporter was a possible transporter for the dye. Transport o f 
Isometamidium occurred in both sensitive and Cymelarsan resistant lines and no increase in 
Isometamidium resistance was observed in the Cymelarsan resistant lines suggesting that the 
transport of Isometamidium was similar between the lines. This suggested that the Alamar 
Blue phenotype was not linked to Isometamidium uptake.
The identification of vesicle-like structures in wliich the reduced Alamar Blue dye 
accumulates inside the trypanosomes and the partial inhibition of the reduction of the dye in 
sensitive lines by 50 pM of chloroquine, suggested uptake via the endocytic pathway. 
Lysosomotropic agents are compounds which reduce the acidity o f organelles in the 
endocytic/lysosomal pathways, Chloroquine is a lysosomotropic agent thought to act on the 
endocytic pathway (Figure 8.13) by increasing the pH of lysosomes preventing the formation 
of secondary lysosomes (Malik et al., 2001; Blanchaid et al., 2000). The use of three other 
lysosomotropic agents (Bafilomycin A l, Concanamycin A and ammonium chloride) had no 
effect on the production of reduced Alamar Blue dye by Cymelarsan sensitive and resistant 
lines. This would suggest that acidic pH in lysosomes is not essential for the production of 
reduced Alamar Blue dye.
Studies on the internalisation by endocytosis of HDL and anti-CRAM IgG revealed that 
exposure of procyclic forms of tiypanosomes to 50 pM of chloroquine completely abolished 
the lysosomal degradation of these molecules (Lee et ah, 1999; Liu et al., 2000). The 
trypanocidal drug such as suramin can enter via the endocytic pathway bound to LDL 
(Coppens et al., 1988; Vansterkenburgh et al., 1993), The oxidised Alamar Blue dye is
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http://cellbio.utmb edu/cellbio/recend2. htm)
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charged and could bind to HDL or LDL in the medium before internalisation via endocytosis.
A preliminary experiment showed that Alamar Blue dye was still able to enter the 
trypanosome and be reduced in the absence of serum in the medium. This would suggest that 
the Alamar Blue dye enters the tiypanosome via a different route. The elimination of the 
endocytic pathway as the route of entry o f the Alamar Blue dye in the cell is further supported 
by the fact that procyclic trypanosomes show low levels of endocytosis (Langreth and Balber, 
1975) and so it is difficult to account for the rapid appearance o f the fluorescent vesicular-like 
organelles thi'ough this pathway. In addition, the vesicular-like structures accumulating the 
reduced Alamar* Blue dye were located throughout the trypanosome cell, while endosomes and 
lysosomes are only observed around the flagellar pocket region (Langreth and Balber, 1975). 
Consequently the action of chloroquine on the reduction of the Alamar Blue dye appears to be 
unrelated to its ability to decrease the acidity of lysosomes. In addition, 50 pM of chloroquine 
had no inliibitory action of the cell lysate and so the mode of action of chloroqume on the 
production of the reduced Alamar Blue dye in the trypanosome has not been determined so 
far.
The vesicular-like structures accumulating the reduced Alamar Blue dye appeared to 
correspond to dense granules that ai*e observed under phase contrast microscopy (Figure 8.14). 
The location of these vesicular-like stmctures and their appearance are characteristic o f 
acidocalcisomes (Docampo and Moreno, 2001). In addition acidocalcisomes have been shown 
to swell in the presence of chloroquine (Coppens et al., 1993) which would explain the larger 
fluorescent vesicles observed when trypanosomes are incubated in the presence of the Alamar 
Blue dye and chloroquine. Acidocalcisomes are acidic organelles described as cytoplasmic 
electron dense granules containing calcium, magnesium, sodium, zinc, non and pyrophosphate
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(Figure 8.15; Miranda et al., 2000; Scott and Docampo, 1998; Rodrigues et al., 1999). The 
low content of S found in these organelles would suggest that they have a low protein content. 
The fimction of these organelles is unknown although Docampo and Moreno recently (1999) 
have suggested four possible functions based on the information available: a) a role in the 
process of calcium storage, b) a role as an energy storage organelle containing large amount of 
pyrophosphate, c) a possible role in the regulation of cytoplasmic pH through the H^ATPases 
present in the membrane and finally d) a role in the control of the process of osmoregulation. 
Analysis of the association between the lowered level of Alamar Blue reduction and 
Cymelarsan resistance in procyclic form of T. brucei has lead to the identification of vesicle­
like structui'es that may be acidocalcisomes. The rapid disappeai'ance o f the fluorescence from 
the vesicles was observed after the addition o f Cymelarsan to the medium. However the 
integrity o f the dense granules was not influenced by the addition of Cymelarsan. The diverse 
functions suggested for acidocalcisomes clearly support the view that these are important 
organelles for the trypanosome. One hypothesis based on the results presented in this chapter, 
is that Cymelarsan could act on the membrane of tlie acidocalcisomes, rendering them leaky. 
This would explain the disappearance of the reduced Alamar Blue dye from the vesicles when 
trypanosomes are incubated in Cymelarsan, as well as suggesting a release of the 
acidocalcisomes’ contents into the cytoplasm. The release of the contents of the 
acidocalcisome is likely to lead to a decrease cytosolic pH with a consequent inhibition of 
metabolic pathways. To test this hypothesis it would &st be necessary to prove that the 
vesicular-like structures accumulating the Alamar Blue dye are acidocalcisomes and this could 
be undertaken by using acidocalcisome specific antibodies (Lemercier et a l, 2002) and 
Alamar* Blue, in a co-localisation study.
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Figure 8.14: Localisation of the Alamar Blue dye in procyclic trypanosomes. Apparent co­
localisation o f the dense granules under phase contrast (A) and the vesicular-like organelles 
(B) accumulating the reduced Alamar Blue dye.
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Figure 8.15: Model of an acidocalcisome in trypanosomes. Calcium ions uptake occurs in 
exchange for by a reaction catalysed by a vacuolar Ca^ -^ATPase which is inhibited by
vanadate. A gradient is established by a Bafilomycin A 1-sensitive vacuolar FT-ATPase and
an aminophenylethylenephosphonate (AMDP)-sensitive vacuolar -Ppase. Chloride (Cl ) 
transport, through a chloride channel is associated with the function of the vacuolar - 
ATPase. Ca^  ^release occurs in exchange for and is favored by sodium-proton exchange. 
The acidocalcisome is rich in pyrophosphate, magnesium, calcium, sodium and zinc. 
(Docampo and Morena, 2001).
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To properly assess the function and involvement of the acidocalcisome in Cymelaisan 
resistance in T. brucei it would be necessary to study the membranes of acidocalcisomes. This 
would require the isolation of a sub-cellular fraction containing weU-preserved 
acidocalcisomes and no other cell membranes. A method has recently been developed for the 
preparation o f  acidocalcisomes (Scott and Docampo, 2000). Measurements of the pH of a 
solution containing acidocalcisomes in the presence and absence o f  Cymelaisan would 
determine the effect o f  Cymelarsan on the membranes of acidocalcisomes.
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Chapter IX 
General discussion
The aim o f this project was to investigate mechanisms of arsenical resistance in the protozoa 
parasite T. brucei. This aim was pm’sued by subtractive analysis of the whole protome from 
drug sensitive and resistant isogenic lines. It was anticipated that differentially expiessed 
proteins between the isogenic lines would be associated with Cymelarsan resistance and could 
deteraiine the mechanisms of ai'senical resistance in T. brucei.
Most drug resistance studies performed so far on T. brucei have relied on biochemical, genetic 
or functional analysis o f a candidate gene. The drawback of these approaches is the need for 
the pre-selection of a gene to analyse. The proteomic approach employed in this study enabled 
the global proteomic expression profiling o f a drug sensitive T. brucei line and its laboratory- 
derived isogenic drug resistant line. The advantage of this approach is that all the possible 
mechanisms of arsenical resistance can potentially be analysed at once.
A recently published protocol for the solubilisation of proteins from T. brucei (van Deursen et 
al, 2003) was developed for the study of Cymelaisan resistance in procyclic forms of the 
parasite. The protocol was simple, reproducible and extracted membrane proteins. The 
limitations of protein identification due to the limited T. brucei genome database were 
assessed with the production of a preliminary proteome map. Forty-two percent of the protein
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spots separated by 2DE and analysed by PMF were identified. Only 30% of the protein spot 
not identified was due to the incomplete T. brucei genome database.
Two pairs o f isogenic lines were used in this study. Preliminary chamcterisation demonstrated 
that the resistance phenotype was stable after passage in mice and cyclic transmission through 
tsetse flies (Scott et al.^ 1996). In addition, both bloodstream and procyclic forms of the 
parasites were shown to express the resistance phenotype and cross-resistance in bloodstream 
forms between Melarsoprol and Melarsen oxide had been shown. Procyclic forms o f the 
parasites were further characterised in this study. No cross-resistance was detectable to either 
Melarsoprol, Pentamidine or Berenil for both pairs o f isogenic lines. This was consistent with 
the fact that no P2 transporter activity can be detected in procyclic forms (de Koning et n/., 
2000) which rules out the involvement of the P2 transporter as the main mechanism of 
Cymelarsan resistance in procyclic forms of these lines. Another known mechanism of drug 
resistance in trypanosomes and other parasites involves the excretion of drugs via an over- 
expressed P-glycoprotein (Shahi et al, 2002). This mechanism was assessed on both pairs of 
isogenic lines by growth inhibition assay in presence of general P-glycoprotem inhibitors. The 
presence of the inhibitors had no effect on the resistance to Cymelarsan. The P-glycoprotein 
inhibitor, verapamil, has been shown to reverse drug resistance in T. cruzi (Neal et a/., 1989) 
and T, congolense (Sutherland and Holmes, 1993), and consequently was expected to inhibit 
the P-glycoprotein from T. brucei. The other two P-glycoprotein inhibitors, TFP and PCP, 
have never been shown to be effective against P-glycoprotein from trypanosomes. The two 
obvious mechanism of dr ug resistance, the alteration of transport by the P2 transporter and the 
increased efflux by a P-glycoprotein, were tested and found to be not associated with arsenical
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resistance in procyclic forms o f the 386 and 247 lines. To identify protein associated with 
arsenical resistance a subtractive analysis of whole cell extract from sensitive and resistant 
lines was performed.
The subtractive analysis of the global expression profile o f386 and 386Mi' lines enabled the 
detection of two protein spots whose lack of expression was associated with Cymelarsan 
resistance in the pan of isogenic lines of 386.
The differential expression of the CAR protein (spot 2) was reproducible over nine 
independent protein extractions separated on pH 4-7 gels and on one protein extraction 
separated on pH 4-5 gel. The CAR protein is adjacent on the 2D gel to a protein spot (spot 1) 
with similai’ molecular' weight but more basic pi. Both the CAR protein and spot 1 from the 
proteins extracted from 386 and 3B6Mr were identified as products of either ORF 274 or 277. 
The presence of an extra form of the CAR protein in the 386 line could be explained by a 
mutation in either one of the ORFs, an absence of transcription of one of the two ORFs in the 
386Mr line, or a post-translational modification of spot 1 which occurs only in line 386.
Analysis of the sequences obtained for the two genes from both 386 and 386Mi' lines showed 
that ORF 274 and 277 from the 386 line were identical to their homologues in the 386Mr line. 
In addition, the predicted sequence of the transcript o f ORF 274 was identical to the predicted 
sequence of the transcript o f ORF 277. PCR on total cDNA from both lines demonstrated that 
both ORFs were transeribed in each line. These results suggested tliat the CAR protein was a 
post-translationally modified spot 1. The simplest way of regulating the activity o f a protein is
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by changing the number of protein molecules in the cell. This is generally achieved by 
regulating gene transcription, mRNA translation, or the rate of mRNA and protein turnover. A 
more rapid increase in protein activity can be achieved by post-translational modification. For 
example, activation of a kinase by protein phosphorylation is a hallmark of intracellular 
signalling cascades (Hunter, 1995). Post-translational regulation o f the CAR protein could 
allow large amounts of the protein to be present in the cell in an “inactive” form.
The identity of spot 2 was confirmed by Western blot analysis using an antibody raised by 
DNA vaccination strategy against the expressed product of ORF 274. The number of isoforms 
present in each line was detected by Western blot analysis o f 2D gels. In total, three isoforms 
were detected at pH 4,2, 34 kDa in the extract from the 386 line and only two isofoms at this 
location in the extract of386Mr. The association of the absence o f the CAR protein with 
Cymelarsan resistance was confirmed in independent extractions, and the identity of the 
protein was confirmed by mass spectrometry and Western blot analysis.
From these results the question arise as to whether the CAR protein is associated with 
Cymelarsan resistance in other T. brucei lines. Analysis of the pair o f isogenic 247 lines 
showed that the CRA protein was not associated with Cymelarsan resistance in these lines. In 
addition, the analysis showed that only one isoform o f the CAR protein could be detected in 
both 247 and 247Mi- lines. Cunently the antibody raised against the tr anscript of ORF 274 is 
being used for immuno-Iocalisation o f the CAR protein m T. brucei to extend our knowledge 
of its potential function.
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Analysis of the amino acid sequence of the CAR protein showed the presence of a NAC 
domain and a UBA domain. The function of this protein in T. brucei is unknown. From the 
presence of the NAC and UBA domains, it seems highly likely that the protein is part of a 
multi-protein complex. Many cellular functions are performed not by individual proteins but 
by large multi-protein complexes. The analysis of complexes formed with the CAR protein 
could help on understanding of the function o f the protein with respect to Cymelarsan 
resistance in T. brucei. This experiment could be performed by immuno-precipitation using 
the antibodies raised against the expressed product of ORF 274. Biochemical purification of 
complexes followed by mass spectrometry has enabled the identification o f multi-protein 
complexes in other contexts (Neubauer et al., 1997).
The second protein spot associated with cymelarsan resistance in the pah of isogenic lines of 
386 was identified by mass spectrometiy as an arginine kinase. Using the mass spectrometry 
analysis it was not possible to determine whether the protein spot was the transcript of ORF 
243 or 242. However, the absence of a protein product from either one of the two ORFs (or 
both) at pH 5.8 on 2D gels was associated with Cymelarsan resistance.
The comparative proteomic analysis o f Cymelarsan sensitive and resistant lines o f386 by 2DE 
enabled the dhect comparison of expression of 1,000 proteins spots separated on 2D gels. It is 
estimated that the trypanosome genome contains approximately 8,000 genes based on 
sequence from chromosome I and II (Hall et al., 2003; El-Sayed et al., 2003) and while all the 
genes will not be expressed at the procyclic stages of culture, it is expected that many proteins 
were not separated or detected in this study. Consequently, the proteomic analysis performed
243
Chapter IX: General discussion
on the sensitive and resistant lines was biased towards highly abundant and soluble proteins. 
The limitation of spatial resolution, which causes spots to overlap on the 2D gel, was first 
reported in 1982 for albumin, for which what was considered a pure protein spot was further 
separated into additional components by using IPG strips o f 0.01 pH/cm (Bjellqvist et al., 
1982). The use of narrow pH range had been shown to increase the separation and resolution 
of protein spots (Cohen et al., 2002). The problem of spatial resolution on 2D gels was 
addressed in this study by using narrow pH range strips. The use of narrow pH IPG strips has 
enabled the detection of another differentially expressed protein spot between sensitive and 
resistant line of 386. However, even using narrow pH range strips, only the most abundant 
proteins were detected. In order to increase the proteomic analysis o f sensitive and resistant 
386 lines, the sample would have had to be pre-fiactionated.
Only a few comparative proteomic analysis o f disease/resistant ceUs/organisms with control 
cells/organisms have been published to date. Compaiative proteomic analysis in these studies 
revealed only a small number of proteins differentially expressed between the two 
cells/organisms. There seems to be a general trend towaids the identification of a higher 
number of differentially expressed proteins when using a quantitative proteomic approach. For 
example, the comparative analysis o f p-53 deficient mice (a tumour suppressor gene) with 
control mice showed only 7 protein spots, out o f 886 analysed by 2DE, were specific to the 
p53 deficient mice (Anaki et al., 2000). Whereas, the comparative and quantitative proteomic 
study of a cancer cell line (T47D) and its antiestrogen-resistant derivative showed 38 protein 
spots differentially expressed (up- or down-regulated by a factor of more than 2) out of 2,500 
spots analysed by 2DE (Huber et al., 2003). Similarly, a quantitative and compai'ative
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proteomic study of mouse-virulent and avirulent Toxoplasma gondii showed 35 protein spots, 
out of 300 spots analysed by 2DE, were up- or down-regulated between the two lines (Niscliik 
et al., 2001).
The resistance to Cymelarsan in this line was induced by prolonged exposure to sublethal 
doses of Cymelarsan, a treatment which is likely to be highly mutagenic and may induce 
changes in addition to dr ug resistance. Consequently, the results presented here will need to be 
confirmed using other methods. It will be difficult to confirm the association between the 
absence the CAR protein (isoform of spot 1) with arsenical resistance as most teclmo logics 
available will remove all forms of the protein (knockout, RNAi) or examine transcript levels 
(micro-arrays) which are probably not involved.
The complete proteome analysis is limited by the teclinology. It is possible that other 
differentially expressed proteins between the sensitive and Cymelarsan resistant lines were not 
identified. Fluorescent two dimensional difference gel electrophoresis (DIGE) allows samples 
labeled with different dyes to be co-separated on the same gel, thereby eliminating the gel-to- 
gel variation (Beaumont et al., 2001). This technique will be very useful in quantitative and 
comparative proteomic studies.
Synteny in coding regions and conservation of strand-switch regions are obseived between 
several trypanosomatid parasites, suggesting an evolutionary pressuie to conserve the close 
association of certain genes within clusters. This organisation suggests that clusters encode 
proteins involved in related cellular processes, requiring co-regulation or similar expression
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level. ORF 274 and 277 are present in a cluster containing mainly putative ORFs with 
homology to enzymes and chaperonme. Of interest is the presence of the Ubiquitin 
conjugating E2 enzyme, containing a UBA domain and involved in the degradation of proteins 
by the ubiquitination pathway (Madura, 2002; Hoffman and Bucher, 1996). The CAR protein 
also contained a UBA domain thought to enable it to bind to ubiquitin and other proteins 
associated with the ubiquitination pathway (Wilkinson et a l, 2001). The presence of the E2 
enzyme gene and ORF 274 and 277 mtliis cluster on chromosome IX, all containing UBA 
domain, would suggest the involvement of the expressed products of ORF 274 and 277 in the 
ubiquitination pathway. The mechanism of resistance to arsenical drugs could thus be linked 
perhaps to a higher turnover of proteins in the cell. Arsenical drugs are known to have a high 
affinity for intracellular thiols such as trypanothione and dihydropoamide plus several 
enzymes including trypanothione reductase (Fairlamb et a l, 1989), 6-phosphogluconate 
dehydrogenase (Hanau et a l, 1996) and glycerol-3 phosphate dehydrogenase (Denise et a l, 
1999), all o f which are essential for trypanosome survival. A higher turnover of these proteins, 
which might be the cellular targets o f arsenicals, would enable the parasite to sui'vive in the 
presence of the drug.
These proteomic analyses o f sensitive and resistant line o f386 liave demonstrated that the 
resistance phenotype was associated with the absence o f an isofoim of the CAR protein. 
Consequently, the mechanism of arsenical ding resistance in these lines might be due to the 
absence o f a post-translatiomnal modification pathway.
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The biochemical analysis of the two pairs of isogenic lines showed the association o f the 
Cymelarsan resistance phenotype with a decrease fluorescence produced flom the metabolism 
of the Alamar Blue dye. Further analysis o f the metabolism of the Alamar blue dye 
demonstrated that the activity o f the reductive enzymes were similar between sensitive and 
resistant lines. The reduced Alamar Blue dye was shown to concentrate into vesicle-like 
structure thought to be acidocalcisomes. The addition of Cymelarsan to the lines incubated on 
the presence of Alamar Blue demonstrated the disappearance of the fluorescence from the 
vesicle-like structure, suggesting that the drug might act on the membrane of the 
acidocalcisomes. Acidocalcisomes are acidic compartments containing pyrophosphate, 
magnesium, calcium, sodium and zinc (Docampo and Morena, 2001). An alteration of their 
membranes could release the high proton content into the cytoplasm, winch would affect many 
metabolic pathways. A protocol has recently been developed for the extraction of pure 
acidocalcisomes (Scott and Docampo, 2000). These could be used to analyse the effect of 
Cymelarsan on the membrane of acidocalcisome, by measui'ing the pH of a solution prior and 
after the addition o f Cymelarsan.
Proteomic methods are “hypothesis generating”. Whilst the significance o f the CAR protein 
and arginine kinase in Cymelarsan resistance in T brucei line 386 remains to be established, 
this study has demonstrated the potential of proteomics to provide unexpeeted insights into 
molecular mechanisms by virtue of its ability to study protein expression in its entir ety without 
pre-supposing a specific mechanism. It appears that the differential expression of the CAR 
protein represents a change in the level o f post-translational modification of an existing gene
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product which could not have been identified by the application of purely nucleic-acid based 
technologies.
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Spot 86 Spot 89 1911.9206 1701.9691
1041.5875 833.4450 2039.9477 1705.8723
1076.5659 861.1168 2093.0882 1718.9267
1125.6867 877.1293 2370.4568 1823.9835
1128.6177 960.7006 2410.1697 2041,1774
1146.6239 1036.5423 2565.8991 2286.1180
1227.6660 1295.7636 2807.4102 2330.1063
1253.7993 1301.1047 2811.2409 2409.3171
1341.6841 1318.7155
1344.5850 1360.6261 Spot 91 Spot 94
1631.8984 1376.6555 Lost 877.1253
1654.8755 1472.1307 906.3609
1679.8131 1578.9490 Spot 92 918.3600
1847.9068 1581.7595 882.4037 1045.5354
2032.9688 1595.8142 1018.3845 1129.5829
2048.9784 1611.7872 1036.4998 1135.5155
2285.1632 1639.4897 1199.6607 1206.2620
2814.3631 1703.7910 1311.5839 1330.6491
1743.9769 1318.5517 1396.7964
Spot87 1849.9297 1323.6628 1412.8203
877.0680 1912.9711 1345.4626 1435.7726
885.3124 1956.4421 1349.7263 1439.8397
1066.0831 2129.8322 1371.6906 1457.8619
1093.2466 2230.3628 1389.7139 1521.8319
1173.7304 2384.9706 1497.7460 1587.7747
1338.5169 2476.5145 1552.6887 1621.8125
1554.0112 2625.3458 1631.7732 1637.6653
1663.9053 2835.1060 1638.8130 1828.8262
1735.8503 1796.7599 1848.9549
1803.9832 Spot 90 1879.9793 1884.0443
1811.8783 877.0901 1911.8802 2065.1811
1918.7002 894.3222 2039.9416 2239.1926
1994.0883 926.4662 2386.1391 2284.1807
2196.7214 1032.5117 2564.0575 2314.0618
2225.0826 1036.5177 2531.6561
2244.0891 1160.4566 Spot 93 2809.4913
2285.0872 1199.6811 919.3633
2436.1253 1349.7585 1064.6084 Spot 95
2656.8334 1766.7501 1132.5812 877.1371
2699.2678 1389.7719 1283.5214 1086.5457
2808.3740 1497.7624 1379.7275 1116.2265
2851.5175 1552.7584 1396.7413 1186.5016
1626.5366 1443.9016 1266.5060
Spot 88 1656.3718 1446.8440 1280.7093
Lost 1795.9000 1525.7592 1323.5916
1880.0513 1664.9552 1406.6952
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1442.7812 929.3589 Spot 100 2566.1265
1459.6922 1062.2995 Lost 2807.3962
1728.8925 1079.5379 2811.3023
1904.5915 1117.5449 Spot 101
2272.7236 1318.7044 889.3893 Spot 103
2482.7892 1461.7263 980.4792 862.1674
2633.6177 1495.7535 1045.5524 870.4652
1619.6981 1095.5840 1045.6407
Spot 96 1688.8119 1092.3815 1167.8628
917.3916 1692.7660 1319.6205 1267.6417
1062.6126 1907.8966 1372.6673 1338.5812
1225.5987 1923.8576 1389.6477 1348.6739
1282.6599 2136.0931 1503.7185 1498.7213
1479.0598 2141.3029 1813.4393 1560.7025
1532.8411 2170.1087 2017.0678 1631.9045
1535.7718 2272.1001 2034.9755 1680.0077
1678.8998 2321.0899 2049.0272 1685.2506
1800.9081 2500.7796 2145.1152 1855.9083
1878.9892 2750.5167 2240.1113 2037.4043
2135.9794 2807.3809 2284.1449 2225.1759
2285.2611 2504.0363 2239.1792
2525.4272 Spot 99 2525.2451 2437.1300
2705.2419 847.3699 2802.2987 2745.8076
2807.3478 870.4827
933.1896
2807.3325
Spot 104
Spot 97 968.3747 Spot 102 861.0598
855.3284 1025.5341 832.3342 883.3925
1034.5321 1109.4820 952.4180 966.4601
1106.6553 1118.5268 1054.5569 1023.5692
1225.5907 1165.6051 1101.5322 1133.5407
1477.6612 1179.6084 1187.5859 1152.5434
1532.8299 1277.7482 1267.5730 1159.5725
1577.8306 1301.6205 1385.6827 1230.6569
1678.9630 1344.6803 1460.8203 1396.6230
1801.9843 1365.6585 1476.7578 1437.7582
1837.9612 1475.7784 1648.8068 1546.8612
1878.9369 1707.7859 1680.9377 1567.8284
2225.2191 1699.8623 1732.9356 1580.7241
2284.1930 1876.1934 1834.9972 1691.8831
2450.8923 1994.0067 1883.0695 1750.8879
2753.2922 2124.8628 1900.0125 1851.8779
2807.4508 2367.2955 2092.3689 2017.3615
2380.8649 2239.1775 2239.1816
Spot 98 2605.3118 2276.2027 2254.0653
919.4670 2808.3029 2285.1742 2285.1959
922.3160 2301.9876 2360.1049
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2469.2518 2587.7650 2807.3559
2523.4968 Spot 107 2658.6843
2786.6636 967.4616 2781.0817 Spot 111
2798.2762 1069.5149 2807.4176 847.4571
2808.4347 1121.5094 973.5366
1283.7063 Spot 109 993.5155
Spot 105 1305.6738 862.2648 1066.4964
899.5029 1310.6566 1008.4855 1109.5320
1273.6732 1439.8175 1016.3843 1118.4859
1288.5165 1479.7922 1045.5423 1165.5898
1309.7281 1502.6401 1050.5785 1179.5879
1327.6197 1537.8319 1233.6998 1234.6532
1343.6013 1567.7890 1297.4043 1285.5678
1415.6080 1578.9384 1402.6578 1320.5819
1812.9290 1639.9688 1501.7603 1383.6348
1930.9603 1710.8699 1534.7585 1427.7370
1966.0155 1763.6771 1570.4992 1475.7156
1968.9667 1880.8951 1730.2498 1614.7838
2003.8935 1907.8761 1905.9161 1699.8099
2007.8026 1927.7592 1946.8762 1707.7543
2239.1890 2057.1848 2068.9083 1716.8236
2284.1932 2239.1563 2239.1524 1965.9640
2300.3406 2284.1777 2288.0019 1993.9622
2643.1712 2421.7330 2516.1008 2003.9037
2807.3110 2564.2060 2688.4009 2078.6143
2577.1685 2807.4220 2368.2266
Spot 106 2808.2972 2384.8308
864.3755 Spot 110 2538.8548
993.5073 Spot 108 873.4682 2638.2676
1049.5325 861.1257 982.4687 2767.2000
1159.4945 925.4844 1126.5988
1301.5933 1158.8608 1176.6501 Spot 112
1351.6716 1171.3839 1213.7142 958.3737
1536.8172 1367.6268 1324.5756 979.4847
1664.7776 1469.8824 1463.7822 1107.5699
1692.8880 1475.7754 1478.5131 1160.5257
1784.3474 1513.8720 1641.0474 1176.6084
1804.8209 1525.8780 1746.9238 1209.4820
1820.9351 1671.1380 1768.8164 1279.5862
2053.8253 1902.8501 1915.8478 1381.6417
2225.0360 1988.1075 1960.0396 1393.6155
2341.0363 1994.0571 2147.0608 1471.7325
2494.1333 2144.2111 2165.1643 1570.7777
2654.9383 2239.1576 2341.9955 1599.8002
2774.1791 2284.1687 2517.2355 1796.6974
2811.1430 2387.1699 2680.6737 1848.7974
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1933.9533 1679.7777 2363.2628 2231.2839
2091.0103 1847.8794 2525.8648 2298.1278
2239.1051 2165.9632 2571.2865 2409.2686
2292.9855 2812.4061 2576.2370 2490.2435
2456.9571 2587.2859 2678.2153
2661.1839 Spot 115
1078.5956
2807.3630 2807.3596
Spot 113 1085.7269 Spot 117 Spot 119
948.4158 1191.4636 856.5818 847.3174
989.4363 1235.6542 906.5262 922.3970
1050.5227 1238.5612 969.5696 942.3566
1118.4926 1251.6058 1033.5699 1106.5453
1141.5947 1289.7211 1045.5607 1127.5123
1188.5144 1432.7804 1122.5478 1144.5927
1205.5971 1626.1480 1138.4455 1333.7580
1293.5450 1765.9137 1180.5706 1344.6708
1370.8315 1821.0027 1222.5389 1446.7786
1390.6757 1881.7495 1238.4518 1551.5389
1500.7479 2063.0507 1308.6466 1708.8050
1513.7777 2065.9962 1390.6724 1763.8375
1587.7858 2240.1451 1437.7221 1994.0457
1654.8367 2494.2283 1453.6457 2214.0365
1821.9918 2509.2094 1518.8039 2239.1606
2070.0327 2616.4129 1595.7636 2284.1662
2152.0608 2620.3487 1696.8676 2447.4458
2225.1149 2807.3942 1699.8117 2606.7610
2284.1259 1712.9466 2777.2861
2419.1894 Spot 116 1905.2081 2807.3696
2576.9565 881.9716 2285.0933 2828.4366
2680.4658 1019.4710 2572.1932
2807.3700 1136.5740 2807.3466 Spot 120
2811.3442 1173.6314 865.4275
2847.0237 1179.6582 Spot 118 1186.6693
1224.6333 877.0588 1189.5970
Spot 114 1413.6297 1379.7077 1237.6073
1059.4419 1430.6175 1396.7199 1321.6927
1076.5408 1512.7819 1443.8600 1347.6031
1146.5995 1558.7109 1446.7187 1593.8344
1253.7840 1592.7386 1525.7383 1867.0761
1274.7260 1821.9967 1664.8989 1887.8289
1341.6608 1932.9505 1668.6160 2214.0506
1344.6088 1972.9948 1701.9190 2386.1796
1481.7469 2086.1297 1718.8604 2614.6444
1631.8342 2101.1311 1774.9700 2807.4373
1654.8324 2207.1540 1880.9375
1670.7877 2284.1496 2040.2090
Appendix I
Spot 121 Spot 123 2810.2709 2349.1609
861.1352 856.5761 2808.3968
877.0936 861.2135 Spot 125
952.4722 898.3428 877.2238 Spot 128
1197.6654 906.5296 891.4060 861.1076
1204.6610 1033.5563 958.2684 950.2158
1389.7536 1067.4750 1036.4276 1045.5295
1461.6118 1122.5343 1045.5870 1058.4986
1560.7492 1175.3052 1066.3905 1082.3173
1569.8191 1180.5357 1072.5980 1090.5218
1609.8137 1217.6007 1204.4897 1245.5295
1781.3263 1289.2640 1244.5944 1397.6066
1913.0522 1437.7104 1381.3509 1440.8159
1929.0326 1453.7294 1466.1916 1448.7338
1947.9026 1518.8114 1568.6575 1621.7765
2106.9586 1595.8031 1759.7904 1800.8555
2261.1575 1696.8635 1862.8471 1837.9882
2283.1747 1699.7986 1940.9096 2020.7978
2453.5530 1859.4209 2096.0172 2033.0676
2807.3575 2052.0036 2193.9511 2194.6551
2811.4570 2219.1928 2221.1638 2225.0890
2239.1544 2239.1567 2239.1846
Spot 122 2284.1691 2283.1137 2284.1766
861.1673 2372.1127 2390.2584 2300.1545
871.3455 2635.6047 2551.6376 2426.4038
883.3741 2807.2933 2564.2342 2577.0531
1045.6199 2808.3409 2679.2436
1139.5343 Spot 124 2847.5803 2753.7985
1151.3794 861.1410 2807.3546
1179.6440 1013.4428 Spot 126
1339.5894 1139.5268 Lost Spot 129
1475.7750 1318.5365 1057.4804
1657.8508 1467.6800 Spot 127 1098.5420
1717.8343 1568.7606 917.4935 1247.6381
1733.7992 1657.8460 1159.4926 1250.6517
1797.0015 1761.8544 1175.4710 1403.7180
1894.0731 1771.2133 1255.6556 1444.8489
2018.0988 1796.9447 1287.5967 1460.7825
2103.1309 1963.9462 1319.6755 1463.7306
2225.0905 2225.1043 1343.6785 1655.1156
2239.0546 2231.2802 1407.6154 1699.7839
2300.2065 2239.1092 1535.7482 1723.9969
2537.7298 2284.1301 1552.6736 1727.8398
2807.3018 2408.0548 1846.8517 1849.9665
2609.6581 2101.0945 1940.9139
2807.3357 2333.1348 2225.0849
Appendix I
2239.1178 2405.0310 Spot 135 2807.4478
2281.1286 2421.0738 861.1616
2606.9437 2781.3848 900.3767 Spot 137
2807.3105 2807.3396 926.4347
1017.5099 Spot 138
Spot 130 Spot 133 1102.4414 980.3368
Lost 1023.4775 1236.4465 1036.4792
1132.5837 1309.7118 1196.2670
Spot 131 1379.7005 1366.2521 1341.6126
861.1316 1396.7271 1396.7326 1424.1857
879.4777 1418.7662 1428.8557 1578.9422
1045.5412 1443.8922 1438.7633 1581.8449
1207.5277 1527.8829 1560.0718 1595.8308
1451.7324 1664.9368 1664.9020 1611.7494
1503.6594 1701.9308 1733.7057 1743.9378
1519.6882 1705.7886 1779.9996 1746.8808
1522.6448 1718.8686 1833.2568 1849.9554
1680.0890 1774.9109 1906.1998 1852.9136
1732.8156 2040.1563 1989.1087 2239.1787
1874.2323 2409.2415 2086.1324 2314.0298
1994.9916 2412.1875 2115.2932 2564.1139
2037.1930 2807.3197 2239.1357 2776.7991
2239.2806 2273.0095 2807.3870
2344.1509 Spot 134 2285.2007 2810.3320
2352.1611 960.4900 2462.5628
2402.2183 1114.9328 2537.1929 Spot 139
2807.3885 1164.1173 2743.1644 855.1166
1432.8713 2807.3686 1060.1680
Spot 132 1448.8354 2810.3096 1076.5378
948.4411 1464.6540 1146.6081
1051.5199 1508.4027 Spot 136 1274,6709
1141.5286 1511.1402 932.3689 1341.6612
1188.5711 1712.5244 981.4681 1344.6186
1263.7519 1746.5257 1079.5765 1481.7338
1390.7709 1749.2106 1170.4774 1631.8536
1568.7624 1762.0927 1194.5181 1857.6858
1590.6996 1813.5155 1411.8242 2094.2651
1742.0205 1905.9187 1513.7407 2283.1401
1794.6673 2056.6879 1531.7873 2444.8631
1940.9357 2237.4109 1661.8068 2641.4423
1994.0041 2390.5337 1742.6344 2810.2689
2069.0399 2394.0046 1885.9725
2225.0847 2421.0621 1904.2386 Spot 140
2239.1278 2748.9314 1933.8738 861.2108
2284.1521 2284.1495 1076.5594
2298.2209 2615.8879 1341.6604
Appendix I
1363.6905 1590.7051 1528.7705 1854.9931
1631.8457 1692.8753 1665.7607 1898.9908
1647.8426 1753.8345 1692.8328 2009.9013
1848.8265 1863.8240 1718.9010 2161.1090
1853.8914 2123.0527 1801.9382 2284.1845
2059.0404 2239.1983 1880.0894 2616.2833
2165.9425 2283.1643 1962.0639 2807.4270
2631.1486 2298.2946 2051.1080 2810.3820
2807.3398 2466.1778 2283.1067
2812.3755 2635.0768 2440.2316 Spot 147
2846.7399 2793.1471 2711.0332 906.4849
2807.3441 2807.4847 969.5411
Spot 141 2814.2527 1033.5722
1076.5217 Spot 145 1045.6121
1125.6948 Spot 143 861.1525 1122.5153
1142.5490 891.3429 884.3008 1294.5416
1285.6226 912.3681 946.3356 1308.6152
1341.6459 1045.5573 1023.4688 1378.7101
1365.6868 1197.6858 1128.3856 1437.7051
1632.8019 1213.5466 1153.4765 1494.6357
1692.7707 1319.7536 1312.5725 1513.7869
1812.0270 1335.7216 1379.6827 1595.7726
1941.0139 1379.7046 1396.7209 1696.8642
2048.9640 1403.7984 1401.7297 1699.7509
2225.1681 1664.8976 1418.7605 1705.7691
2239.1989 1701.9297 1443.9155 1941.9345
2283.2089 1855.0671 1664.9801 2143.7423
2408.2380 1861.0105 1701.9694 2225.0986
2456.7421 1880.0713 1718.9110 2239.1410
2628.6289 2004.3557 1769.5306 2446.2292
2747.2544 2237.1258 2040.2092 2807.4041
2807.4021 2253.1693 2223.1167
2813.4723 2370.4672 2409.3377 Spot 148
2409.2174 2412.2808 861.1257
Spot 142 2582.0691 2506.2511 1023.4638
846.3486 2743.4224 2808.4618 1045.5694
990.3833 2807.4198 1379.6547
1071.4103 Spot 146 1396.7228
1125.6847 Spot 144 984.2869 1443.8557
1146.5956 919.5152 1073.6825 1446.8129
1252.6644 994.4893 1175.6757 1527.8778
1300.7034 1071.6147 1293.7227 1664.8967
1341.6414 1285.7103 1476.8338 1701.9100
1390.7153 1288.6663 1664.8801 1705.7891
1462.6754 1461.7252 1707.8842 1718.8489
1502.7248 1500.7528 1815.0059 2040.1410
Appendix I
2105.8373 Spot 151 1652.8181 1794.5787
2283.1249 Lost 1816.1227 1815.7518
2409.2251 2120.1137 1903.6235
2808.2976 Spot 152 2125.4390 2002.9624
861.1808 2283.1409 2077.1325
Spot 149 928.3869 2291.3737 2088.0333
982.4251 1087.5161 2357.0479 2213.9589
1179.3804 1137.5468 2666.3353 2234.1903
1195.3334 1307.4023 2816.2769 2477.9175
1236.4207 1528.7697 2807.4475 2694.7743
1366.3251 1630.5567 2764.9364
1476.3486 1652.7834 Spot 155 2808.4211
1514.3476 1897.9356 861.1088
1517.2906 2081.9232 920.3020 Spot 157
1542.3003 2239.1377 1051.3261 Lost
1662.3174 2461.9208 1063.5374
1717.2273 2790.7939 1395.6688 Spot 158
1886.1837 2807.3446 1428.8389 987.5347
2102.9115 1433.7651 1076.5886
2163.0563 Spot 153 1600.8696 1146.6206
2448.1502 943.5509 1815.0703 1214.7252
2806.7548 967.5647 1875.9874 1220.6396
1040.5031 1959.9425 1228.6730
Spot 150 1128.4821 1984.1350 1234.5610
856.4474 1137.5644 2041.0453 1331.6613
870.4832 1284.7806 2187.2541 1376.7608
928.4056 1435.3810 2225,1319 1401.7849
1080.2071 1517.8116 2283.1873 1404.6839
1186.7109 1652.8183 2504.0766 1473.7221
1189.5650 1656.7067 2744.8547 1566.8304
1193.2955 1824.0213 2807.3515 1569.8200
1321.7137 2008.7211 1659.8675
1352.1342 2120.0661 Spot 156 1718.7769
1400.1590 2239.1441 861.0641
1575.0317 2496.5388 864.3722 Spot 159
1653.8434 2644.7124 944.4657 1087.5619
1750.1359 2808.3369 1066.1439 1220.8449
1991.2697 1132.5114 1228.8629
2231.3239 Spot 154 1222.6199 1377.0485
2285.2216 877.1681 1276.9249 1402.0821
2436.4243 896.2444 1450.5339 1474.0777
2755,9879 1006.2610 1481.8271 1502.1012
2807.4310 1137.5348 1593.7967 1567.2406
2811.5170 1247.5397 1641.7659 1666.2453
1253.5261 1361.9969 1720.2388
1517.7880 1676.9752 1724.1858
Appendix I
1958.7484 2083.0119 1940.9913 1341.7031
2209.9143 2284.1248 1965.9824 1456.6890
2513.5871 2467.3386 2003.8648 1484.9154
2471.31898 2239.0969 1649.7894
Spot 160 2648.5279 2284.1610 1654.9252
861.1651 2808.3076 2299.1065 1667.6735
855.3069 2431.3152 1673.8618
917.3690 Spot 162 2531.3152 1940.9842
1032.4851 928.2775 2638.3205 1994.0919
1048.5256 969.4153 2725.3924 2201.3449
1195.9341 1045.4804 2807.3557 2215.1872
1237.4179 1214.6345 2225.1656
1294.5169 1228.5605 Spot 164 2239.2140
1318.6269 1258.6250 862.2108 2283.2268
1323.6775 1376.7477 1045.5933 2420.2747
1349.7545 1401.7357 1058.1426 2645.1759
1455.8482 1434.7531 1205.6140 2679.2944
1582.6262 1474.6388 1263.4304 2809.2977
1732.6804 1566.7781 1447.6977
1795.8457 1623.6993 1578.9261 Spot 166
1968.9162 1659.8392 1595.7324 870.3774
2131.0317 1719.7358 1628.7596 1034.4184
2225.0520 1788.7648 1743.8988 1045.6165
2300.0491 1994.0241 1788.8132 1271.2121
2325.9369 2070.9991 1924.1545 1329.6560
2451.9880 2214.0185 1940.9125 1368.6197
2469.0349 2239.0973 1986.9773 1422.6901
2511.7928 2248.2478 2141.4652 1493.8384
2605.5245 2302.1743 2222.0369 1695.9561
2689.1190 2500.3618 2225.1419 1859.9450
2807.3535 2565.4619 2230.2430 1869.9930
2810.1755 2715.6535 2239.1705 1919.0067
2731.3098 2283.1791 1940.9383
Spot 161 2808.3436 2413.2847 1974.9614
928.4466 2565.2295 2159.9849
1045.5720 Spot 163 2721.2806 2225.1694
1189.7928 987.5107 2781.4695 2239.1430
1282.7323 1273.6728 2254.0925
1438.7404 1285.5982 Spot 165 2283.1681
1448.7130 1309.7109 861.2674 2298.2367
1569.7683 1327.6605 917.2857 2490.1904
1607.7485 1343.6546 1004.3324 2642.2016
1784.6644 1512.7059 1045.5698 2789.2210
1918.0201 1657.7782 1155.7029 2808.3683
1925.7849 1744.8645 1179.7276
1940.9236 1932.0154 1309.7506
Appendix î
Spot 167 1307.6561 1139.4664 1376.6947
1045.5494 1413.8257 1314.6067 1396.7198
1319.2762 1460.5394 1352.6624 1443.8737
1485.1247 1699.8615 1405.6973 1486.7513
1637.8964 1862.5934 1566.6961 1492.7890
1934.6268 2014.9014 1569.7827 1502.7044
1940.9554 2135.2227 1607.6603 1664.9446
2083.1222 2225.1456 1736.1377 1701.9202
2231.2625 2239.1079 1911.8921 1705.7591
2225.1336 2297.2251 1918.0249 1718.8696
2239.1305 2410.2319 1966.5910 1893.0326
2283.1817 2565.3420 2225.1047 1912.9364
2297.1806 2676.3178 2370.2745 2004.0134
2409.1187 2747.2662 2552.7611 2044,0893
2566.2547 2807.3892 2808.4043 2269.2325
2791.1744 2810.3429
Spot 172
2272.0844
2346.0499
Spot 168 Spot 170 917.3239 2409.3130
869.4562 861.0943 958.3712 2564.2705
1024.4606 904.2795 1076.5688 2792.3606
1157.6210 1046.5792 1216.4188 2807.3662
1200.6836 1220.6044 1278.7524
1210.4452 1308.5981 1333.7423 Spot 174
1219.4696 1330.6313 1399.6887 966.4594
1338.6513 1510.8639 1430.8202 1042.5482
1482.8005 1581.8508 1433.7002 1024.4286
1485.7298 1627.8237 1441.9123 1243.6553
1610.8865 1791.7625 1525.8324 1301.6904
1701.8397 1941.9020 1680.9407 1446.8491
1725.7896 2092.1303 1893.9433 1598.7229
1755.9971 2233.1185 1940.9548 1608.7769
1940.8517 2239.1688 2231.2506 1774.8973
1977.0794 2283.2251 2234.0788 1790.9038
2221.0173 2287.1609 2239.1543 1867.8670
2225.1446 2435.5260 2271.9936 1985.9934
2285.1607 2496.2401 2283.2113 2023.0342
2409.0195 2561.2726 2497.1430 2055.9979
2575.3658 2786.8451 2663.3974 2150.1202
2808.3888 2807.3960 2808.3365 2163.2452
2811.2999 2810.3376 2216.0096
2829.5032 Spot 173 2225.1272
Spot 169 1023.4149 2231.0634
963.3794 Spot 171 1045.5241 2259.0883
1046.5427 847.4679 1266.5816 2306.2258
1130.4076 891.4196 1341.7812 2467.0283
1207.6892 1045.5857 1360.7265 2484.2577
Appendix I
2634.8580
2807.3704
Spot 175
894.4858
966.4958
972.6127
982.5667
1025.6480
1129.6329
1298.7578
1539.7521
1720.8437
2285.2139
2545.3800
2809.3399
Spot 176
894.4606
966.4831
982.5474
1025.6193
1036.5441
1298.7455
1539.7173
1720.8515
2178.1715
2283.2188
2544.3626
2810.3419
Spot 177
966.5254
972.6016
982.5849
1115.3833
1129.6982
1298.7179
1357.5760
2539.7988
1720.7191
1874.9519
2065.6086
2231.3099
2505.2991
2524.1369
2726,4553
2808.3017
Spot 178
830.4200
862.3587
966.4927
982.5596
1036.4279
1060.5092
1067.5942
1179.6890
1219.2546
1277.7902
1337.8582
1428.1008
1475.7977
1550.9146
1572.1023
1716.9942
1791.8388
1843.7586
1928.9635
1994.2019
2117.5192
2298.0028
2381.1517
2518.9724
2811.7879
Spot 179
928.5414
966.4429
972.5548
982.5187
1025.6041
1162.6483
1539.7533
1720.8155
1767.8524
2179.1841
2351.1615
2544.4187
2807.4168
Spot 180
966.4929
972.6002
982,5534
1025.6184
1137.4762
1162.6840
1208.5084
1539.7805
1544.8227
1554.7577
1713.9199
1720.7919
2017.0120
2075.1094
2225.1240
2523.1898
2609.3126
2807.4631
Spot 181
966.4681
972.5708
982.5236
1025.5837
1162.6623
1463.0845
1539.7412
1554.6722
1720.7661
1890.9703
2075.0815
2226.0524
2523.1327
2544.3905
2805.2785
Spot 182
972.5883
979.5633
982.5618
1025.6086
1049.5533
1162.6845
1298.6724
1539.8049
2554.7358
1720.8024
2016.9861
2075.0796
2225.1325
2526.0788
2609.2838
2807.3616
Spot 183 
966.4676
982.5520
1025.6477
1055.5261
1137.4798
1162.6756
1264.4368
1539.6875
1543.7357
1554.7013
1712.8195
1964.1435
1990.0363
2075.0218
2194.8873
2239.0668
2523.0386
2526.0409
2609.1300
2692.5805
2807.2467
2850.0959
Spot 184
899.5133
1013.4571
1045.4968
1055.4857
1194.6443
1200.6349
1255.5607
1271.4995
1346.6983
1356.7764
1473.7955
1654.8006
Appendix I
1672.1437 1839.0482 2807.4825 1233.7529
1915.7933 2060.0242 1370.6440
2152.1690 2226.1367 Spot 189 1425.7655
2220.0742 2299.1150 905.3227 1508.8665
2279.1427 2449.6824 1005.5325 1550.8741
2455.8902 2710.5130 1020.5426 1567.6979
2617.3524 2807.3641 1105.5293 1794.8670
2792.0494 1178.6238 1917.0043
2807.3411 Spot 187 1175.5734 1980.0244
832.4033 1192.5865 2149.1510
Spot 185 863.3263 1230.6626 2191.2345
861.1705 1045.5447 1253.6587 2271.1473
903.4708 1110.5869 1278.6823 2286.1310
1051.4191 1233.7295 1529.1238 2299.1906
1102.6102 1249.6542 1603.9603 2545.7653
1259.7849 1307.6237 1701.7966 2804.3695
1446.8457 1363.7248 1705.6898 2807.3365
1472.8940 1550.8486 1930.0133
1581.9349 1553.7811 2293.1278 Spot 192
1676.8174 1777.0180 2310.2543 Lost
1743.6820 1916.9489 2384.1412
1852.9862 1997.7137 2606.1410 Spot 193
1904.0147 2225.1281 2637.2016 853.4973
1937.0236 2690.1109 2804.3034 1045.5401
2186.3928 2807.3387 2807.3053 1124.6059
2225.1103 1162.6655
2298.1694 Spot 188 Spot 190 1226.5487
2493.1635 861.2050 894.4588 1348.6051
2720.0191 1045.5593 939.3601 1406.8042
2807.3268 1186.5424 1120.4970 1557.6414
1194.6563 1233.7425 1790.4561
Spot 186 1230.6491 1276.7640 2004.1979
861.1798 1291.7345 1425.7665 2225.1177
878.2884 1346.7463 1508.8628 2239.1498
1023.5406 1441.7056 1511.8111 2298.1279
1038.5089 1444.8077 1777.0299 2609.3155
1110.6044 1523.0678 1831.1101 2613.5243
1233.7840 1733.9455 1916.9915 2808.4030
1246.5776 1757.7573 2129.5186
1262.5386 1753.9790 2369.1920 Spot 194
1321.6990 1916.9579 2574.0609 856.4009
1446.8716 2152.1739 2805.2325 878.3158
1540.8669 2239.1402 926.3230
1563.7415 2353.4547 Spot 191 972.3679
1593.7956 2539.2838 894.4405 1207.6499
1723.8434 2751.3884 1110.5897 1246.5998
Appendix I
1269.7016 Spot 196 Spot 198
1446.8552 861.0863 1040.4305 Spot 200
1591.7876 877.0680 1056.4665 861.2053
1663.8530 885.3124 1086.671 945.3925
1680.6991 1066.0831 1103.7226 1027.5136
1754.9376 1093.2466 1242.6947 1045.5785
1758.6904 1173.7304 1359.4990 1199.1442
1804.0600 1338.5169 1369.6247 1362.6622
1811.8679 1554.0112 1372.5761 1518.0520
1844.0758 1663.9053 1530.8948 1569.6701
2040.5075 1735.8503 1558.6759 1779.9599
2221.9921 1803.9832 1590.6454 1939.8822
2225.0960 1811.8783 1601.7995 2161.8400
2245.9935 1918.7002 1719.9297 2222.1230
2278.1020 1994.0883 1937.9733 2225.1202
2500.7198 2196.7214 1988.0130 2239.1363
2722.6229 2225.0826 2066.0588 2408.1587
2808.2557 2244.0891 2215.0252 2564.1893
2285.0872 2225.1372 2615.2317
Spot 195 2436.1253 2239.1488 2758.9829
870.4567 2699.2678 2331.1978 2807.4622
997.4866 2808.3740 2408.1804 2810.3103
1042.3342 2564.1877 2835.2999
1045.5721 Spot 197 2568.7931
1169.5689 927.5663 2759.4775 Spot 201
1259.8414 970.5565 2808.3236 1044.4653
1269.6533 1241.6779 1110.5873
1399.6603 1253.7685 Spot 199 1179.6468
1446.9112 1287.6032 882.2428 1233.7507
1531.6062 1291.5767 1045.5290 1307.7220
1619.7500 1369.8194 1166.6198 1363.7899
1663.7943 1445.9854 1210.6419 1425.7312
1696.7241 1632.9965 1226.6109 1475.8010
1803.9956 1804.0538 1429.6742 1550.9188
1806.9517 1948.7635 1615.7809 1632.7453
1811.8378 2134.9202 1845.8855 1716.7454
1941.8808 2225.1085 1941.9437 1791.7815
2176.2938 2239.0940 2109.7469 1853.8983
2225.1434 2284.2629 2225.1327 1917.0300
2239.1853 2302.9220 2274.3018 1994.1408
2244.0969 2562.2416 2298.1940 2082.1920
2443.9870 2741.4020 2444.8437 2225.1809
2750.1027 2781.8805 2619.6721 2285.1639
2807.3713 2807.3967 2720.3379 2297.2300
2808.3647 2526.9576
2828.6379 2706.1150
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2807.4780 939.5475 1907.9974 1659.6982
1024.5304 1919.9841 1702.8845
Spot 202 1132.6323 2191.3114 1918.1567
894.4160 1267.6280 2225.1001 2074.5150
1051.4705 1169.5593 2233.0094 2239.1916
1132.5554 1360.7737 2296.1977 2264.0949
1233.7263 1370.7276 2330.0821 2409.1633
1337.7724 1379.6754 2575.2553 2610.8828
1425.7655 1396.7743 2593.1028 2807.5000
1508.8732 1443.9426 2807.3886 2810.3572
1511.7708 1623.1074 2812.5041
1703.9629 1664.9892 Spot 208
1916.9850 1701.9681 Spot 206 870.4075
1940.9445 1704.8061 890.4355 929.5374
1982.7316 1718.9115 1025.3962 1003.4887
2138.1403 1774.9577 1046.5664 1134.5213
2225.1283 1823.9797 1139.5879 1217.6203
2293.1239 1969.2034 1143.5497 1233.5456
2301.2114 2225.1327 1265.6673 1396.6443
2553.0651 2285.1173 1303.7178 1493.7411
2807.3533 2330.1213 1489.7448 1655.8334
2812.2318 2345.9526 1505.6857 1903.8863
2409.3289 1658.8361 2022.9413
Spot 203 2536.4692 1786,8504 2204.0216
861.2115 2807.3910 1814.1244 2367.8415
978.4902 2810.3021 1959.9085 2564.1345
1132.5794 1962.8597 2807.5273
1267.5650 Spot 205 2067.9877
1283.5289 862.3286 2086.9544 Spot 209
1396.7336 949.5259 2239.1681 917.4770
1443.8919 1042.5230 2286.1202 979.4859
1525.7838 1081.5156 2320.2045 1146,4707
1532.7676 1146.4965 2442.0625 1255.6376
1664.9489 1230.6103 2487.2606 1287.5762
1701.9494 1235.7054 2655.2356 1319.6381
1704.8669 1267.6143 2761.7099 1343.6599
1718.9440 1292.6481 2808.3719 1407.6188
1774.9667 1396.7253 1498.7705
1823.9415 1444.8002 Spot 207 1535.8295
2225.1590 1525.7767 878.1894 1552.6948
2330.0824 1606.8201 1036.4701 1693.8908
2409.3522 1609.7400 1080.4913 1846.8313
2807.4161 1701.8867 1193.4128 1866.9252
1758.9109 1201.4977 2032.0156
Spot 204 1776.9084 1475.7555 2101.1197
862.3224 1870.9692 1656.7849 2283.1589
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2333.1156 2603.8658
2807.3656 2757.2073
2807.8159
Spot 210 2851.5814
861.1406
950.4834
984.4715 
1013.4189 
1053.5769 
1219.7891 
1222.3347 
1231.6360 
1417.6273 
1613.8268
1630.8076 Values of peptide masses (M+H*") entered for searcliing the
1649.5562 NCBInr and T. brucei databases with the MASCOT® search
1724.8840 engine. The underline masses correspond to the peptides
1913.8248 matching onto a protein in the database.1940.9498
2123.7980
2284.1168
2289.4715 
2469.1120 
2679.4007 
2807.3951 
2843.5926
Spot 211
862.0753
926.3137
1054.4480
1080.4193
1154.3019
1228.4678
1342.4154
1614.3255
1631.3039
1679,2333
1730.5781
1801.9735
1986.7920
2225.1211
2239.0957
2242.0477
2299.0950
2409.1462
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775xxxO
774xxxl
775xxx0
774xxxl
775xxx0
774xxxl
775xxx0 
774xxxI
775xxx0
774xxxl
775xxxO
774xxxl
775xxx0 
774xxxI
775xxx0
774xxxl
MGKEKVHMNLVVVGHVDAGKSTATGHLIYKCGGIDKRTIEKFEKEAADIGKASFKYAWVL
-l|4irGrSQADAAlLilASA( 
NÜÜITGPKLKAERERGITlDlALWKFESPKSVFTIlDAPGHRDFIK MIT TSQADAAnJIASAI
MVVCCNKMDDKg fT y G Q]j|YDEIVKEVSAYIKK 
MVVCCNKMDDK^^mO#yDEIVKEVSAYIKK
atfXiDNM
VGYNVEKVi
VGYNVEKV
VY
VYKj
Kgnmwwmv
kem TV PV G av
SEKMPWYKGPTLLEALDMLEPPVRPSDKPLRLPLQD
SEKMPWYKGPTLLEALDMLEPPVRPSDKPLRLPLQD
ETGVMKPGDVVTFAPANVITEVKSIEMHHEQLAEA TPGDNVGFN V 
ETGVMKPGDVVTFAPANV rrEVKSlEMHHEQLAEAl PGDNVGFNV
KNVSVKDIRRGNVCGNTKNDPPKEAADFTAQVIILNHPGQIGNGYAPVLDCHTSHIACKF
KNVSVKDIRRGNVCGNTKNDPPKEAADFTAQVIILNHPGQIGNGYAPVLDCHTSHIACKF
AEIESKIDRRSGKELEK.APKSIKSGDAAIVRMVPQKPMCVEVF'NDYAPLGI 
AEIESKIDRRSGKELEKAPKSIKSGDAAIVRMVPQKPMCVEVFNDYAPEGRt^
VAVGllKAVTKKDGSGGKVTKAAVKASKK 
VAVGHKAVTKKDGSGGKVTKAAVKASKK
Figure 1: Protein isoform versus gene family. Alignment of the protein sequences from 
ORF 775 and 774 o f 71 brucei encoding elongation la  demonstrate high homology 
between different genes o f the same family. The highlighted sequences correspond to the 
peptides identified by PMF.
Appendix IV
Sample Score Peptide Score Sequence gi/number
386/3 74 4 28 INVYFDEATGGR 9366734
19 SVLIDLEPGTMDSV
18 GHYTEGAELIDSVL
10 FWEVISDEHGVDPT
386/4 204 4 42 FPGQLNSDLR 9366734
55 INVYFDEATGGR
47 SVLIDLEPGTMDSV
61 GHYTEGAELIDSVL
386/5 469 10 30 EQYPDR 9366734
31 LREQYPDR
37 LAVNLVPFPR
45 FPGQLNSDLR
46 KLAVNLVPFPR
51 INVYFDEATGGR
70 SVLIDLEPGTMDSV
58 EIVCVQAGQCGNQI
58 GFIYTEGAELIDSVL
45 AGPYGQIFRPDNFI
386Mr/3 143 5 31 EQYPDR 9366734
54 INVYFDEATGGR
21 SVLIDLEPGTMDSV
27 GHYTEGAELIDSVL
11 AGPYGQIFRPDNFI
386Mr/4 142 5 30 EQYPDR 9366734
50 INVYFDEATGGR
27 SVLIDLEPGTMDSV
21 GHYTEGAELIDSVL
15 AGPYGQIFRPDNFI
386Mr/5 437 11 29 EQYPDR 9366734
17 LREQYPDR
31 LAVNLVPFPR
45 FPGQLNSDLR
68 INVYFDEATGGR
51 SVLIDLEPGTMDSV
65 EIVCVQAGQCGNQI
55 GHYTEGAELIDSVL
44 AGPYGQIFRPDNFI
27 FWEVISDEHGVDPT
6 EAESCDCLQGFQIC
Table 1: Detailed results from the MASCOT search engine for spot 3, 4 and 5 for 386 
and 386Mr lines.
Appendix IV
Sample Score Peptide Score Sequence gi/number
247/1 223 4 51 LAVNLPFPR 9366734
58 FPGQLNSDLR
49 INVYFDEATGGR
65 SVLIDLEPGTMDSV
274/2
274/3 133 3 52 INVYFDEATGGR 9366734
58 SVLIDLEPGTMDSV
24 EIVCVQAGQCGNQI
274/4 116 2 57 INVYFDEATGGR 9366734
58 SVLIDLEPGTMDSV
274/5 404 7 29 LSGGVAVIR 18277736
19 ITDALCSTR
79 VGGASEVEVNEK
69 YVNMFEAGIIDPAR
42 DDTVLLNGGGDVAMMK
81 ALDGLLQDQSLTADQR
86 VLENTDAAVGYDAQLDR
247Mr/l 270 6 14 LREQYPDR 9366734
51 LAVNLVPFPR
49 FPGQLNSDLR
43 INVYFDEATGGR
63 SVLIDLEPGTMDSV
45 EIVCVQAGQCGNQI
247Mr/2 143 3 45 FPGQLNSDLR 9366734
47 INVYFDEATGGR
51 SVLIDLEPGTMDSV
247Mr/3 123 2 57 INVYFDEATGGR 9366734
65 SVLIDLEPGTMDSV
247Mr/4 99 2 53 SVLIDLEPGTMDSV 9366734
46 GHYTEGAELIDSVL
247Mr/5 65 2 21 LSGGVAVIR 18277736
44 VGGASEVEVNEK
Table 2: Detailed results from the MASCOT® search engine for spot 1,2, 3, 4 and 5 for 
247 and 247Mr lines.
Appendix V
Name Old Accession number New Accession number
CAR protein Tryp9.0.000322-274 Tb09.211.0120
CAR protein Tryp9.0.000322-277 Tb09.211.0130
Arginine kinase ORF 342 Tb09.160.4560
Arginine kinase ORF 343 Tb09.160.4570, AKl
Arginine kinase ORF 345 Tb09.160.1590, AKl
Table 1; Update of accession numbers given by GeneDB (httD://www.genedb.org/) 
for the CAR protein and arginine kinase, as searched on the 11/02/2004.
What we see depends mainly on what we look for.
John Lubbock
GLASG
